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ABSTRACT
The intestinal epithelium serves as a dynamic barrier which, in the course of its normal 
function, maintains regulated uptake of nutrients and water at the same time as excluding 
potential pathogens. Colonic epithelial cells participate in normal homeostasis, innate 
immunity and regulation of acquired immunity. They produce bioactive cytokines and 
other immunoregulatory molecules, such as nitric oxide, either constitutively or in 
response to stimuli including other cytokines or microorganisms. Enteropathies, including 
inflammatory bowel disease (IBD) result in, or perhaps even from, perturbed epithelial 
function. The pathophysiology, tissue damage and symptomatology of IBD are due to 
inappropriate or exaggerated immune reactions, such as unregulated production of pro- 
inflammatory cytokines or inadequate synthesis of anti-inflammatory cytokines.
Using a colonic epithelial cell line, HT-29, the modulation of the production of nitric oxide 
was examined. These cells were found to produce nitric oxide (NO) with specific 
combinations of the pro-inflammatory cytokines interleukin (IL)-la, interferon (IFN)-y 
and tumour necrosis factor (TNF)-a. This NO generation was via the induction of the 
inducible nitric oxide synthase (iNOS) enzyme, since iNOS mRNA and NO was generated 
after stimulation with cytokines. Modulation of this effect was achieved with the use of 
pharmacological agents, indicating a complex array of interacting signalling pathways. The 
T cell-derived anti-inflammatory cytokine, IL-13 significantly reduced this NO generation 
and iNOS expression.
Specific combinations of the same pro-inflammatory cytokines initiated programmed cell 
death in HT-29 cells, an effect that IL-13 was also able to inhibit. An investigation into the 
intracellular signalling pathway utilised by IL-13 to mediate these effects was undertaken. 
In this study IL-13 is shown to activate phosphatidylinositol 3-kinase (PI 3-kinase) 
possibly via the recruitment of the insulin receptor substrate (IRS)-l. PI 3-kinase activation 
was both essential for the down-regulation of iNOS and critical as a survival signal.
IL-13 also activates protein kinase B (PKB) in a PI 3-kinase-dependent manner. This 
enzyme is thought to provide the anti-apoptotic signal. In addition, IL-13 delayed the 
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1.1 ANATOMY OF THE COLON
Colonic mucosa is the innermost layer of the large bowel wall. It consists of the colonic 
epithelium, which covers both the absorptive surface and the crypts, and the lamina propria, 
found immediately beneath the epithelium (see figure 1A). Colonic epithelium is composed 
of columnar epithelial cells (which represent the main population), mucus secreting goblet 
cells and endocrine epithelial cells, whilst intraepithelial lymphocytes (IELs) infiltrate 
throughout the epithelium. The primary function of the intestinal epithelium is the 
absorption of nutrients, water and electrolytes from the lumen to the body. However, more 
recently it has been realised that because most of the antigens encountered by the normal 
immune system gain access to the body via a mucosal surface, colonic epithelium itself is 
involved in various immunological and inflammatory processes. The gut-associated 
lymphoid tissues (GALT) comprise the Peyer’s patches (PP), mesenteric lymph nodes 
(MLN) and large numbers of lymphoid cells scattered throughout the lamina propria (LP) 
and epithelium of the intestine (figure IB). The PP, with clearly defined T- and B-cell 
dependent areas, lie in the submucosa separated from the intestinal lumen by a single layer 
of cuboidal epithelial cells, the follicle-associated epithelium (FAE). In addition to 
conventional enterocytes, this epithelial layer contains many lymphoid cells of all types, as 
well as a unique population of specialised epithelial cells (M cells), whose function is the 
uptake and transport of antigen into the lymphoid tissue. This arrangement facilitates a close 
interaction between the epithelial and the lymphoid elements that are found in the PP. 






























Figure 1.1. Schematic representation of the gut. A. Colon (x40) (adapted from 
Freeman and Bracegirdle, 1976) and B. Crypts (xl40) (adapted from Potten, 1997)
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In addition to the organised tissues of the PP and MLN, the crypt units of the colon contain 
large numbers of scattered lymphocytes, both in the epithelium itself and in the deeper layer 
of the lamina propria. In contrast to the PP and MLN, which probably act as inductive sites, 
these scattered LP and IELs play a central role as the effector arm for local intestinal 
immunity.
1.2 IMMUNOLOGICAL ROLE OF COLONIC EPITHELIUM
The intestinal epithelium represents an important interface between the host and external 
environment serving both as a surface for absorption and as a defence against ingested pathogens 
(McKay and Perdue, 1993). Both non-immune and immune mechanisms protect the 
environment of the lamina propria from challenge by foreign antigens. Intestinal motility, 
commensal microflora and the mucous coat or glycocalyx comprise some of the non­
specific protective barriers. The immune mechanisms can operate within the lumen of the 
gut, at the mucosal surface or within the lamina propria (Abreu-Martin and Targan, 1996). 
The intestinal epithelial cells constitute a barrier between the environment and the host tissue and 
they are the first cells to come in contact with many pathogens. From this position, intestinal 
epithelial cells might play a crucial role as an outpost of the immune system located in the 
underlying intestinal mucosa. Soluble mediators produced by these cells might function as an 
early signal to neighbouring immune cells and be involved in the recruitment of cells during the 
inflammatory response. Finally, the interplay between the colonic epithelial cells, as 
“professional” antigen presenting cells (APCs), and IELs may complete the immunological role 
of colonic mucosa.
Introduction 3
The epithelium and lamina propria represent highly distinct compartments of the immune 
system, despite being separated only by a thin layer of basement membrane. The LP 
contains most components of the immune system, with large numbers of B cells, plasma 
cells, macrophages, dendritic cells and T cells of both the CD4+ and CD8+ subsets. 
Approximately 10 -  15 % of the cells within the normal colonic mucosa are lymphocytes, of 
which > 90 % are T cells and the majority of those (-80%) are of the CD8+ subset (Mowat 
and Viney, 1997). IEL are located between the epithelial cells adjacent to the basement 
membrane and are the only lymphocyte population situated so close to antigen in the entire 
body.
A role for colonic epithelial cells in inflammatory and immune reactions is increasingly 
recognised. These cells present antigens via major histocompatibility complex (MHC) Class II 
molecule expression and act as APCs to T cells (Mayer et al., 1991 and Lowes et al., 1992). 
Class II MHC determinants are expressed on normal small intestinal epithelial cells but not 
on colon epithelial cells unless the colon is inflamed (Selby et al., 1983). Expression of 
Class II antigens may be modulated by IFN-y produced by activated CD8+ T cells in the 
epithelium (Cerf-Benussan et al., 1984). The expression of human leukocyte antigen (HLA) 
molecules by colonic epithelial cells was found to activate CD3+/CD8+ IELs (Hoang et al., 
1992). Colonic epithelial cells express adhesion proteins, such as intercellular adhesion molecule 
(ICAM)-l (Kaiserlain et al., 1991 and Kvale and Brandzeig, 1995). In addition, they generate 
soluble inflammatory mediators. These include arachidonic acid derivatives (Gustafson and 
Tagesson, 1990 and Dias et al., 1992), platelet activating factor (Ferraris et al., 1993), cytokines 
(Hedges et al., 1992; Eckmann et al., 1993; Schuerer-Maly et al., 1994; Kolios and Nakos, 1995 
and Gross et al., 1995) and chemokines (Mazzucchelli et al., 1994 and Jung et al., 1995), all of 
which contribute to the communication between inflammatory epithelial cells and lymphocytes of
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the immune system (R. B. Sartor, 1994). Colon epithelial cells appear to be programmed to 
provide a set of signals for the activation of the mucosal inflammatory response in the 
earliest phases of microbial invasion (Jung et al., 1995). The involvement of colonic epithelial 
cells in immune and inflammatory reactions in inflammatory bowel disease is discussed in the 
next section.
1.3 INFLAMMATORY BOWEL DISEASE
The term inflammatory bowel disease (IBD) describes two major pathological conditions 
involving the gastrointestinal tract, namely ulcerative colitis (UC) and Crohn’s disease 
(CD). In UC the inflammatory disorder is superficial in the mucosa and submucosa and 
limited to the large bowel, affecting the rectum and a variable extent of the colon. 
Histologically, the disease is characterised by an infiltration of both acute and chronic 
inflammatory cells (such as neutrophils, monocytes and plasma cells) in the lamina propria 
and the crypts, leading to the formation of microabscesses. The deeper layers of the 
intestinal wall are characteristically not involved. CD is a transmural inflammation that may 
occur anywhere throughout the alimentary tract from the mouth to the anus. The disease 
can affect the deeper layers of the bowel wall producing superficial and deep ulceration and 
also leading to collagen deposition and fibrosis. The cellular infiltration consists of 
lymphocytes and macrophages and the presence of granulomas is a predominant feature of 
the disease. Both of these diseases are characterised by chronic relapses and are associated 
with many extra-intestinal manifestations. (B. E. Sands, 1998).
Despite extensive investigation for decades the aetiology and pathogenesis of both major 
forms of IBD remains unknown. Increasing evidence suggests that these two disorders are
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partly and, possibly, wholly distinct in their initial aetiological event, although they share 
important common pathogenetic mechanisms. It is likely that the aetiology of IBD is not a 
single cause and effect relationship and probably represents an interaction between various 
agents. A number of genetic predisposing factors, exogenous and endogenous triggers and 
modifying factors is involved and their interaction is an inflammatory process, in which 
tissue injury seems to be mediated by the immune system (R. P. MacDermott, 1998). The 
prognosis of ulcerative colitis and Crohn's disease has much improved over the years, but an 
aetiologic cure has not yet been found, emphasising the need for further investigation of 
these challenging diseases. Until the cause of these diseases has been clearly identified 
therapeutic strategies for these conditions must be based on interrupting the 
immunopathogenetic mechanisms involved and inhibiting the gut inflammation; hence the 
widespread use of immunosuppressives in their treatment (W. J. Sandborn, 1998 and 
D’Haens and Rutgeerts, 1998). In the following section, Table 1.1 A summarises the most 
important factors that condition, cause and promote IBD (C. Fiocchi, 1998). Thereafter, a 
selection of features relevant to this research project will be reviewed in more detail.
Aetiology of IBD
The cause of IBD is likely to be multifactorial. Although the aetiology of IBD remains 
obscure, a number of genetic, environmental, microbial, and immunological factors 
responsible for the cause of this disorder have been suggested and multiple aetiological 
theories have been proposed (Table 1.1B), reviewed in (C. Fiocchi, 1998).
Introduction
Table 1.1A. Factors thought to Contribute towards the Aetiology of IBD
Component UC CD
Environmental factors
Beneficial effect of 
smoking 
No beneficial effect of diet 
Normal intestinal 
permeability in healthy 
relatives
Detrimental effect of 
smoking 
Symptoms improved by 
selective diets 
Increased intestinal 
permeability in healthy 
relatives
Genetic associations Largely different from CD Largely different from UC
Microbial agents
Limited role of bacterial 
flora
No association with M. 
paratuberculosis 
No association with 
measles virus




Some association with 
measles virus





Evidence of autoimmunity 




Limited evidence for 
autoimmunity 




infiltration in the mucosa 
Normal/hyporeactive T 
cells
Normal T-cell apoptosis 
(?)
Prominent T-cell 
infiltration in the mucosa 
Hyperreactive T cells
Resistance of T cells to 
apoptosis
Cytokines and mediators




production limited to 
involved mucosa




production in involved and 
uninvolved mucosa
ANCA, antineutrophil cytoplasmic antibodies
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Pathogenesis of IBD
Although the primary aetiological agents in IBD are still elusive, it is now known that 
disease activation involves two processes. First, an early increase in expression of surface 
adhesion molecules on vascular endothelial cells, with consequent diapedesis and activation 
of circulating leukocytes in gut mucosa (R. P. MacDermott, 1998). Second, an increased 
synthesis and release of a wide range of inflammatory mediators and cytokines are likely to 
contribute to the clinicopathological features of IBD (Kolios et al., 1997). The sources of 
these mediators include not only resident and newly recruited mucosal inflammatory cells 
such as neutrophils, macrophages and mast cells, but also platelets, colonic epithelial cells, 
vascular endothelial cells, fibroblasts, smooth muscle cells and enteric neurons (C. Fiocchi, 
1998). Figure 1.2 shows the components and events involved in EBD aetiopathogenesis.
Cytokines and IBD
Cytokines are a large family of structurally diverse proteins of 8-30 kDa, which are 
produced by most nucleated cells, particularly, but not exclusively, immune cells. These 
proteins are mediators of immunoregulation and inflammation and probably play a key role 
in intestinal inflammation via the induction and suppression of inflammatory processes. In 
addition they have a role in the regulation of healing and repair by activating effector cells 
(Stadnyk and Waterhouse, 1997), by increasing their proliferation and providing 
chemotactic messages. Individual cytokines modulate the secretion, not only of other 
cytokines, but also other mediators, such as chemokines. Thus cytokines may be responsible 
for many of the symptoms experienced by patients with IBD via their local and systemic 
effects or by inducing the production of other mediators and initiating a cascade of effects 



























Figure 1.2. Diagram showing components and events involved in IBD 
aetiopathogenesis. Interacting environmental and genetic factors in combination 
with the microbial intestinal flora or a still unidentified specific microorganism 
trigger an event that activates intestinal immune and nonimmune systems. The 
cell-mediated immune response induces effector T cells and activates 
macrophages, neutrophils and other leukocytes, whereas the humoral response 
stimulates B cells to produce antibodies. Through secretion of soluble mediators 
and expression of cell adhesion molecules, immune and nonimmune cells 
exchange signals, resulting in further cell activation and amplification of the 
production of antibodies and autoantibodies, cytokines, growth factors, 
eicosanoids, neuropeptides, ROMs, NO and proteolytic enzymes culminating in 
inflammation and tissue damage.
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and TNF-a) or anti-inflammatory (e.g. IL-4, IL-13 and IL-10). These cytokines and their 




EL-1 is the term for two polypeptides (IL-la and IL-lp) that are distinct gene products, but 
recognise the same receptor and share biological properties. IL-1 is a 31-33 kDa pro-cytokine 
that is enzymatically cleaved into a 17 kDa bioactive polypeptide with a large range of biological 
activities, including the induction of cytokines, chemokines, adhesion molecules, and enzymes 
such as cyclo-oxygenase, soluble phospholipases and collagenases (L. A. J. O’Neill, 1995). It is 
now considered to be a major pro-inflammatory cytokine, with a wide variety of targets 
(including epithelial cells). Its production can be stimulated in an antigen-dependent or 
independent fashion in most cell types. Antigen-dependent stimulation can occur either 
directly, during antigen presentation when a T cell is in contact with an APC, or indirectly, 
as a result of the release of cytokines, such as IL-2 or interferon (IFN)-y, from an activated 
T cell. Antigen-independent induction of IL-1 can occur when pathogens such as viruses or 
bacteria, or certain irritants such as asbestos or silica, come into contact with monocytes or 
macrophages. In addition, other cytokines, such as granulocyte/macrophage (GM)-colony 
stimulating factor (CSF), transforming growth factor (TGF)-P, tumour necrosis factor 
(TNF)-a, IFN-a and p, as well as EL-1 itself, can trigger IL-1 release from monocytes or 
macrophages (C. A. Dinarello, 1996). Some of the consequences of EL-1 production include
(i) progression from early to late Gi in the cell cycle of activated helper and cytotoxic T 
cells, (ii) induction of prostaglandin synthesis in endothelial and smooth muscle cells, (iii) 
induction of fever and (iv) initiation of the acute phase response. Thus, EL-1 has potent
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pleiotropic effects that can be either local or systemic and is critical in the mediation of host 
responses to injury and infection (C. A. Dinarello, 1996).
Signalling
In the immune system, the production of IL-1 is typically induced, generally resulting in 
inflammation. Its effects are mediated by binding to specific receptors, IL-1R Types I and II. 
IL-1RI signals whereas IL-1RII does not and seems to act as decoy receptor (Stylianou et 
al., 1992 and Colotta et al., 1993). The IL-1 receptor antagonist (IL-lra) also binds both 
receptors and acts a true receptor antagonist. Most of the immune and inflammatory genes 
induced by IL-1 are nuclear factor (NF)-KB-regulated; making it a key mediator of IL-1 
effects in cells (Stylianou et al., 1992).
NF-kB regulates the transcription of genes bearing the kB consensus motif. Transmigration 
of NF-kB from the cytoplasm to the nucleus is regulated by the IkB family of inhibitory NF- 
kB -binding proteins. The dissociation of the NF-kB/IkB complex requires both 
phosphorylation and degradation of IkBs. Numerous stimuli, including IL-1 and TNF-a 
(Henkel et al., 1993 and Beg et al., 1992) ubiquitinate a kinase that phosphorylates I-kBoc 
at serine residues 32 and 36 on the N-terminus of the molecule (Chen et al., 1996). 
Phosphorylated IkBoc is then selectively ubiquitinated and rapidly degraded via a 
nonlysosomal, ATP-dependent, 26S proteolytic complex composed of a 700 kDa 
proteasome (M. Hochstrasser, 1996 and Baeuerle and Baltimore, 1996).
Following TNF-a stimulation, TNF receptor-associated factor-2 (TRAF-2) is recruited to 
the cytoplasmic portion of the TNF-R1 via the intermediate action of TNF receptor- 
associated death domain (Hsu et al., 1996). In contrast, IL-1 signals through the action of
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IL-1R-associated kinase (IRAK), which associates with IL-1R1 and activates TRAF- 6  (Cao 
et al., 1996). Activated TRAF-2 and TRAF- 6  are then able to associate/activate the NF-kB- 
inducing kinase (NIK) (Malinin et al., 1997). NIK, in turn, associates/activates the IkB 
kinase (IKK) complex (Stancovski and Baltimore, 1997 and Verma and Stevenson, 1997), 
which is composed of the IKK-1 and IKK-2 subunits, both critical in mediating cytokine- 
induced IkB phosphorylation (Mercurio et al., 1997; Woronicz et al., 1997 and Zandi et al., 
1997). Activation of the IKK complex leads to specific IkB a  phosphorylation/degradation 
and subsequent release of NF-kB, which migrates to the nucleus and activates transcription 
of KB-specific genes. TRAF-2 has been shown to play an important role in transducing the 
TNF-a signal through the IkB/NF-kB axis (Rothe et al., 1995; Liu et al., 1996; Min et al., 
1997; Tobin et al., 1998; Song et al., 1997 and Natoli et al., 1997).
Apart from NF-kB, there are other targets for IL-1 signal transduction. Mitogen-activated 
protein kinases (MAPKs) are involved in a number of cell signalling pathways. These 
enzymes are proline-directed serine/threonine kinases that are activated by dual 
phosphorylation of threonine and tyrosine residues, in response to a multitude of 
extracellular stimuli (Kyriakis and Avruch, 1996). There are at least three distinct MAP 
kinase signal transduction pathways, each leading to activation of either the extracellular- 
regulated kinases (ERKs), c-Jun N-terminal kinase/stress-activated protein kinase 
(JNK/SAPK) or p38 (Kyriakis and Avruch, 1996). ERK, JNK and p38 are phosphorylated 
by dual-specificity MAPK kinases (MAPKKs or MEKs), which, in turn, are activated by 
serine/threonine phosphorylation by MAPK kinase kinase (MEKK). Mammalian ERK1 and 
ERK2 and their upstream activators MEK1 and MEK2 are acutely stimulated by growth 
and differentiating factors, e.g., EGF, PDGF and NGF, by receptor tyrosine kinases, 
heterotrimeric G-protein-coupled receptors, or cytokine receptors. The mammalian JNKs
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and p38 are implicated in responses to cellular stress, inflammation and apoptosis. They are 
activated by lipopolysaccharides, pro-inflammatory cytokines, ionising or ultraviolet 
radiation, heat shock or hyperosmotic stress (Kyriakis and Avruch, 1996).
IL-1 activates the three major MAP kinase cascades (L. A. J. O’Neill, 1996). IRAK 
activates JNK1 mediated by TRAF6  (Knop et al., 1998 and Song et al., 1997) and may 
provide a mechanism for the activation of the transcription factor, AP-1 (Song et al., 1997). 
In addition, IL-1 activates another kinase termed TNF/IL-1 -induced protein (TIP) kinase 
(Guesdon et al., 1997), although the functional relevance of this is as yet unknown.
Relevance to IBD
Inappropriate or prolonged production of IL-1 has been implicated in the pathogenesis of 
conditions such as inflammatory bowel disease. In active IBD, isolated peripheral blood 
mononuclear cells were found to produce increased levels of IL-1 compared to controls 
(Grottrupwolfers et a l 1996), but reverted to control levels in the inactive stages. Significant 
correlation between the IL-1 (3 production and the activity index of the diseases has been found 
(Nakamura et al 1992). IL-lp mRNA was found in colonic biopsies from patients with 
infectious and ischaemic colitis. These results suggest that production of IL-lp is not unique to 
active IBD but is also increased in intestinal inflammation (Isaacs et al 1992). Organ cultures of 
involved IBD mucosa spontaneously produced increased amounts of IL-lp compared to 
normal mucosa (Reimund et a l 1996). The increased IL-1 production at the mucosal level in 
those patients with active IBD is probably derived from the presence of increased number of cells 
capable of synthesising IL-1 in the inflamed intestinal mucosa (Grottrupwolfers et a l 1996). 
Macrophages have been suggested as the major source of IL-1 in IBD mucosa (Mahida et al
1989), although there may be cell types other than macrophages involved in IL-1 production,
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such as T cells and fibroblasts. Finally, levels of EL-Ira were markedly lower in patients with 
IBD. An imbalance in the ratio of tissue IL-1 and IL-lra levels in the intestinal mucosa of 
patients with IBD has been proposed (Cominelli and Pizzaro, 1996).
(ii) Tumour necrosis factor (TNF)-a
Biology
TNF-a (or catchetin) is a representative member of a large family of cytokines that exert a 
fundamental effect on cell proliferation and death, inflammation and immunological and neuronal 
cell function (Orlinick and Chao, 1998). TNF-a is a non-glycosylated polypeptide that exists as 
either a 26 kDa transmembrane protein or as an 85 kDa soluble protein. TNF-a is produced by 
activated monocytes/macrophages and T-cells and inhibits the growth of certain tumour 
cells, although the alteration of growth, differentiation and metabolism of other cells has 
also been attributed to TNF, particularly during development, hematopoeisis and 
reproduction (Aggarwal and Natarajan, 1997). That this protein is capable of producing 
such a wide variety of effects is attributable to, (i), the ubiquity of its receptor, (ii), its ability 
to activate multiple signal transduction pathways and (iii), its ability to induce or suppress 
the expression of a vast number of genes; including those for growth factors and cytokines, 
transcription factors, receptors, inflammatory mediators and acute phase proteins (Aggarwal 
and Natarajan, 1997).
Signalling
TNF-a assembles into homotrimeric complexes in its biosynthesis (Jones et al., 1989). The 
transmembrane form is bioactive and can bind to its cellular receptors (Perez et al., 1990). 
A non-cleavable form of TNF-a serves as a superior ligand relative to soluble TNF-a (Grell 
et al., 1995). TNF ligand family members include TNF-a and FasL. Distinct properties of
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these ligands include their orientation in the membrane (their type II topology) and their 
cleavage within their extracellular domains by metalloproteases to yeild soluble, biologically 
active protein (Orlinick and Chao, 1998).
Two transmembrane proteins serve as receptors for TNF-a, termed p55 (TNFR I) or p75 
(TNFRII) (Schall et al., 1990; Loetscher et al., 1990; Smith et al., 1990 and Nophar et al.,
1990). TNFR I has four cysteine-rich domains (CRDs) which are required for efficient 
ligand binding to TNF-a (Marsters et al., 1992), whereas the Fas receptor requires all three 
of its CRDs for binding to the FasL (Orlinick et al., 1997). TNF-a binds to both TNFR I 
and TNFR II and to soluble TNF-binding proteins (which are proteolytic fragments of the 
full-length receptors shed from the cell surface by proteolytic processing) (Seckinger et al., 
1988; Engelmann et al., 1990 and Gantanga et al., 1990). TNFR I has shown a clear role in 
TNF-mediated cytotoxicity and can stimulate activation of NF-kB (Orlinick and Chao, 1998), 
whereas TNFR II is thought to act by “ligand passing” to provide increased local concentrations 
of ligand for TNFR I, which initiates intracellular signalling (Tartaglia et al., 1993).
TNFR-I and Fas (CD95) possess and additional homology in their intracellular domains in a 
region of about 80 amino acids termed the “death domain”. This domain is required for receptor- 
mediated cytotoxic activity (S. Nagata, 1997 and Itoh and Nagata, 1993) and NF-kB activation 
(Tartaglia et al., 1993), which mediates many of the pro-inflammatory and immunoregulatory 
effects of TNFR-I (Baeuerle and Baltimore, 1996). The death domain appears to be a novel 
protein-protein interaction motif used for the specific recruitment of cellular signalling molecules. 
TNF and Fas receptors do not possess intrinsic catalytic activity associated with their 
intracellular domains and thus rely on cytosolic factors to transduce their signals. Several of the 
interacting signalling molecules, such as FADD/MORT1, TRADD and RIP, have death domains
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that are used for interacting with TNFR-I and Fas (Chinnaiyan et al., 1996; Boldin et al, 1995; 
Hsu et al., 1995 and Stanger et al., 1995). Receptor activation of TNFR-I and Fas occurs by 
clustering, mediated by the binding of multimeric ligands (Schlessinger and Ullrich, 1992; 
Engelmann et al., 1990 and Kischkel et al., 1995). After oligomerisation, the Fas receptor 
recruits the signalling molecule FADD/MORT1 through its death domain (Chinnaiyan et al., 
1995 and Boldin et al., 1995). This recruitment, in turn, leads to the recruitment and activation 
of the caspase proteases FLICE/MACH/caspase- 8  and FLICE/caspase-10, which then cleave 
other caspases to initiate the apoptotic signal-transduction pathway (Boldin et al., 1996; Muzio 
et al., 1996 and Vincenz and Dixit, 1997). TNFR-I also uses this pathway, recruiting 
FADD/MORT1 through the adapter protein TRADD (Hsu et al., 1995; Chinnaiyan et al, 1996 
and Hsu et al., 1996). TNFR-I can also recruit the protein kinase RIP through the adapter 
TRADD (Hsu eta l, 1996).
Unlike the Fas apoptosis-inducing system, TNF-stimulated cell death often requires the addition 
of RNA or protein synthesis inhibitors such as actinomycin D or cycloheximide, respectively, to 
unmask a cell-death activity. This may be a result of the ability of TNFR I and TNFR II to 
stimulate NF-kB activity, which appears to depend upon signal transduction through the RING- 
finger protein TRAF2 and the adapter protein TRADD or other cytoplasmic proteins (Hsu et al., 
1996c). It has been demonstrated that TNF-a has an enhanced apoptosis-inducing activity when 
NF-kB activation is blocked (Beg and Baltimore, 1996; van Antwerp et al., 1996 and Wang et 
al, 1996). NF-kB activation is thought to lead to the production of anti-apoptotic proteins that 
attenuate the TNFR-I-transmitted death signal.
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Relevance to IBD
Pathological effects of TNF are associated with many diseases such as diabetes, childhood 
chronic inflammatory bowel disease and septic shock. Studies on TNF-a production have 
detected no significant differences in serum or mucosal specimens between IBD patients and 
normal controls (Greenfield et a l 1993), whereas organ cultures of involved IBD mucosa 
were found to produce increased amounts of TNF-a compared to normal mucosa (Reimund 
et a l 1996). Tissue levels of TNF-a mRNA were not increased in IBD specimens using PCR 
amplification (Isaacs et al 1992). It has been suggested that the increase of IL- 6  in IBD, which 
inversely regulates TNF-a production, may be responsible for the apparent decreased expression 
of TNF-a in intestinal inflammation (Isaacs et al 1992). The systemic levels of TNF-a were not 
found to be elevated in an experimental model of chronic colitis compared to controls. It has 
been suggested that other pro-inflammatory mediators with biological properties parallel to those 
of TNF-a, such as IL-1, may be responsible for the systemic manifestations of chronic colitis 
(Mack et a l 1992). In another study the amount of TNF-a in the stools has been referred as a 
marker of intestinal inflammation (Braegger et al 1992). TNF-a has a large range of biological 
activities, most similar with those of IL-1, including the induction of cytokines and enzymes that 
are involved in the generation of inflammatory mediators (Beutler & Cerami, 1995). In addition, 
TNF-a has been found to increase adhesion molecule expression on the cell membranes of 
monocytes and granulocytes and it has been suggested that this cytokine might be responsible for 
leukocyte recruitment into the bowel wall in IBD (Greenfield et a l 1993; Lo et al 1989).
(iii) Interferon (IFN)-y
Biology
IFN-y is a noncovalent 34 kDa homodimer (Fountoulakis et al., 1992). It is a 
multifunctional protein, produced by T cells and natural killer cells, first observed to have
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antiviral activity by inhibiting viral replication (Kerr and Stark, 1992). Its functions are 
largely immunomodulatory and include (i) stimulation of bactericidal activity of phagocytes
(ii) stimulation of antigen presentation through class I and class II major histocompatibility 
complex (MHC) molecules (iii) orchestration of leukocyte-endothelium interactions (iv) 
effects on cell proliferation and apoptosis, as well as (v) the stimulation and repression of a 
variety of genes with obscure function (Boehm et al. 1997).
Signalling
A published model for the cellular response to IFN-y (Greenlund et al., 1994) describes the 
sequential events that follow binding of IFN-y to its receptor. Initially, binding induces 
dimerization of the receptor and activation of the Janus tyrosine kinases JAK1 and JAK2. 
The IFN-y receptor and an additional protein termed signal transducer and activator of 
transcription (STAT)la (or gamma-interferon activating factor (GAF)) are subsequently 
phosphorylated. Phosphorylated STA Tla dimerizes and possibly in combination with 
another protein enters the cell nucleus where the complex binds to distinct sites within the 
promoter of IFN-y responsive genes, e.g., the gamma-interferon activation site (GAS) and 
the interferon-stimulated response element (ISRE). This binding induces gene expression 
and the strength of the response of an IFN-y activated gene is, in part, dependent on the 
presence or absence of a positive-acting GAS or negative-acting silencing flanking sequence 
adjacent to the ISRE. A family of transcription factors, termed interferon regulatory factors 
(IRFs) recognise ISREs. IRFs are inducible by IFN-y (Sims et al., 1993) and, interestingly, 
TNF-a (Fujita et al., 1989). Of note is the induction of iNOS gene depends on IRF-1 
(Kamijo et al., 1994).
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Many genes, that are inducible by IFN-y are also inducible by TNF-a. This synergy is likely 
due to the fact that these genes contain an ISRE and an NF-kB-site in their promoter. Also, 
TNF-a can induce IRF-1 via the NF-KB-site within its promoter (Fujita et al., 1994) and 
IFN-y can activate NF-kB (Siebenlist et al., 1994). The anti-inflammatory cytokine, IL-4, 
exerts antagonistic actions on the induction of many genes induced by IFN-y (Boehm et al., 
1997), e.g., inducible nitric oxide synthase (iNOS) (Liew et al., 1991).
Relevance in IBD
The reports about IFN-y production in IBD are contradictory (Radford-Smith & Jewell, 1996). 
Decreased production by intestinal mucosal mononuclear cells in both forms of IBD was initially 
reported (Lieberman et al. 1988). Subsequent reports suggested particular relevance of this 
cytokine to CD, as indicated by the spontaneous release of IFN-y and increased IFN-y mRNA 
expression by lamina propria mononuclear cells (Fais et al. 1991) and the presence of IFN-y- 
secreting T cells in actively inflamed mucosa (Breese et al. 1993). In other reports, the 
production of IFN-y in peripheral blood mononuclear leukocytes of patients with IBD, was 
found to be the same as that in controls (Nakamura et al. 1992). Mitogen activation of peripheral 
blood mononuclear cells from IBD patients showed normal or decreased levels of IFN-y (Miura 
& Hiwatashi, 1985; Stalnikowiczetal. 1985; Mutchnick etal. 1988). However, in experimental 
models, inflamed colonic mucosa from mice lacking the G protein, Gai2, with colitis exhibited 




T-cell-derived cytokines IL-4, IL-10, and IL-13 are thought to have anti-inflammatory 
effects and changes in their production may be associated with the pathogenesis of IBD 
(Kucharzik et al. 1997).
(i) IL-10
Interleukin-10 is produced by a variety of cells including activated human T-cells. It is a potent 
suppressor of cytokine and chemokine generation by activated monocytes/macrophages (Moore 
et al., 1993; Hsu et al., 1990; Vieira et al, 1991; de Waal Malfyt et al., 1991; Fiorentino et al,
1991) and polymorphonuclear cells (PMNs) (Kasama etal., 1994). IL-10 mRNA expression is 
decreased in the majority of UC patients (Nielsen et al., 1996). IL-10 was able to down- 
regulate all proinflammatory cytokines in active IBD as well as in controls (Kucharzik et al., 
1996 and Murata et al., 1995) and IL-10 deficient mice were found to develop chronic 
enterocolitis (Kuhn et al. 1993; Rennick et al. 1997). In vivo topical application of IL-10 
induces down-regulation of proinflammatory cytokine secretion both systemically and 
locally (Schreiber et al., 1995).
(ii) IL-4 and IL-13
IL-13 is a potent suppressor of cytokine and chemokine expression by activated monocytes and 
macrophages (Minty et al., 1993; McKenzie et al., 1993; Zurawski and de Vries, 1994; de Waal 
Malefyt et al., 1993), and endothelial cells (Marfaing-Koka et al., 1995). In addition IL-13 
induces the production of IL-1 ra (Muzio et al., 1994) and modulates the expression of cell 
surface proteins such as class II MHC antigens (de Waal Malefyt et al, 1993). The results 
concerning IL-13 production in IBD patients are contradictory so far (Radford-Smith and
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Jewell, 1996). The inhibitory effect of IL-13 on TNF-a and IL- 6  production in 
differentiated macrophages was diminished in IBD patients and the anti-inflammatory 
activity of IL-13 was found to be partially reduced in patients with active IBD (Kucharzik et 
al., 1996). A more detailed discussion of IL-13 can be found in section 1.5.
Similar biological activities are also displayed by IL-4, in addition both cytokines are potent 
stimulators of B-cell IgE production, while IL-4 alone has an effect on human T-cells (Zurawski 
and de Vries, 1994). IL-4 mRNA expression is decreased in intestinal tissue from CD 
patients, while IL-10 mRNA expression is decreased in the majority of UC patients, 
suggesting different immunopathogenesis of the two diseases (Nielsen et al., 1996). 
Activated monocytes with increased expression of proinflammatory cytokines play a major 
role in IBD. It is interesting to note, therefore, that immunoregulatory cytokines such as IL- 
4 and EL-10 can effectively suppress the proinflammatory response of activated monocytes 
(Kucharzik et al., 1997). With regard to IL-13 and IL-4, there was no significant 
suppression of TNF-a and EL-6 in those patients with active IBD (Kucharzik et al., 1996), a 
finding compatible with an impaired systemic and mucosal anti-inflammatory activity in 
IBD.
Reactive oxygen and nitrogen metabolites in IBD
Abundant infiltration by PMN leukocytes has long been considered a hallmark of active IBD 
(Saxon et al., 1990), but the role of these cells in inflammation and tissue injury has not been 
investigated adequately. The contribution of PMNs to IBD pathogenesis has come under 
renewed attention after recognition that they are the main source of potent toxic molecules such 
as reactive oxygen metabolites (ROMs) and reactive nitrogen metabolites (C. Fiocchi, 1998). 
With the explosion of interest in nitric oxide as a crucial signalling and bioactive molecule in the
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gastrointestinal tract, its role in IBD has become the focus of a new investigation. There is 
evidence from animal models that ROMs are involved in gut inflammation (Keshavarzian et al.,
1990) and the same appears true for NO through the modulation of inducible NO synthase 
(Ribbons et al., 1995). Inhibition of inducible NO synthase by compounds such as L-arginine 
analogues can significantly decrease the extent and severity of tissue injury in experimental colitis 
(Rachmilewitz et al., 1995).
These findings from animal models may have parallel in human IBD. Chemiluminescence probes 
show large quantities of ROMs in the mucosa of patients with CD and with UC that correlate 
with disease severity (Simmonds et al., 1992). Elevated NO synthase activity was reported 
initially in UC but not CD colonic tissue, but subsequent studies showed that NO generation and 
synthase activity are increased in both forms of IBD (Boughton-Smith et al., 1993 and 
Rachmilewitz et al., 1995). Normal colonic epithelium does not express inducible NO synthase 
activity, but its expression is induced in the epithelium involved by IBD and other types of 
inflammation (Singer et al., 1996). The functional role of NO in IBD is far from settled in view 
of its dual toxic and protective effects (see section 1.4). A complementary aspect to the elevation 
of ROMs and NO in inflammation is the observation that IBD mucosa is relatively depleted of 
oxidant defences, rendering it susceptible to oxidative injury (Buffington et ah, 1995), and 
reactive metabolites cause direct epithelial cell damage in active IBD (McKenzie et al, 1996). 
This has led to the assumption that limiting production of these highly reactive molecules may 
improve IBD. Adding methylprednisolone to mucosal organ culture decreases NO activity 
(Rachmilewitz et al., 1995), and sulfasalazine, mesalamine and olsalazine have a scavenger effect 
on superoxide radical formation (Gionchetti et al., 1991). This indirectly suggests that some of 
the therapeutic effect of drugs commonly used in IBD is mediated by their antiradical activity.
Introduction 21
Apoptosis and IBD
Apoptosis is a process of controlled or programmed cell deletion or death and is important in 
regulating overall cell number in virtually all tissues undergoing cell replication, from 
invertebrates and developing embryos to adult normal and malignant tissues (A. H.Wyllie, 1987). 
It is also involved in the removal of damaged cells from the embryo or adult tissue and could be a 
determinant of carcinogenetic change within a tissue (Kerr et al., 1972). Cells in the human 
intestinal epithelium (i.e. the mucosal cells lining the gastrointestinal tract) undergo continuous 
turnover. Rapidly proliferating simple columnar epithelium is restricted to the crypts, which 
supply cells to replenish the differentiated cells on the surface of the large bowel. In the small and 
large intestines, new cells originate from stem cells located near the base of the crypts. These 
differentiate as they migrate away from the crypt base over the course of 3-7 days (Figure 1.3), 
finally undergoing apoptosis (programmed cell death, PCD) at the mucosal surface (Potten et al., 
1997). Apoptosis is a process of fundamental biological importance and will be discussed at 
greater length in section 1.6. Briefly however, it is suffice to say that there may be a role for 
dysregulated apoptosis in the pathogenesis of IBD, in that too much cell death could contribute 
to tissue injury and the disruption of intestinal barrier function resulting in increased permeability 
(Gardiner et al., 1998). A leaky barrier would intensify antigen absorption, which, in turn, could 
lead to an exaggerated immune stimulation reflected at the systemic level by an excessive number 
of mature B cells (C. Fiocchi, 1998). An increased frequency of epithelial apoptosis mediated 
by the CD95-CD95L system is seen in UC (Strater et al., 1997 and Iwamoto et al., 1996). 
Thus, colonic epithelial cell injury, resulting in impaired barrier function, could contribute to 
the pathogenesis of IBD (Gardiner etal., 1998).
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Figure 1.3. Schematic diagram summarising current views on distribution 
of stem cells, proliferative cells, apoptosis and some gene products affecting 
apoptosis in the large intestine. Arrows indicate approximate cell positions 
over which an indicated protein or feature is observed. Wedges indicate 
gradients of protein expression. * Observations made after irradiation. For 
more detail on gene products, see section 1.6. Adapted from Potten, 1997.
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Summary
The aetiology of IBD appears to be immunologically mediated and factors such as cytokines, 
reactive oxygen species and nitric oxide all with their inflammatory and regulatory properties 
appear to play a role in pathogenesis of UC and CD. These molecules have simultaneous 
protective effects that are important in the resistance to infectious agents and possibly in the 
healing phase of inflammation. The relative balance of the inflammatory and protective properties 
of the cytokine network may determine the chronicity of inflammation and the tendency of 
reactivation of these diseases.
Conclusions
Although the aetiology of IBD remains obscure, it seems most likely that environmental 
factors, for example dietary or microbial, trigger an inappropriate mucosal inflammatory 
response in individuals having a genetically abnormal immune system, or dysregulated gut 
permeability, or irregular mucus and/or colonocyte metabolism. Although the pathogenesis 
of IBD is gradually being elucidated, we remain ignorant of the mechanisms underlying the 
chronicity of mucosal inflammation and relapse of quiescent disease in those patients with 
IBD. For example, is chronicity due to persistence of an exogenous stimulus of 
inflammation, or to genetically defective down-regulation of the immune response 
(Podolsky, 1991)? Answers to these questions are a priority if major strides are to be made 
in the understanding of the pathogenesis of IBD, and in its treatment.
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1. 4 NITRIC OXIDE 
Background and Chemistry
During the 1980’s it was shown that vascular endothelial cells could produce a chemical 
that resulted in relaxation of the smooth muscle of the walls of the blood vessels. It has been 
demonstrated that this messenger, previously known as endothelium-derived relaxing factor, 
is nitric oxide (NO) (Ignarro et al., 1987).
NO is a fairly unreactive inorganic radical, which has diverse biological functions in the 
cardiovascular, nervous and immune systems. Once formed, NO diffuses to adjacent cells 
where it activates soluble guanylate cyclase, resulting in the formation of cGMP, which in 
turn mediates many, but not all, of the biological effects of NO. The specific activation of 
guanylate cyclase by NO is most likely due to its binding properties to iron hemes. The 
inherent lack of reactivity of NO makes it a fairly innocuous species unless it is coupled with 
other radical species, such as superoxide (0 2‘). This chemical property thus allows NO to be 
utilized as a physiological messenger molecule and, under certain conditions, as a cytotoxic 
effector molecule as well (J. M. Fukuto, 1995).
Primary reactions of NO (figure 1.4) can result in a variety of secondary products ranging 
from innocuous nitrate (NO3'), nitrite (N 02‘) and nitroxyl (NO') to reactive intermediates 
such as nitrosonium (NO+), peroxynitrite (ONOO') and nitrogen dioxide ( N 02). Reaction of 
NO with hydrogen peroxide yields singlet oxygen, which is highly toxic (Feldman et al.,
1993).
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Figure 1.4. Reaction products of NO with oxygen or reactive oxygen intermediates.
NO has been reported to inhibit critical iron-sulfur-containing enzymes involved in 
mitochondrial respiration , inhibit ribonucleotide reductase , cause ADP-ribosylation of 
proteins and damage DNA directly. In addition, the production of NO has been implicated 
in reoxygenation injury following ischaemia , glutamate-mediated neuronal toxicity , 
inflammation, graft-versus-host disease and as a major arm of host defense against viruses, 
bacteria and other intracellular parasites (Karupiah et al., 1993).
The number of reports suggesting that NO may promote inflammation-induced cell and 
tissue dysfunction equals the number of reports demonstrating that NO possesses potent 
anti-inflammatory properties. The reasons for these apparent paradoxical observations are 
not entirely clear, however the physiological chemistry of NO and its metabolites may 
provide clues to help distinguish between the regulatory/anti-inflammatory properties of NO 
and its deleterious/proinflammatory effects (Grisham et al., 1999 and figure 1.5).
Physiological aspects NO chemistry may be categorised into direct and indirect effects 
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Figure 1.6. Physiological chemistry of NO. RNOS, reactive nitric 
oxygen species.
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biological molecule or target and are thought to occur under normal physiological 
conditions when the rates of NO production are low. Generally, these types of reactions 
may serve regulatory and/or anti-inflammatory functions (Grisham et ah, 1999). Indirect 
effects are those reactions mediated by NO-derived intermediates such as reactive nitrogen 
oxide species derived from the reaction of NO with oxygen or superoxide and are produced 
when fluxes of NO are enhanced. These types of reactions may predominate during active 
inflammation. Thus, the relative rates of production, sites of production and steady-state 
concentrations of reactive species, antioxidants and tissue mediators critically influence the 
observed apparent toxic or protective effects of NO in biological systems (Crow and 
Beckham, 1995). The cellular and anatomic sites of production of 0 2' and NO as well as the 
dominant operative mechanisms of oxidant damage in tissues at the time of 0 2‘ and NO 
production, also profoundly influence expression of the differential oxidant injury-enhancing 
and protective effects of NO. Under pathological conditions NO can reach concentrations 
of 4 x 10'6 M, resulting in competition between 0 2' and NO for the actions of the enzyme 
superoxide dismutase (SOD) and, therefore, a fraction of 0 2' reacts with NO to produce 
peroxynitrite. ONOO' is a potent oxidant as well as a nitrating and hydroxylating agent. 
Tyrosine residues in proteins are readily nitrated by ONOO' due to the ability of SOD to 
selectively enhance nitration in complex media such as the milieu of a cell and nitrated 
proteins have been implicated in a number of diseases and conditions. This nitration 
pathway would inhibit tyrosine phosphorylation (Grisham et al., 1999) and may, in some 
circumstances, mimic phosphorylation in an irreversible manner. By introducing a negative 
charge onto tyrosine, nitration may alter protein conformation and function, perhaps 
‘tagging’ a protein for proteolysis. Also, nitrotyrosine structurally resembles dinitrophenol, 
a strongly antigenic compound used for making haptens and endogenous nitration may, 
therefore, initiate autoimmune processes. In addition, it has been shown that ONOO' reacts
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quite rapidly with zinc-thiolate centres such as those present in numerous transcription 
factors. Oxidation of such “zinc fingers” could dramatically alter their ability to recognise 
and bind DNA. Thus, ONOO' could exert significant effects on gene regulation. (Crow and 
Beckham, 1995).
Nitric Oxide Synthases
The nitric oxide synthases (NOSs) constitute a family with at least three distinct isoforms. 
These include the neuronal (nNOS, NOS1), inducible (iNOS, NOS2) and endothelial 
constitutive (ecNOS, NOS3) NOSs (Nathan and Qiao-Wen, 1994). The three isoforms are 
distributed across a wide spectrum of cell types and tissues. Furthermore, findings indicate 
that a cell may express more than one isoform of NOS (Salter et al., 1991), complicating 
the interpretation of NO derived from any given cell. The NOSs are P-450-like 
hemeproteins (Wang et al., 1993) with a reductase domain at the COOH terminus and an 
oxidative domain at the NH2 terminus (figure 1.7). The primary amino acid sequences of 
NOS isoforms share common consensus sequence binding sites for calmodulin, NADPH, 
flavin-adenine dinucleotide (FAD) and flavin mononucleotide (FMN) (Wang and Marsden,
1995). Each enzyme functions as a dimeric protein in catalyzing the NADPH-dependent 
five-electron oxidation of L-arginine to generate NO. L-citrulline is a by-product. Electrons 
are supplied by NADPH, transferred along the flavins and calmodulin and presented to the 
catalytic heme centre. The NOS apoenzyme requires tetrahydrobiopterin, prosthetic heme, 
calmodulin, FMN and FAD as cofactors for monomer assembly and/or catalytic activity 
(figure 1.8). The nNOS and ecNOS isoforms are constitutively expressed, but enzyme 
activation requires stimulation of the calcium/calmodulin signaling pathway. The synthesis 
and release of NO by constitutive NOS isoforms are rapid and do not depend on new 
protein synthesis. Calmodulin, in the presence of an elevated level of intracellular free
oxidative domain reductase domain
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Figure 1.7. Schematic alignment of the deduced amino acid sequences of nitric oxide symthases (NOSs) and the cytochrome P450 reductase. 
Depicted are consensus binding sites for heme, L-arginine, calmodulin (CaM), flavin mononucleotide (FMN), flavin-adenine dinucleotide 








Figure 1.8. Nitric oxide (NO) production from the amino acid L-arginine by the family of enzymes named nitric oxide synthases (NOS).
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calcium, activates constitutive NOS activity. In contrast, cytokines or lipopolysaccharide 
(LPS) stimulates the expression of iNOS over a period of many hours. This process is 
dependent on new mRNA and protein synthesis Szabo et al., 1995). Once it has been 
induced, this enzyme produces large amounts of NO and its activity is independent on 
intracellular calcium levels due, in part, to calmodulin being tightly bound to this enzyme. 
The iNOS gene is predominantly regulated at the level of transcription by synergistic 
combinations of proinflammatory cytokines and bacterial cell wall products (Morris and 
Billiar, 1994). Sequence analysis of the 5’-flanking region revealed consensus sequences 
that are implicated in cytokine-modulated gene expression, namely, NF-kB, NF-interleukin- 
6  (IL-6 ), y-IRE, a palindromic TNF-RE-like site and a liver-specific transcription factor 
consensus sequence, AABS. However, there appears to be much variation in the specific 
requirements of induction, not only between cell types, but also between cells of the same 
type in different mammalian species. For example, murine macrophages express high levels 
of iNOS upon exposure to bacterial LPS, with strong synergy occurring when IFN-y is 
added (Lorsbach et al., 1993), whereas IL-1 is a potent inducer in chondrocytes, smooth 
muscle cells, hepatocytes and islet cells (Geller et al., 1993).
NOS inhibitors
A number of strategies have emerged with regard to a pharmacological control of 
pathological NO production and new therapeutic approaches are studied, that may provide 
new means for clinical medicine (Pfeilschifter et a l, 1996). Since the various isoforms of 
NOS are distributed in cells and tissues according to their function, there is the possibility 
that manipulation of NO levels can be accomplished by designing specific pharmacological 
agents targeted at a single NOS isoform (Fukuto and Chaudhuri, 1995). Since the 
development of NO as a field of research, multiple NOS inhibitors have been utilised to
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characterise the functions of NO as well as attempt to therapeutically intervene in disease 
processes.
Based on early studies showing that N“-monomethyl-L-arginine (L-NMMA) blocked 
macrophage mediated L-arginine-dependent tumour cell cytostasis (Hibbs et al., 1987), a 
variety of N^-substituted-L-arginine derivatives have been investigated as potential 
inhibitors of NOS. ecNOS and iNOS. These show some differences in their affinity for N“- 
monosubstituted arginine analogues, which compete with L-arginine for binding sites in the 
NO synthase enzymes and inhibit their activity Gross et al., 1990 and 1991). Thus, N“- 
nitro-L-arginine (L-NNA) and N“-amino-L-arginine (L-NAA) are more potent inhibitors of 
ecNOS and iNOS, respectively, while N“-monomethyl-L-arginine (L-NMMA) was found to 
be an effective inhibitor of both NOS types. The L-arginine analogues are selective 
inhibitors of NOS activity, in comparison to other known inhibitors (Knowles and Moncada,
1994).
NG-monomethyl-L-arginine (NMMA) is an amino acid NOS inhibitor, which is recognised 
by and associates with the substrate binding site for L-arginine (Griffith and Kilbourn, 
1996). It is a reversible, competitive inhibitor, which, at 0.1-1.0 mM, is able to inhibit all 
NOS isoforms substantially, but not completely (>50 %; usually >90 %, depending on levels 
of L-arginine in the medium).
In 1992 amino guanidine was described as an inhibitor with high selectivity for iNOS 
(Corbett et al, 1992). Subsequently, aminoguanidine was shown to be as potent as L- 
NMMA in inhibiting the cytokine-mediated expression of iNOS in cultured insulinoma cells 
(Hasan et al, 1993). In contrast to L-NMMA, which has been shown to be a competitive
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inhibitor, it has not been established whether aminoguanidine inhibits iNOS in a competitive 
manner. Aminoguanidine (AG) is a nucleophilic hydrazine compound that contains 
chemically equivalent guanidino nitrogens. It is believed that the hydrazine moiety is 
essential for its selectivity for iNOS without affecting ecNOS (Corbett and McDaniel,
1996). The hemisulfate form is freely soluble in aqueous solution and was the chemical form 
used in these experiments. Both AG and NMMA display nearly identical inhibitory effects 
on iNOS activity and are readily taken up by whole cells (Corbett and McDaniel, 1996).
Garvey et al, 1997, showed N-(3-(Aminomethyl)benzyl)acetamidine (1400W) to be a slow, 
tight binding inhibitor of human iNOS. 1400W is a highly selective inhibitor of iNOS in 
vitro and in vivo (Knowles et al, 1997). Inhibition was either irreversible or extremely 
slowly reversible and 1000-fold selective for iNOS versus ecNOS. The inhibition of ecNOS 
was rapidly reversible and, thus, relatively inefficient. This inhibitor shows potential as a 
new therapeutic agent.
NOS and IBD
In the gastrointestinal tract, NO synthesis has been shown to be increased in colonic mucosa 
from patients with ulcerative colitis (Middleton et al., 1993 and Boughton-Smith et al., 
1993) and leukocyte derived NO has been found to induce colonic circular smooth muscle 
relaxation (Middleton et al., 1991). Active ulcerative colitis is associated with increased 
vascular permeability and mucosal vasodilatation. In fulminant ulcerative colitis impaired 
colonic motility is associated with toxic megacolon, which may lead to perforation 
(Boughton-Smith, 1994). The generation of high levels of NO by the inflammatory stimuli- 
induced iNOS in the intestinal mucosa and the subsequent formation of reactive products 
could underlie all these features (Moncada and Higgs, 1993). Indeed, it has been 
demonstrated that epithelial cells of the colonic mucosa derived from patients with
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ulcerative colitis are a rich source of iNOS (Singer et al., 1996 and Kolios et a l,  1998). 
This correlates with the increase in pro-inflammatory cytokines and suggests a specific role 




Interleukin -13 (IL-13) is a pleiotropic cytokine that is secreted by activated Th2 cells with 
immunoregulatory activities that partially overlap those of IL-4 (Minty et al., 1993 and 
McKenzie et al., 1993). In B-lymphocytes, IL-13 induces proliferation and differentiation, 
promotes CD23 expression and production of certain immunoglobulins such as IgG and IgE 
(Cocks et al., 1993; Deffance et al., 1994 and Punnonen et al., 1993). In monocytes, IL-13 
induces morphological changes (McKenzie et al., 1993), up-regulates expression of 
members of the integrin superfamily and MHC class II antigen expression and down- 
regulates expression of CD 14 and FcyR receptors (Malefyt et al., 1993). In 
lipopolysaccharide-stimulated monocytes, IL-13 also acts as a suppressor of pro- 
inflammatory cytokines (eg. TNF-a, IL-1 and IL-6 ), chemokines (eg. IL-6 , macrophage 
inflammatory protein-la) and hematopoietic growth factors (eg. granulocyte/macrophage- 
colony stimulating factor, granulocyte-colony stimulating factor) expression by activated 
monocytes/macrophages or endothelial cells (Minty et al., 1993 and Malefyt et al., 1993). 
Another target for IL-13 is epithelial cells and it has recently been demonstrated that IL-13 
can modulate IL- 8  generation from and inhibit iNOS and COX-2 expression in the human 
colonic epithelial cell line, HT-29 (Kolios et al., 1996 and 1998 and Jobin et al., 1998). In
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addition, IL-13 induces IL-lra (Yanagawa et al., 1995) and inhibits PKC-triggered 
respiratory bursts (Sozzani et al., 1995).
Interestingly, IL-13 also exhibits pro-inflammatory functions. For example, IL-13 can 
activate and inhibit apoptosis in eosinophils (J. E. de Vries, 1998). It induces tissue 
inflammation, mucous hyperproduction, goblet cell hyperplasia, subepithelial airway 
fibrosis, crystal deposition, airways obstruction and airways hyperresponsiveness (Zhu et 
al., 1999). Blockade of IL-13 completely reverses allergen-induced AHR by the reversal of 
allergen-induced increases in mucous-containing cells in the airways (Wills-Karp et al.,
1998).
Receptor structure
Little is currently known about IL-13 signal transduction, although evidence points to 
similarities with IL-4 signal transduction. For instance, IL-13 can cross-compete with IL-4 
for binding, leading to the suggestion that their receptors (IL-4R and IL-13R) share a 
common component (Zurawski et al., 1993). Both the IL-4R a  chain and the common y 
chain subunit have been proposed as likely candidates, (Kondo et al., 1993; Russell et al., 
1993; Obiri et al., 1995 and 1997 and Welham et al, 1995). A common receptor may 
explain the observations that IL-4 can mimic every cellular response mediated by IL-13. 
This is typified in a model of experimental asthma, whereby the asthmatic phenotype is IL- 
13-dependent and IL-4-independent, but the functional outcome is mediated by the IL-4Ra 
chain (Griinig et al., 1998). In contrast, human T cells and mouse T and B cells respond to 
IL-4, but not to IL-13 (Callard et al., 1996).
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More recently, two different EL-13R chains have been cloned (Hilton et a l, 1996 and 
Miloux et al., 1997). The IL-13Ral is a 65-70 kDa protein and has a 50% homology to IL- 
5R a  chain on a DNA level (Caput et al., 1996). Alone, this receptor binds IL-13 with low 
affinity, but when complexed with the IL-4Ra chain, shows high affinity binding for both 
IL-13 and IL-4. IL-13Ra2 binds IL-13 with high affinity (Caput et al., 1996 and Donaldson 
et a l, 1998), although its involvement in signal transduction has not been shown, possibly 
due to a short cytoplasmic tail. It has been detected in a soluble form, possibly shed from 
cells (Zhang et al., 1997), but its role in IL-13 biology has not been determined. Thus, there 
are four potential IL-13R complexes, formed by IL-13Ra21, IL-13Ra2, IL-4Ra and y 
chain (Obiri et al., 1997). The type of receptor expressed depends upon the cell and which 
of the possible receptor components are present. As a result, different cells can display 
different binding properties for IL-13 and IL-4 (see Table 1.2). A simplified view is depicted 
in figure 1.9.
Table 1.2 Interleukin-13 Receptor Complexes. For references to the data presented in the 
table, see text and Obiri et al., 1995 and 1997 and Zurawski et al., 1993 and 1995.
Ligand-Binding Properties
IL-13R Complex Example IL-4 IL-13
IL-13Ral, IL-13Ra2 RCC and U251 cells no competition competes with
with IL-13 IL-4
IL-13Ral, IL-4a Cos-7, A431 and competes with high affinity;
Colo201 cells IL-13 competes with IL-4
IL-13Ral, IL-4Ra, TF-1 cells competes with competes with IL-4
y chain IL-13
IL-13Ral (low levels), Raji and binds well to limited binding; no
IL-4Ra, y chain MLA-144 cells all chains competition with IL-4
eg. Monkey fbroblasts COS-7, 
human epidermoid carcinoma A431, 
human ovarian cancer PA-1, 





Type I I IL-13R 
eg. renal cell carcinoma cell line RCC, 
glioblastoma cell line U251, 
ovarian cancer cell line IGROV-1.
IL-13oc2 IL-13ocl/2
Figure 1.9. IL-13 receptor structure model. In the first model, IL-13R may be 
composed of heterodimeric proteins of IL-13Ral and the 140 kDa IL-4Ra chains 
(4a). Both IL-4 and IL-13 bind to both proteins; however, there is barely detectable 
IL-13 binding to 4a, while IL-4 binding to a l  is strong and can be detected by cross- 
linking. Because of the conformation, both IL-4 and IL-13 can cross-compete for each 
other’s binding. In the second model, IL-13 binds to two 65-70 kDa isomers (a l and 
a2) and one of these (a l)  also binds to IL-4. In this arrangement, IL-13 will have 
greater binding affinity to a l  than IL-4. Thus, IL-13 can compete for 125I-IL-4 
binding; however, IL-4 cannot compete for the 125I-IL-13 binding. It is conceivably 
possible that there could exist a homodimer of a 2 , although this has not been shown.
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Receptor signalling
The receptors for IL-13 belong to the haemopoietic receptor family, which lack intrinsic 
tyrosine kinase activity. Unlike other cytokines, IL-4 and IL-13 do not induce tyrosine 
phosphorylation of the adaptor protein She or its association with Grb-2 and they do not 
activate the mitogen-activated family of protein kinases such as Erk 1 and 2 (Welham et al., 
1995). However, Janus family kinases (JAKs) and Signal Transducers and Activators of 
Transcription (STATs) have been shown to be significant signal transduction components of 
cytokine receptors (Lin et al., 1995 and J. Ihle, 1996).
Four members of the Jak (Janus kinase or Just another kinase) family have been identified: 
Jakl (135 kDa), Jak2 (135 kDa), Jak3 (120 kDa) and Tyk2 (140 kDa). Jakl, Jak2 and 
Tyk2 are all ubiquitously expressed while Jak3 is found in myeloid cells, natural killer cells 
and T lymphocytes (J. Ihle, 1996). The Jak proteins consist of 7 Jak homology (JH) 
domains. JH1 is the kinase domain and contains an important KDYY (Jak3) or KEYY 
(Jakl, 2 and Tyk2) domain in the catalytic core. Phosphorylation of this site has been 
associated with an increase in catalytic activity (Hanks et al., 1998; Feng et al., 1997). 
Indeed, the EL-4Ra chain associates with JAK1, whilst the common y chain associates with 
JAK3 and both are required for IL-4 activation of STAT6  (Linn et al., 1995; Ihle et al., 
1995; Hou et al., 1994; Palmer-Crocker et al., 1996 and Rolling et al., 1996). Jakl, Tyk2 
and STAT6  are also activated by IL-13, but JAK3 is not (Welham et al., 1995).
IL-4 and IL-13 share the ability to induce phosphorylation of several cellular proteins. 
These include the IL-4a chain itself (Welham et al., 1995 and Smerz-Bertling and Duschl,
1995) and a pl70 protein (Welham et al., 1995; Lefort et al., 1995 and Wang et al., 1995), 
recently identified as insulin receptor substrate-2 (IRS-2) (Sun et al., 1995). IRS-2, like its
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homologue IRS-1, contains multiple specific YXXM motifs which, after tyrosine 
phosphorylation, may bind the SH2 domains of the p85 regulatory subunit of the protein 
tyrosine kinase/SH2-coupled phophatidylinositol (PI) 3-kinase (Sun et al., 1995 and 
Songyang et a l, 1993). Indeed, several groups have shown that phosphorylation of the 
p i70 kDa protein results in its tight association with phosphatidylinositol (PI) 3-kinase 
following IL-4 and IL-13 treatment (Welham et al., 1995; Lefort et al., 1995 and Izuhara 
and Harada, 1993).
The specific role of each receptor chain in IL-13 signalling is unclear. Donaldson et al., 
1998 observed that Ba/F3 cells transfected with IL-13Ral displayed a mitogenic response 
to IL-13, but cells transfected with mouse IL-13Ra2 did not. A soluble EL-13Ra2/Fc fusion 
protein blocked the mitogenic response to IL-13. They suggested that IL-13Ra2 could 
serve as a dominant negative inhibitor or decoy receptor for IL-13. Wills-Karp et al., 1998 
found that administration of IL-13 was sufficient to induce airway hyper-responsiveness 
(AHR), which was found in allergic asthma. In vivo administration of soluble IL-13Ra2 
completely reversed IL-13-mediated AHR. Griinig et al., 1998 found that neutralisation of 
IL-13 activity prevented development of experimental asthma. Both human IL-13Ral and 
IL-13Ra2 genes are located on the X chromosome (Donaldson et al., 1998, possibly 
suggesting a role in X-linked immune diseases. Research focussing on IL-13 and the IL-13R 
complex could have significant impacts into the understanding and treatment of X-linked 
immune diseases, allergen-induced asthma and experimental asthma.
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1.5 PHOSPHATIDYLINOSITOL 3-KINASE 
Structure and Function
Phosphatidylinositol-3 kinases (PI 3-kinases) are a growing subfamily of lipid kinases that 
catalyse the addition of a phosphate molecule to the hydroxyl group at the 3-position on the 
inositol ring of phosphoinositides. Phosphatidylinositol (PI), the precursor of all 
phosphoinositides, constitutes less than 1 0 % of the total lipid in eukaryotic cell membranes 
(figure 1.10). However, less than 0.25% of the total inositol-containing lipids are 
phosphorylated at the 3-position, consistent with the idea that these lipids exert specific 
regulatory functions inside the cell, as opposed to a structural function (Rameh and Cantley,
1999). To date, nine members of the PI 3-kinase family have been isolated from mammalian 
cells. They are grouped into three classes, according to the molecules that they 
preferentially utilise as substrates (figure 1.11), as suggested by Domin and Waterfield, 
1997. Four different lipid products can be generated by the different PI 3-kinase members: 
PI 3-monophosphate (P), PI-(3,4)-bisphosphate (P2), PI-(3,5)-bisphosphate (P2) and PI-
(3,4,5)-trisphosphate (P3), respectively (figure 1.10).
PI 3-kinase was first described as a PI kinase activity associated with the viral oncoproteins, 
v-Src, v-Ros and polyomavirus middle T (Sugimoto et al., 1984). Mutational studies more 
than 10 years ago indicated a critical role for the associated PI kinase in cell transformation 
(Courtneidge and Heber, 1987). Subsequent work has confirmed a role for PI 3-kinases and 
their products not only in growth regulation, but also in various other cellular responses, 
such as membrane ruffling, chemotaxis and glucose transport (Wennstrom et al., 1994; 
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Figure 1.10. The pathways for PI synthesis. The orange boxes indicate the PI 3-kinase products. The classes of PI 
3-kinase enzymes that catalyse the phosphorylation of the different PI 3-kinase substrates are indicated on top of the 
horizontal arrows. Class I enzymes include Class IA and Class IB. Kin, kinases; Ptase,phosphatases. Adapted from 
Rameh and Cantley, 1999.
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Figure 1.11. The classification of PI 3-kinase family members. The assignment of catalytic subunits to a particular class is based on sequence 
homology within the catalytic domain (Zvelebil et al, 1996). To date, PI 3K-C2a is the only class II member which has been shown to 
phosphorylate PI(4,5)P2. PI3K_68D is a Drosophila protein whilst m-cpk and p i70 are murine proteins. The yeast enzyme Vps34p and its 
human homo;ogue PI 3-kinase can only phosphorylate PI (Volinia et al, 1995). The C2 domain was originally defined as the second of four 
regions within mammalian PKC where it conferred a Ca2+ sensitive phospholipid binding (Kaibuchi et al, 1980). *  p85-interaction region in 
class IA enzymes. Adapted from Domin and Waterfield, 1997.
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findings that PI 3-kinase activation prevents cell death (Franke and Cantley, 1997) have led 
to increased interest in these enzymes.
There are three classes of PI 3-kinases:
Class I
These PI 3-kinases phosphorylate the phospholipids PI, PI-(4)-P and PI-(4,5)-P2, although 
their preferred substrate is thought to be PI-(4 ,5 )-P2. This class interacts with active GTP- 
bound Ras and forms heterodimers with adapter proteins (Rodriguez-Vicinia et al., 1994; 
Kodaki et al., 1994; Rodriguez-Vicinia et al., 1996; Vanhaesebroeck et al., 1997 and Marte 
et al., 1997). They can be divided into two types (Class IA and I b )  according to the nature 
of the interactions with adapter proteins (figure 1.11). The prototypical Class IA PI 3-kinase 
consists of an 85 kDa regulatory subunit, which is responsible for the protein-protein 
interactions via SH2 domain-phosphoprotein interactions, and a catalytic 110 kDa subunit. 
There are several isoforms of the catalytic subunit and they include the mammalian pi 10a, 
(3 and 8  which interact with the regulatory subunits (or p85 proteins, based on the molecular 
weight of the first two isoforms, a  and p). There is no evidence that different regulatory 
subunit isoforms pair preferentially with different pi 1 0  isoforms, however, it may be that 
different p85 subunits may associate with different subsets of intracellular proteins 
(Vanhaesebroeck et al., 1997). Class IB PI 3-kinase consists of a distinct p i 10 catalytic 
subunit that is stimulated by G-protein py subunits, designated pllOy (Stoyanov et al.,
1995). This isoform contains a PIK domain, a kinase domain and a ras-binding domain, but 
does not interact with p85 proteins. A putative regulatory subunit, plOl, has been found 




This class of PI 3-kinases are larger (>200kDa) and phosphorylate only PI and PI 4-P. 
They contain a synaptotagmin (synaptic vesicle membrane protein) C2 domain in their C- 
terminal region, which is involved in the Ca2+-dependent binding of proteins to lipid vesicles 
(A. C. Newton, 1995). However, certain Asp residues important for Ca2+ binding are absent 
in the C2 domains of class II PI 3-kinases and phospholipid binding is Ca2+-independent 
(MacDougall et al., 1995).
Class III
These PI 3-kinases have a substrate specificity restricted to PI and are homologous to the 
yeast Vps34p. Vps34p is essential for the trafficking of newly formed proteins from the 
Golgi to vesicles (Herman et al., 1992 and Shepherd et al., 1996). These PI 3-kinases also 
appear as heterodimers. Vsp34p forms a complex with a 170 kDa serine/threonine kinase 
Vspl5p which activates Vsp34p and recruits it to the membrane (Herman et al., 1992). 
Similarly, human Vps34p associates with a p i50 that serves to target PI 3-kinase to a 
perinuclear position. The current hypothesis is that the class III PI 3-kinases and their 
PI(3)P lipid product fulfill a housekeeping role in constitutive membrane trafficking and 
vesicle morphogenesis (De Camilli et al., 1996; Herman et al., 1992 and Shepherd et al.,
1996), although class I and II enzymes also have a function in vesicular trafficking, eg., in 
post-endocytic sorting of ligand-stimulated receptors.
Regulation of D-3 PI lipids
The metabolism of the PI 3-K lipid products is an important point of regulation and 
evidence indicates that they are not susceptible to hydrolysis by known isoforms of 
phospholipase (PL) C (Serunian et al., 1989), however, recent evidence suggests there is
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regulation at the level of PI(3,4,5)P3 by three distinct cytosolic isozymes of Pi-specific 
PLDs (Ching et al., 1999) that convert PI(3 ,4 ,5 )P3 to Ins(3,4,5)P3 and phosphatidic acid. 
More commonly accepted is the notion that different types of lipid phosphatases mediate the 
major degradative pathway via dephosphorylation. For example, there exist multiple 
inositide polyphosphate 5-phosphatases that transform PI(3,4,5)P3 to PI(3,4)P2, through 
which the ratio of these two lipid second messengers is controlled. These enzymes include 
PI(3,4,5)P3 5-phosphatases (Jackson et al., 1995 and Woscholski et al., 1995), SHIP (SH2- 
containing inositol 5-phosphatase), (Damen et al., 1996; Lioubin et ah, 1996 and Drayer et 
al., 1996) or SIP (signalling inositol polyphosphate 5-phosphatase) (Kavanaugh et al.,
1996) and synaptojanin (Woscholski et al., 1997). Especially noteworthy is the recent 
finding that the tumour suppressor protein, PTEN, is a 3-phosphatase that dephosphorylates 
PI(3,4,5)P3 (Maehama et al., 1998), thus terminating the second messenger activities of 
PI(3,4,5)P3 by converting it to PI(4,5)P2.
Class IA PI-3-kinases
Structure
Three mammalian class IA PI 3-kinases have been identified to date, pi 10a and p i 10(3 (Hu 
et al., 1993) appear to be ubiquitously expressed while pi 106 (Vanhaesebroeck et al.,
1997) is exclusively found in leukocytes. The pi 10 subunits are llOkDa proteins that 
interact with the p85 adapter subunits through amino acids 20-108 of their N-terminal 
domain (Dhand et al., 1994). As mentioned earlier, they contain a ras-binding domain and a 
C-terminal lipid kinase core. In addition to their lipid kinase activity class IA PI 3-kinases 
also possess serine/threonine protein kinase activity. The regulatory p85 subunit is a 
substrate of this kinase activity and phosphorylation on ser 608 results in a marked decrease 
in PI 3-kinase’s kinase activity (Dhand et al., 1994; Carpenter et al., 1993). Interestingly,
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unlike p85 a/p, p i 108 is unable to phosphorylate p85 but undergoes autophosphorylation, 
which inhibits its lipid kinase activity (Vanhaesebroeck et al., 1997). A schematic 
representation of the PI 3-kinase subunits is shown in figure 1.11.
There are two mammalian isoforms of the p85 adapter subunit a  and p. These 85kDa 
proteins contain two Src homology (nSH2 and cSH2) regions linked by an inter-SH2 
domain (iSH2), a Src homology 3 (SH3) domain and a break point cluster region (BCR). 
SH2 domains mediate protein-protein interactions by binding phosphotyrosine residues 
within a pYXXM motif (Pawson et al., 1995). However, coupling PI 3-kinase can be 
mediated through other motifs in T cells (Ward et al, 1996). Amino acid residues 479-513 
in the inter-SH2 domain have been shown to be the region of p85 that interacts with the 
pi 10 subunit (Dhand et al, 1994a; Dhand et al., 1994b; Klippel et al., 1993). The roles of 
the SH3 and BCR domains are not well defined. SH3 domains bind proline rich regions 
containing the motif PXXP and, like SH2 domains, are thought to mediate protein-protein 
interactions. Interestingly, activation of PI 3-kinase via the SH3 domains binding to one 
pro line-rich region (residues 84 to 99) of p85 has been reported (Pleiman et al., 1994).
Receptor Coupling to PI 3-kinase
(i) Direct coupling
The SH2 domains of the p85 regulatory subunit control receptor coupling to PI 3-K. These 
domains have a high selectivity for binding phosphorylated YXXM sequences, which are 
present on activated growth factor receptors, such as the PDGF-R. This is followed by an 
increase in the catalytic activity of the pi 1 0  subunit and also targets the signalling complex 
to the cellular membrane where the PI 3-K substrates are located, although the precise 
mechanism by which catalytic activity is increased is not fully understood. In the case of
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PDGF, binding of ligand to the receptor results in receptor autophosphorylation on tyrosine 
residues in the YXXM motif of the interkinase domain. PI 3-K is activated following the 
interaction of p85 SH2 domains with these phosphotyrosine residues (Escobedo et al, 
1991; Kazlauska et al, 1990; Coughlin et al, 1989).
(ii) Adapter-mediated coupling
PI 3-K is activated in response to a number of growth factors including IL-3, IL-4, SCF, 
GM-CSF and IL-5 (Gold et al, 1995). The receptors for these growth factor do not contain 
YXXM docking sites for p85 SH2 domains. Instead they use adapter proteins to target p85 
to the receptor complex, thus activating PI 3-K. For example, insulin activates PI 3-K by 
recruiting it to the receptor via the insulin receptor substrate (IRS) proteins. IRS-1 (Sun et 
al, 1991) and IRS-2 (also known as 4PS) (Sun et a l, 1995) associate with and are 
phosphorylated by the intrinsic insulin receptor in the YXXM motif upon activation. This 
forms a site for p85 SH2 domain association leading, ultimately, to the activation of pi 10 
catalytic subunit (Backer et al, 1992).
Like insulin and also insulin-like growth factor 1 (IGF-1), IL-4 utilises the IRS proteins to 
target p85 SH2 domains and activate PI 3-K. IL-4 stimulation of T-lymphocytes results in 
complex formation of Jakl with both IL-4R and IRS2 and the phosphorylation of all these 
proteins {Yin et a., 1994). Studies in the haemopoietic cells line FDCP-2 found PI 3-kinase 
activity associated with the phosphorylated 170kDa IRS-2 protein after IL-4, insulin and 
IGF-1 stimulation (Wang et al, 1992). When IRS-1 was transfected into these cells it was 
rapidly and transiently phosphorylated by all three growth factors indicating that IL-4 can 
also signal through IRS-1 (Wang et a l, 1993). In common with the receptors for insulin 
and IGF-1, IL-4R contains an I4R motif (PLX4NPXYXSXSD) in the juxtamembrane
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region, which has been implicated in IRS binding to these receptors. Mutation of Y497 to 
phenylalanine blocked IL-4-induced IRS-1 phosphorylation and proliferation in IRS-1 
transfected 32D cells (Keegan et al., 1994). Taken together, these data point to a 
mechanism for IL-4 activation of PI 3-kinase, whereby IL-4 binding to the IL-4R results in 
activation of Jakl and its subsequent phosphorylation as well as receptor phosphorylation 
on a number of tyrosine residues including Y497 in the I4R domain. This creates a receptor 
binding site for IRS-1 and results in phosphorylation in the YXXM motif which is 
recognised by the p85 adapter subunit SH2 domains, thus activating the p i 10 catalytic 
PI3K subunit.
Targets of D-3 PI Lipids
It is generally hypothesised that PI 3-kinase lipid products interact with certain proteins and 
modulate their localisation and/or activity. The recent characterisation of protein modules, 
such as pleckstrin homology (PH) domains (Haslam et al., 1993), which can bind lipids, 
supports this view. Many of the reported downstream effectors of PI 3-kinase contain PH 
domains. These include PKB (Klippel et al., 1997), PLCyl (Falasca et al., 1998), tyrosine 
kinases such as ITK (August et al., 1997) and Bruton’s tyrosine kinase (Salim et al., 1996) 
and the guanine nucleotide exchange factor Vav (Han et al., 1998). Of the number of 
putative downstream targets of PI 3-kinase, a key few will be discussed below.
(i) Protein Kinase B
Protein kinase B (PKB, also known as Akt and Rac) was identified in 1991 by three 
independent groups. Two of these (Jones et al., 1991; Coffer and Woodgett, 1991) 
identified PKB from it’s homology to PKA and PKC hence the names were coined PKB and 
RAC (related to A and C). The third group (Bellacosa et al., 1991) isolated the cellular
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homologue of the vAkt, an oncogene from AKT8 , an acute transforming retrovirus isolated 
from a rodent T-cell lymphoma. PKB is a serine/threonine kinase that has 6 8 % and 73% 
homology to PKA and PKC, respectively. Three isoforms have been identified PKB a  (Jones 
et a l , 1991; Coffer and Woodgett, 1991; Bellacosa et al., 1991), PKBp (Cheng et al, 
1992) and PKBy (Konishi et al, 1995a) which have approximately 80% homology. PKBa 
and P encode 60kDa proteins and PKBy is 55kDa due to a truncated C-terminus. Both 
PKBa and p appear to be ubiquitously expressed (Konishi et al, 1995b), while PKBy is 
found predominantly in the brain and testis and is absent from liver and kidney (Konishi et 
al, 1995a).
All three isoforms contain an N-terminal pleckstrin homology (PH) domain (residues 1- 
166). PH domains bind the charged headgroups of phosphatidylinositols and are thought to 
be involved in mediating interactions with both phospholipids and other proteins. The PH 
domain is within a region often referred to as the AH (Akt homology) region which spans 
residues 1-148. The catalytic serine/threonine kinase domain (residues 148-412) lies 
between the AH domain and the C-terminal tail region.
Activation of PKB
PKB is activated in response to a number of growth factors. These include PDGF (Franke 
et a l, 1995), insulin (Cross et a l, 1995; Kohn et al., 1995) EGF, bFGF (Burgering et al.,
1995), IL-3, (Franke et a l, 1995; Burgering et al., 1995; Songyang et a l, 1997; del Peso et 
al., 1997; Datta et a l, 1997; Scheid and Duronio, 1998). Activation of PKB is inhibited by 
the PI 3-kinase inhibitors wortmannin and LY294002 (Franke et a l, 1995), as well as a 
dominant negative PI 3-kinase mutant (Ap85), (Burgering and Coffer, 1995). Klippel et al.,
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1997 indicate that the growth factor induced activation of PKB is mediated through lipid 
products of PI 3-kinase.
Both phosphorylation and the PH domain appear to be important for growth factor induced 
activation of PKB. In response to growth factor treatment PKB is phosphorylated on T308 
(T309 in PKBp and T309 in PKBy) in the kinase loop and S473 (S474 in PKBp, there is no 
corresponding site in PKBy due to it’s truncated C-terminal) in the C-terminal tail region 
(Alessi et al, 1996). Mutation of these residues to alanine inhibit the growth factor induced 
PKB activation while mimicking the negative charge of the phosphate group by mutation to 
aspartate results in PKB activation in unstimulated cells.
A kinase which phosphorylates PKB on T308 has been identified and named PDK1 (PI-
(3,4,5)-P3 dependent kinase-1) (Alessi et al, 1997). PDK1 is a 63 kDa PH domain 
containing protein, which is ubiquitously expressed. It is dependent on the PI 3-kinase lipid 
products PI (3,4) P2 and PI (3,4,5) P3 for activation. A kinase (referred to as PDK2) is 
thought to phosphorylate S473 in vivo is yet to be identified, although MAPKK2 is able to 
phosphorylate this site in vitro but is unlikely to do so in vivo (Alessi et al., 1996). 
Balendran et al., 1999 have presented evidence that PDK1 can be converted to a form that 
phosphorylates both S473 and T308 via interaction with a small peptide corresponding to 
the carboxy-terminal region of protein kinase C-related protein kinase-2 (PRK2). These 
observations suggest that PDK1 and PDK2 may be the same enzyme, the specificity of 
PDK1 towards T308 and S473 being regulated through its interaction with other cellular 
components (Balendran et a l, 1999).
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The PH domain is essential for the activation of PKB in a number of systems (Datta et al, 
1996; Franke et al, 1997; Datta et al, 1995; Andjelkovic et al, 1996) but in some systems 
it does not appear necessary (Kohn et al, 1996). The PH domain binds with high affinity 
and specificity to both PI (3,4) P2 and PI (3,4,5) P3 (Franke et al, 1997), although the 
interaction with PI (3,4) P2 is about ten-fold weaker (James et a l, 1996). The oncogene 
vAkt is located at the cell membrane due to an N-myristylated gag fusion and is 
constituatively active (Bellacosa et al, 1991). Targeting PKB to the cellular membrane by 
the fusion of the src myristylation sequence results in the constitutive activation of PKB and 
the phosphorylation of both T308 and S473 (Kohn et al, 1996). Therefore, binding of the 
PH domain to the phospholipids in the cell membrane is thought to mediate the 
translocation of PKB to the membrane and alter the conformation of PKB, allowing access 
of its kinases to phosphorylation sites (J. Downward, 1998 and Alessi and Cohen, 1998). 
PDK1 also binds both phospholipid products of PI 3-kinase through its PH domain 
(Anderson et a l, 1998), thus targeting this kinase to the membrane into proximity of PKB, 
facilitating its activation (figure 1 .1 2 ).
Downstream Effects of PKB
PKB phosphorylates serine and threonine residues which lie within the consensus sequence 
RXRZYS/THyd, where Y and Z are small residues (not G), X is any amino acid and Hyd is 
a bulky hydophobic residue (Alessi et al, 1996). Direct downstream substrates of PKB that 
have been identified to date are listed in Table 1.3 below. The glycogen synthesis 
upregulator glycogen synthase kinase-3 (GSK-3) (Cross et a l, 1995) and the proapoptotic 
Bcl-2 family member Bad (del Peso et a l, 1997; Datta et a l, 1997; Scheid and Duronio,
1998) were the first targets to generate interest in the role of PKB in cellular function and 











Figure 1.12. The mechanism of activation of PKB. Stimulation of PI 3-kinase leads 
to an increase of PI (3,4,5) P3 at the plasma membrane. PKB then interacts with PI
(3,4,5) P3 and/or PI (4,5) P2, the immediate breakdown product of PI (3,4,5) P3, 
through its PH domain, and is thus recruited from the cytosol to the plasma 
membrane. The interaction of PKB with PI (3,4,5) P3 alters its conformation so that 
Thr308 and (perhaps) Ser473 becomes accessible for phosphorylation by PDK1 and 
PDK2, respectively. Phosphorylation at Thr308 and Ser473 activates PKB. The 
existence of PDK2 is hypothetical. P, phosphorylation. Adapted from Alessi and 
Cohen, 1998.
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1995; Shaw et al., 1997). Inactivation of GSK-3 results in the activation of glycogen 
synthase and the subsequent increase in glycogen synthesis.
PKB has been implicated in providing cells with a survival signal. Studies using PI 3-kinase 
inhibitors and mutants have shown this signal to be mediated through PI 3-kinase (Dudek et 
al., 1997; Kauffmann-Zeh et al., 1997; Kennedy et al., 1997; Songyang et al., 1997; 
Khwaja et al., 1997). The second direct substrate of PKB, Bad, is a member of the Bcl-2 
family of proteins, which are intracellular regulators of programmed cell death (apoptosis). 
When phosphorylated on a critical serine residue (136Ser) by PKB, Bad is then bound 
preferentially to a cytosolic protein termed 14-3-3 (Zha et al., 1996). This sequestration of 
Bad by phosphorylation results in the loss of its pro-apoptotic activity (Datta et al., 1997). 
The protease, caspase 9, is phosphorylated by PKB, which suppresses its pro-apoptotic 
function (Cardone et al., 1998).
If PKB is a central mediator of cell survival, it may phosphorylate and regulate the activity 
of transcription factors that control death genes, such as CD95L (Fas ligand). Indeed, it has 
been found that PKB-induced phosphorylation and subsequent inhibition of the formation of 
the CREB/CBP complex modulate the activity of the nuclear factor, cAMP response 
element-binding (CREB) (Du and Montminy, 1998). In addition, the phosphorylation of a 
subunit of human telomerase reverse transcriptase (hTERT) enhances the activity of human 
telomerase (Kang et al., 1999).
PKB regulates the activity of members of the Forkhead family of transcription factors 
(Brunet et al., 1999 and Kops et al., 1999). PKB phosphorylates FKHRL1, leading to its 
association with 14-3-3 proteins and its retention in the cytoplasm. Dephosphorylation by
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the withdrawal of survival factors results in the nuclear translocation of FKHRL1 where it 
targets gene activation (Nakae et al., 1999; Tang et al., 1999; Rena et al., 1999 and Guo et 
a l, 1999).
Table 1.3. Substrates phosphorylated by PKB. See text for details.
PROTEIN TARGET FUNCTION REFERENCE
H2B histone Nucleosome structure Alessi et al., 1996
Glycogen synthase kinase 3a/p Glycogen synthesis Franke et al., 1997
6 -phosphofructo-2 -kinase Glycogen synthesis Toker and Cantley, 1997
BAD Cell survival del Paso et al., 1997
Caspase-9 Cell survival Cardone et al., 1998
CREB Cell survival Du and Montminy, 1998
FKHRL1/AFX Cell survival Brunet et al., 1999
hTERT Cell survival Kang et al., 1999
eNOS NO production Fulton et al., 1999
Cardiovascular homeostasis Dimmeler et al., 1999
(ii) p70 S6  kinase
This kinase becomes activated upon mitogenic stimuli and plays an important role in the 
progression of cells from the G1 to S phase of the cell cycle. It phosphorylates the S6  
protein component of the 40S ribosomal subunit during mitogenic responses, but might also 
be involved in the regulation of other cellular process (R. L. Erikson, 1991). The role of S6  
phosphorylation seems to correlate with an increase in translation from specific mRNAs 
encoding proteins essential for G1 progression (Kozma and Thomas, 1994).
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Activation of p70 S6  kinase is regulated by multiple independent serine/threonine-directed 
phosphorylations. This activation is independent of the Raf/MAPK pathway, but involves PI 
3-kinases and the PIK-related kinase, mTOR (for mammalian target of rapamycin), as well 
as PKC and pro line-directed kinases such as mitogen-activated protein kinases (MAPK). 
PDK1 can also phosphorylate the activation loop of p70 S6  kinase (Alessi et al., 1997 and 
Pullen et al., 1998), which is essential for activation.
(iii) PKC isoforms
Both the lipid substrates and products of PI 3-kinases have been reported to activate, in 
vitro, a broad panel of PKC family members, namely the novel isoforms 8 , 8  and T| and the 
atypical isoform £ (Chou et al., 1998 and Le Good et al., 1998). It is likely that the activity 
of these isoforms is affected by PDK1 phosphorylation (e and Q as well as by a direct 
interaction with PI (3,4) P2 and PI (3,4,5) P3 (e). Inhibition of PI 3-kinase blocks insulin- 
dependent activation of PKC£ in vivo (Standaert et al., 1997 and Mendez et al., 1997) and 
PDGF-dependent membrane recruitment and activation of PKCe in vivo (Moriya et al.,
1996). However, the enzymatic activity of PDK1 is not dependent on phosphoinositides 
(Alessi et al., 1998) and the requirement of PI 3-kinase for PDK1-dependent 
phosphorylation probably reflects a role for PI (3,4) P2 and PI (3,4,5) P3 in co-localising 
PDK1 and its substrates at specific membranes (Alessi et al., 1998).
(iv) Others
The PH domain of the Bruton’s tyrosine kinase (Btk) was shown to interact with PI (3,4,5) 
P3 and its head group, inositol 1 ,3 ,4 ,5 -P4 , with high affinity (Fukuda et al., 1996; Salim et 
al., 1996 and Rameh et a l, 1997). Phosphorylation of Btk by Src family kinases leads to its 
activation (Li et al., 1997) and PI (3,4,5) P3 is involved with modulating this and the
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subsequent elevation in cytosolic calcium in response to this B cell stimulation, perhaps by 
recruiting PLCy to the membrane (Scharenberg et al., 1998).
Wheres PI 3-kinases phosphorylate PI (4,5) P2, PLCy hydrolyses this lipid to produce 
diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (IP3) and hence mediates intracellular 
calcium release and PKC activation (Rhee et al., 1997). Recent work has revealed the 
existence of cross-talk between PI 3-kinase and PLCy signalling. The activity of PLCy is 
enhanced by 3-phosphoinositides both indirectly (via Btk-related tyrosine kinases, see 
above) and directly through binding of PI (3,4,5) P3 to the amino-terminal PH domain and 
the tandem SH2 domains of PLCy (Bae et al., 1998; Rameh et al., 1998 and Falasca et al.,
1998).
The protein Grpl (general receptor for inositides) has a PH domain very selective for PI
(3.4.5) P3, which regulates Grpl by recruiting it to membranes where Arf is localised 
(Klarlund et al., 1998). These small G proteins are involved in vesicle budding, thus PI
(3.4.5) P3 may regulate coating and budding of intracellular vesicles (Klarlund et al., 1997 
and 1998.
PI 3-kinase has a role in chemotaxis and membrane ruffling by activating GTP exchange 
factors such as Vav2 (Han et al., 1998). The consequent binding of Rac to GTP (Hawkins 
et al., 1995) may explain the mechanism by which PI 3-kinase is involved in growth factor- 
and Ras-stimulated cytoskeletal rearrangements that lead to cell migration (Rameh and 
Cantley, 1999).
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The transcription factor E2F, cyclin D3, p27kipl and Rb are all components of the cell cycle 
machinery and Brennan et al., 1997 established a crucial link between PI 3-kinase/PKB 
activation and progression into the cell cycle by the modulation of the activity of these 
critical components. E2F is known to have an important role in the regulation of apoptosis 
and cell cycle progression (Field et al., 1996 and Yamasaki et al., 1996).
1.6 APOPTOSIS
Background
The concept that accumulation of unwanted cells is due to uncontrolled cell proliferation 
has been amended. Cells also accumulate when proliferation rates are normal but death rates 
are lower. The realisation that cell death is a normal process in development and cellular 
homeostasis has opened a completely new avenue for exploration of the causes and 
treatments of disease (Kerr and Wyllie, 1972).
Failure of cells to die is an integral mechanism in some cancers and autoimmune disorders. 
Conversely, an abnormal increase in cell death is observed in neurodegenerative disorders 
and ischaemic injury. During development the number of cells differentiating into a cell type 
designed to perform specific functions often exceeds the number of cells required to 
perform the functions (e.g., innervation) (R. W. Oppenheim, 1991). The superfluous cells 
are eliminated through cell death (Nagata and Goldstein, 1995 and Jacobson et al., 1997). A 
miscue in this process is detrimental to the development of the organism.
Pathogens have evolved molecules that affect the death pathway. HIV appears to induce 
cell death by attacking the molecular machinery involved in inhibiting cell death (Strack et
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al., 1996). Other pathogens preserve their host by inhibiting the induction of a cell death 
pathway. In eukaryotic multicellular organisms a mechanism has evolved that eliminates 
unwanted cells with minimal disturbance to the organism. This process of "programmed cell 
death" or "cell suicide" is called apoptosis (figure 1.13). The apoptotic elimination of 
unwanted cells is through a program engrained within the targeted cell (Weil et al., 1996). 
The suicide program leads to partial autodigestion of intracellular components, with the cell 
splitting into plasma-membrane limited vesicles called apoptotic bodies. The lipid 
distribution between the outer and inner leaflets of the plasma membrane enclosing the 
apoptotic bodies is critical for elimination of these cellular remnants. Phosphatidylserine, 
normally present in the inner leaflet and excluded from the outer leaflet, is exposed in the 
outer leaflet of apoptotic bodies. The presence of phosphatidylserine in the outer leaflet 
serves to mark apoptotic bodies for elimination by phagocytic cells (Fadok et al., 1992). 
Thus, the process of apoptosis does not elicit an inflammatory response. This is in marked 
contrast to the inflammatory response during necrosis, where loss of plasma membrane 
integrity and release of cytoplasmic contents into the surroundings accompanies cell death 
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Figure 1.13. Schematic representation of the process of programmed cell 
death (apoptosis). Cells committed to undergo apoptosis condense and 
fragment into apoptotic bodies which are removed by neighbouring cells 
and macrophages. See text for more detail.
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Table 1.4. Distinguishing features between apoptosis and necrosis.
APOPTOSIS NECROSIS






First apparent cellular changes Shrinking
Convolution
Swelling
Nuclear changes Condensation, segmentation 
DNA fragmentation
Cell membrane changes Surface protrusions, budding 
Changes in PS distribution
Smoothing, lysis
Mitochondrial changes Release of cytochrome c Swelling
Metabolic/Synthetic changes Active changes in gene expression 
(eg., Bcl2, Bax);
Active protein synthesis; 
Protease activation
Induction
Metazoan cells appear to be programmed to die by default and they undergo apoptosis if 
they do not receive appropriate survival cues from their environment. In addition, metazoan 
cells have internal sensors for well-being that can initiate apoptosis if the cell is unable to 
repair defects such as DNA damage. For example, the p53 protein is essential for the 
induction of apoptosis as a response to chromosomal damage, e.g. due to y-irradiation. It 
acts by blocking DNA replication of damaged cells. If the chromosomal lesions cannot be 
repaired within a certain period of time, the cells die by apoptosis. Cells deficient for p53 
replicate in spite of the DNA damage, which favours the accumulation of further mutations 
and reduces the efficiency of chemotherapeutic drugs (Agarwal et a l, 1998).
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Higher metazoans have evolved an additional signalling mechanism that actively directs cells 
to die by apoptosis. For example, certain hormones like glucocorticoids can induce 
apoptosis (figure 1.14). This pathway appears to be particularly significant in the case of 
thymocytes and can explain at least in part the immunosuppressive effect of the 
glucocorticoids. How these drugs induce apoptosis is not exactly known but it is reasonable 
to assume that it is the well-established gene regulatory activity of the glucocorticoid 
receptor complex, which is responsible for this effect (King and Cidlowski, 1998).
This type of ‘instructive apoptosis’ is critical in the immune system where the deletion of 
activated lymphocytes at the end of an immune response or the elimination of virus-infected 
cells or cancer cells by cytotoxic lymphocytes is important. Granzyme B, also known as 
CTL proteinase-1, fragmentin-2, and RNKP-1, is a serine protease which is released by 
cytotoxic T-cells as part of the cytolytic granules upon a specific interaction with a target 
cell (figure 1.14). Delivery of granzyme B to the cytoplasm of a target cell is sufficient for 
the induction of apoptosis, a hallmark of CTL killing. Perforin is a constituent of the 
cytolytic granules and is capable of forming transmembrane pores in a process that requires 
calcium. These pores are probably responsible for membrane damage but appear not to be 
sufficient to kill a cell. In fact, it is assumed that a major function of these pores is to 
facilitate the entry of granzyme B (J. A. Trapani, 1995).
Cytokine-related mechanisms of apoptosis can be sub-divided into two pathways: (i) 
positive induction by ligand binding to a plasma membrane receptor and (ii) negative 
induction by loss of a suppressor signal (see figure 1.14 for a schematic view of the 
apoptotic pathways).
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(i) Positive Induction o f Apoptosis
The tumour necrosis factor (TNF) family of receptors (TNFR) is characterised by homology 
in the extracellular domains. Some of these receptors initiate apoptosis, some initiate cell 
proliferation and some initiate both. Signalling by this family requires clustering of the 
receptors by trimeric ligand and subsequent association of proteins with the cytoplasmic 
region of the receptors (Jones et al., 1989).
The TNFR family contains a sub family with homologous cytoplasmic 80-amino-acid 
domains. This domain is referred to as a death domain (DD), so named because proteins 
that contain this domain are involved in apoptosis.8 The distinction between members of the 
TNFR family is exemplified by two TNFRs coded by distinct genes. TNFRI (55 kDa) 
signals both the initiation of apoptosis and the activation of the transcription factor NFkB. 
TNFRII (75 kDa) functions to signal activation of NF-kB but not the initiation of apoptosis. 
TNFRI contains a DD; TNFRII does not (S. Nagata, 1997).
Other members of the TNFR family with DD are Fas/APO-l/CD95 and DR-3 (Ashkenazi 
and Dixit, 1998). Aggregation of these receptors initiates apoptosis. Aggregation of the 
receptors by trimeric ligand orients the DD in a conformation that recruits adapter proteins. 
The adapter proteins also contain a DD and association of adapters with the receptor is via 
a homotypic DD interaction. As will become obvious below, homotypic domain interactions 
between proteins involved in revving up the cell for self-destruction is a common theme of 
apoptosis.
Aggregation of TNFRI through association with trimeric ligand induces association of the 
adapter proteins TRADD (TNFR associated protein with a DD) and FADD (Fas associated
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protein with a DD) (Hsu et al., 1996 and Chinnaiyan et al., 1995). FADD also contains a 
'death effector domain' (DED). The DED of FADD recruits the zymogen form of the 
cysteine protease FLICE/Machal. FLICE/Machal zymogen contains a large pro-region 
that is homologous to the DED of FADD (Muzio et al., 1996 and Boldin et al., 1996). This 
pro-region is removed during activation. The large DED-containing pro-region appears to 
distinguish FLICE/Machal from most of the other cysteine proteases that contain small, 
DED-lacking pro-regions, suggesting that the proteases activated earliest in the apoptotic 
proteolytic cascade have large DED-containing pro-regions.
TNF can also induce activation of NF-kB when bound to TNFRI. The adapter TRADD has 
at least two binding domains, DD and TRAF (TNFR associated factor), of approximately 
280 amino acids located near the N-terminus and C-terminus, respectively (Hsu et al.,
1996). DD causes TRADD to associate with TNFRI, and TRAF, through homotypic TRAF 
do main interactions, recruits TRAF-2. The C-terminus of TRAF-2 contains a "ring 
domain" that binds and activates NFkB (Hsu et al., 1996 and Rothe et al., 1995). NF-kB is 
then transported into the nucleus where it promotes transcription.
The TNFRII subgroup receptors contain a cytoplasmic domain different from TNFRI. 
Oligomerisation of TNFRII leads to the binding of two proteins, TRAF-1 and TRAF-2, 
which form an oligomer through homotypic interaction of their TRAF domains (Rothe et 
al., 1995). TRAF-2 then binds and activates NFkB. CD40-mediated activation of NFkB 
proceeds through a similar pathway except that an additional protein, TRAF-3, is involved 
(Hu et al., 1994).
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Fas/APO-l/CD95-initiated cytosolic adapter complex is similar to the complex formed on 
the cytoplasmic domains of aggregated TNFRI. An additional protein, RIP (receptor 
interacting protein), has been identified in the complex formed on Fas (Stanger et al., 1995). 
RIP contains a DD at its N-terminus and a serine kinase-domain at its C-terminus (Hsu et 
al., 1996). The function of the kinase is unknown. RIP also interacts with and activates NF­
kB. There is an adapter protein named RAIDD (RIP-associated ICH1 homologous protein 
with a DD) that binds to the pro-region of ICH1 and links RIP to the cysteine protease 
ICH1 (Duan and Dixit, 1997).
Similar to the complex formed on TNFRI, the DED of the adapter FADD binds the DED 
present in the pro-region of the cysteine protease FLICE/Machal (Boldin et al., 1996). 
Thus, there appears to be redundant pathways by which apoptosis can be initiated by a 
single receptor. RIP has also been found associated with the TNFRI (Duan and Dixit,
1997). The pro-region released after proteolytic cleavage of FLICE/Machal has been 
found on the DD complex associated with Fas (Boldin et al., 1996). It appears that active 
FLICE/Machal is released to initiate the cysteine protease cascade, with the DED- 
containing pro-region remaining with the complex.
Many of the proteins in the cytoplasmic apoptotic-inducing complexes have been identified, 
but their regulation is unknown. Many are phosphorylated, but significance of post- 
translational modifications is unclear. Other proteins also associate with the cytoplasmic 
receptor-associated complexes. Two mammalian proteins, c-IAP-1 and c-IAP-2 (cellular 
inhibitor of apoptosis), are found associated with TRAF-1, TRAF-2 and TNFRII 
cytoplasmic complex (Duan and Dixit, 1997). These proteins contain regions homologous 
to the baculoviral inhibitors of apoptosis (all contain BIRs, baculovirus IAP repeats whose
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functions are unknown). Clarification of the functions of these proteins and the 
identification of other complex-associated proteins will undoubtedly aid in dissecting the 
involvement and functions of proteins involved in direct activation of apoptosis and of other 
signalling events that depend on the TNFR family.
(ii) Loss of Cytokine-Dependent Suppression of Apoptosis
The viability of many cells is dependent on a constant or intermittent supply of cytokines or 
growth factors. In the absence of the factor, the cells under go apoptosis. The Bcl-2 family 
of proteins are central components to apoptosis resulting from the absence of incoming 
signals generated by cytokine binding. Over-expression of some family members (e.g., Bcl-2 
and Bcl-xL) suppresses apoptosis when cytokines are withdrawn. Over-expression of other 
members (e.g., Bad, Bax and Bik) override the incoming signals from the cytokine-receptor 
and induce apoptosis. The suppresser members of the Bcl-2 family form homodimers or 
heterodimers with inducer-type members. Suppressor members prevent apoptosis when 
homodimerised but are ineffective in protecting from apoptosis when heterodimerised with 
an inducer member. Thus, the dimerisation state of the suppressor members of the Bcl-2 
family is one determinant of cellular life or death. Recent reports have begun to unite the 
Bcl-2 family of proteins with other components into a single pathway that, although similar 
in many aspects to the TNF/Fas pathway, is unique and provides an additional method to 
eliminate unwanted cells (Chao and Korsmeyer, 1998).
Molecular mechanisms
The molecular mechanisms of apoptosis caused by withdrawal of cytokines may be best 
understood by starting with the roles of the Bcl-2 family members. The suppressers Bcl-2 
and Bcl-xL are integral membrane proteins (Nguyen et al., 1993) found as dimers facing the
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cytosol. They are predominantly located in the outer mitochondrial membrane, with less in 
the endoplasmic reticular and nuclear membranes (Krajewski et al., 1993). Dimerised Bcl-2 
or Bcl-xL have regions that bind to a protein that, in mammalian cells, is the homologue to 
CED-4, an adapter protein identified in the nematode Caenorhabditis elegans (Wu et al., 
1997 and Chinnaiyan et al., 1997). The mammalian homologue of CED-4 has not been 
identified, but there is evidence for its existence (Chinnaiyan et al., 1997).
CED-4 also binds to zymogens of cysteine pro teases that contain large pro-regions. In this 
tripartite configuration, the cysteine protease is maintained as a zymogen (inactive). When 
the CED-4 interaction with Bcl-2 or Bcl-xL is disrupted, CED-4 interaction with the 
zymogen appears to be altered to induce autoproteolytic activation of the cysteine protease. 
FLICE/Machal is a member of the family of cysteine proteases that associate with CED-4. 
As in the TNFRI/Fas pathway, FLICE/Machal may be one of the earliest proteases 
activated during initiation of the proteolytic activation cascade.
The finding that the adapter protein CED-4 prevents zymogen activation when bound to 
Bcl-2 or Bcl-xL homodimers but activates zymogens when not bound likely explains the 
ability of overexpressed Bcl-2 or Bcl-xL to protect cells from apoptosis caused by 
numerous cellular signals or insults. When Bcl-2 or Bcl-xL homodimer levels are high, 
CED-4 is bound to the homodimers and is, therefore, unable to activate the cysteine 
protease cascade. This would also explain the anti-apoptotic activity of Bcl-2 and Bcl-xL 
truncated forms missing the mitochondrial targeting amino acid sequence (Bomer et al.,
1994). As long as Bcl-2 or Bcl-xL can homodimerise, they have the potential to sequester 
ah of CED-4.
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Bcl-xL heterodimerization with the inducer family members, Bax, Bak or Bik, causes 
release of the CED-4-zymogen heterodimer from Bcl-xL (Chinnaiyan et al., 1997). During 
or after dissociation from Bcl-xL, CED-4 induces the zymogen to undergo autoproteolytic 
activation. Thus, activation of cysteine proteases in this pathway directly depends on the 
dimerization state(s) of the Bcl-2 family members, and the dimerization state appears to be 
controlled by the availability of the apoptosis inducer members. The availability of inducer 
members for heterodimerization with Bcl-2 or Bcl-xL may be regulated by signals generated 
by the binding of cytokines.
Bad is a proapoptotic member of the Bcl-2 family and is sequestered in the cytosol when 
cytokines are present (Zha et al., 1996). Sequestration occurs through the binding of Bad 
by a multifunctional protein, 14-3-3 (Zha et al., 1996). This protein binds to phosphorylated 
proteins, and the Bad that is bound by 14-3-3 is phosphorylated on serine residues. Upon 
removal of cytokines, Bad becomes dephosphorylated at specific serine residues, dissociates 
from 14-3-3 and heterodimerizes with Bcl-xL. Bad phosphorylation and reassociation with 
14-3-3 can be induced by addition of cytokines. Furthermore, hyper-phosphorylated Bad 
does not bind to Bcl-xL. These results suggest that the cytokine-engaged receptor prevents 
apoptosis by inducing the phosphorylation of the apoptotic-inducing members of the Bcl-2 
family, thereby making them unavailable for dimerization with Bcl-2 or Bcl-xL.
The identity of the kinase pathway that couples cytokine receptor binding to 
phosphorylation of the pro-apoptotic Bcl-2 family members is under intense study. 
Activated PKB has been shown to prevent the apoptotic cell death of Rat-1 cells that are 
induced by c-myc (Kaufmann-Zeh et al., 1997). Growth factor-dependent activation of 
PKB is through PI (3,4) P2 generated by PI 3-kinase whose activation depends on the GTP-
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binding protein Ras. PI 3-kinase is active when cytokines are bound to their receptors (see 
section 1.5). A potential role for the Ras activation of another kinase, Raf, has also been 
suggested (Wang et al., 1996). Similarly, other phosphorylation events have been shown to 
affect apoptosis under experimental conditions (Nishina et al., 1997 and Haidar et al.,
1995). The great advances in understanding the pathways that trigger apoptosis sets the 
stage for investigations into the regulation of the pathways by kinases and by levels of 
expression of proteins (e.g., the Bcl-2 family).
The suppressive signal appears to regulate the function of mitochondrial ion and/or water 
channels (Chao and Korsmeyer, 1998). Loss of the suppressive signal, when the anti- 
apoptotic cytokines are not available to the cell, leads to the failure of the channels to 
maintain the normal ion potential across the inner mitochondrial membrane and to the 
failure to maintain proper mitochondrial volume. Bcl-x and Bcl-2, are channel forming 
proteins responsible for maintaining normal mitochondrial physiology. Regulation of their 
activities is central to apoptosis (Chao and Korsmeyer, 1998).
Inhibition of Bel activities leads to altered mitochondrial membrane permeability resulting in 
the release of cytochrome c into the cytosol. In the cytosol, cytochrome c is bound by the 
protein Apaf-1, an acronym for apoptotic protease-activating factor, which also binds 
caspase 9 and dATP. Binding of cytochrome c triggers activation of caspase 9, which then 
accelerates apoptosis by activating other caspases (Green and Reed, 1998).
The mechanism for cytochrome c release from the mitochondria is becoming clearer. 
Inhibition of normal mitochondrial channel function causes mitochondria to swell, rupture 
and release cytochrome c (Green and Kroemer, 1998). The inner mitochondrial membrane
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has more surface area than the outer membrane. Swelling of the matrix extends the inner 
membrane, which then appears to cause rupture of the outer membrane, releasing 
cytochrome c from the inter-membrane space. This is consistent with the findings by many 
groups that the majority of cytochrome c in apoptotic cells is in the cytosol. Inhibitors of 
caspase activity did not prevent outer mitochondrial membrane rupture, indicating that the 
membrane rupture did not depend on caspase activity (Green and Kroemer, 1998).
An involvement of permeability transition pores in apoptosis has also been suggested 
(Green and Reed, 1998). These pores are multiprotein complexes that are present at sites 
where the inner mitochondrial membrane contacts the outer mitochondrial membrane. The 
relationship between the transition pores and members of the Bcl-2 family remain to be 
determined. Although the exact details require more investigation, it is clear that regulation 
of mitochondrial physiology by the Bcl-2 family and release of cytochrome c into the 
cytosol are critical events in the process of apoptosis that occurs in the absence of many 
viability-sustaining cytokines.
The Bcl-2 family may also be central to another type of apoptosis induction. It has long 
been recognised that the Bcl-2/Bcl-xL dimerisation state regulates the sensitivity of cells to 
death induced by free radicals (Hockenberry et al., 1993 and Kane et al., 1993). Free 
radical-induced cell death is accompanied by lipid peroxidation. Bcl-2 overexpression 
prevents free radical-induced lipid peroxidation. Cytochrome c is a one-electron carrier in 
mitochondrial electron transport. It is possible that cytosolic cytochrome c propagates or 
initiates free radical production. Although the mechanism for activation of apoptosis by 
these events is unknown, the findings suggest a function for the Bcl-2 family in regulating 
free radical damage. Bcl-xL forms pores in artificial membranes (Minn et a l, 1997) and has
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a crystal structure similar to the p-subunit of diphtheria toxin (S. W. Muchmore, 1996). 
Diphtheria P-subunit translocates the a-subunit across membranes. Thus, Bcl-xL and Bcl-2 
have the potential to translocate materials across membranes. Mitochondrial membrane pore 
formation and subsequent loss of mitochondrial transmembrane potential has been found to 
be one of the earliest cellular events associated with apoptosis (Castedd et al., 1996). The 
molecular relationship between cytochrome c, the Bcl-2 family, activation of cysteine 
proteases, and free radicals remains to be determined.
Caspases -  the executioners
While studying the develoment of the nematode Caenorhabditis elegans, two genes 
referred to as ced-3 and ced-4 were found to be essential for the programmed cell death 
which is crucial during ontogenesis of this simple organism (Yuan et al., 1993). The ced-4 
gene encodes a polypeptide of unknown function whereas the ced-3 gene encodes a protein, 
which exhibits a high similarity to a family of cysteine proteases which includes the 
interleukin-1-P-converting enzyme (ICE). These observations lead to the assumption that 
proteases like CED-3 and ICE are crucial for triggering the biochemical events, which lead 
to apoptotic cell death, in that they are responsible for the deliberate disassembly of the cell 
into apoptotic bodies during apoptosis (Thornberry and Lazebnik, 1998).
It is now well established that ICE is the prototype member of a family of related proteases. 
To unify the nomenclature of the ICE-like proteases, they are now referred to as caspases 
(cysteine proteases which cleave proteins after an aspartic acid residue). Caspases are 
present as inactive pro-enzymes that are activated by proteolytic cleavage. Caspases 8, 9 
and 3 are situated at pivotal junctions in apoptosis pathways. Caspase 8 initiates disassembly 
in response to extracellular apoptosis-inducing ligands and is activated in a complex
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associated with the cytoplasmic death domain of many cell surface receptors for the ligands 
(Thornberry and Lazebnik, 1998). Caspase 9 activates disassembly in response to agents or 
insults that trigger the release of cytochrome c from mitochondria and is activated when 
complexed with apoptotic protease activating factor 1 (APAF-1) and extra-mitochondrial 
cytochrome c. The Apaf-family of proteins in humans is homologue to the ced-family in C. 
elegans. Three genes, ced-3, ced-4, and ced-9 encode the general apoptotic and anti- 
apoptotic program in C. elegans. Recently it has been shown that Apaf-3 turned out to be 
caspase-9, which has a similar structure to ced-3. Apaf-1 was the long sought mammalian 
homologue of ced-4. Apaf-1 needs a cofactor in order to bind to and therefore activate 
caspase-9. This cofactor was named Apaf-2 and seems to be identical with cytochrome c 
(Zou et al., 1997 and Li et al., 1997). Caspase 3 appears to amplify caspase 8 and caspase 9 
initiation signals into full-fledged commitment to disassembly (Thornberry and Lazebnik, 
1998 and Cryns and Yuan, 1998). Caspase 8 and caspase 9 activate caspase 3 by proteolytic 
cleavage and caspase 3 then cleaves vital cellular proteins or other caspases (Thornberry 
and Lazebnik, 1998 and Cryns and Yuan, 1998). Work with cells from caspase 3-/- and 
from caspase 9-1- mice suggests that the caspase pathway used for disassembly is cell-type 
specific (Hakem et al., 1998; Kuida et al., 1998; Kuida et al., 1996 and Woo et al., 1998). 
Embryonic stem cells (ESC), embryonic fibroblasts (EF), thymocytes, and splenocytes from 
caspase 3-/- and from caspase 9-/- mice were subjected to a wide array of agents or insults 
that induce apoptosis in cells from mice homozygous or heterozygous for the wild-type 
alleles. Whereas, ESC, EF, and thymocytes from caspase 9-/- mice were resistant to 
etoposide, splenocytes were sensitive. Caspase 9-/- ESC and EF were resistant to UV 
irradiation, however, thymocytes and splenocytes were sensitive. Cells from the caspase 3-/- 
mice showed a cell-type specificity for sensitivity to UV and y irradiation.
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The results suggest four possible caspase pathways. The first requires both caspase 3 and 
caspase 9. ESC from caspase 3-1- and from caspase 9-1- mice are resistant to UV irradiation 
and many other agents suggesting that this pathway involves cytochrome c release from 
mitochondria, caspase 9 activation, and subsequent cleavage of caspase 3 by caspase 9. The 
second pathway requires neither caspase 9 nor caspase 3. Thymocytes and splenocytes from 
caspase 3-1- and from caspase 9-1- mice are sensitive to UV irradiation suggesting the 
involvement of other caspases. The third requires caspase 9 but not caspase 3. Thymocytes 
from caspase 9-1- mice are resistant to y-irradiation and dexamethasone, whereas 
thymocytes from caspase 3-1- mice are sensitive, suggesting that other caspases are directly 
activated by caspase 9. The fourth requires caspase 3 but not caspase 9. Activated 
splenocytes from caspase 3-1- mice are resistant to anti-CD95 whereas splenocytes from 
caspase 9-1- mice are sensitive. This pathway likely involves caspase 8 which then activates 
caspase 3.
Interpretation of the results is complicated by the existence of inhibitors that act by binding 
to caspases Deveraux et al., 1997) or by competing against pro-caspases for binding to the 
protein complexes that activate caspases (Irmler et al., 1998). Generation of the caspase 9 
mutations involved substitution for a segment of caspase 9 required for enzymatic activity. 
The pro-domain that interacts with CARD (caspase recruitment domain) found in APAF-1 
was left intact. Thus, mutant caspase 9s could compete with other caspases for binding to 
APAF-1.
The effects of caspase 3 and caspase 9 mutations in vivo are striking. Both cause perinatal 
mortality, and the most obvious effect is on brain development. Brain morphology in 
caspase 9-/- mice was more aberrant than in caspase 3-/- mice. Caspase 9-/- mice often
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developed brain tissue outside the skull. This difference suggests that both caspase 9-, 
caspase 3-dependent and caspase 9-dependent, caspase 3-independent apoptosis pathways 
are involved in brain development. Altered brain morphology appeared to result, in part, 
from decreased apoptosis of neuroepithelial progenitors indicating that caspase 9 and 
caspase 3 are required to cull this population of cells.
Other gross morphological defects were not observed. Tissue remodelling involving 
retraction of the interdigital webbing in the foetal hand occurred normally in caspase 9-1- 
mice indicating that apoptosis during this developmental process is caspase 9-independent 
(Kuida et al., 1998). Although the mutations confer resistance to thymocytes and 
splenocytes to many inducers of apoptosis, the mutation did not appear to affect thymic 
selection. Lymph nodes were, however, enlarged in the caspase 9-1- mice that survived 2 
weeks.
The caspases are probably the most important effector molecules, which induce apoptosis. 
The apoptotic signal transmitted by activated caspases can be downregulated by caspase 
inhibitors like the CrmA protein of poxviruses, the p35 protein of baculovirus or proteins 
encoded by the IAP (inhibitor of apoptosis) gene family that are endogenous mammalian 
apoptosis suppressers. However, it is thought that once Apoptosis Inducing Factor (AIF) 
and cytochrome c are released from the mitochondria during the apoptosis-induced 
permeability transition of the mitochondrial membrane, the activation of proenzymatic 
caspases and downstream events the point-of-no-retum has been reached, after which the 
apoptotic events become irreversible. (Alnemri et al., 1996; G. M. Cohen, 1997 and 
Nicholson and Thornberry, 1997).
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D N A  fragmentation - the end
One consequence of proteolysis of cellular proteins is the activation of Ca/Mg-dependent 
nucleases, especially DNAse I, which degrade the chromosomal DNA. This leads to 
multiple nicks and breaks within the DNA and finally results in the generation of DNA 
oligomers, their sizes being multiples of nucleosome-associated DNA. Thus, if the DNA 
from cells undergoing apoptosis is analysed by gel electrophoresis, a typical ladder pattern is 
observed which is a hallmark of apoptotic cell death (A. H. Wyllie, 1987). Recently it has 
been shown that during apoptosis a specific DNase, referred to as CAD, is activated. CAD 
and ICAD are complexed and caspase 3 cleavage releases the DNase activity, which causes 
DNA fragmentation in the nucleus (Enari et al., 1998).
Many of the targets of activated caspases have already been characterised as being involved 
with the degradation of DNA. They include poly(ADP-ribose) polymerase (PARP) and 
DNA-dependent protein kinase (DNA-PKs) which are both involved in sensing DNA- 
damage and repair, U1 ribonucleoprotein, nuclear laminins, PKC-8 and cytoskeleton 
components like actin. PARP is one of the best examined targets of activated caspases. 
PARP is a DNA repair enzyme whose expression is triggered by DNA-strand breaks. In 
cells undergoing apoptosis PARP is cleaved from a 116 kD peptide into 24 kD and 89 kD 
polypeptides. It appears plausible that cleavage of PARP facilitates the degradation of 
cellular DNA, which is a hallmark of apoptosis (Lippke et al., 1996 and De Murcia and De 
Murcia, 1994).
However, it is still unclear whether the caspases are directly responsible for apoptosis by 
destroying crucial cellular components or whether they activate further effector molecules. 
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Apoptosis in colonic epithelium
As shown in figure 1.13, a wide array of proteins is involved in monitoring cellular 
proliferation and cell survival. In particular, there are two important factors that relate to 
intestinal apoptosis:
(i) Differential expression of Bcl-2 may regulate susceptibility to epithelial apoptosis 
and colon carcinoma. Stem cells at the base of the colonic crypts express higher levels of 
Bcl-2 than those of the small intestine and therefore have a greater chance of survival in a 
background of genomic damage, which may progress to cancer (C. S. Potten, 1997). 
However, another Bcl-2 family member, Bak, has also been shown to inhibit the anti- 
apoptotic effect of Bcl-2 and lead to rapid and extensive apoptosis. Whilst Bak’s function 
has been likened to that of Bax, it shares greater sequence homology with Bcl-2 and Bcl-xL 
Chittenden et al., 1995). This raises the possibility that the structural elements that are 
shared by Bak and Bax may be responsible for their functional similarity. It is suggested that 
Bak and Bax operate at different points in the apoptosis pathway, where Bak may act 
directly on one of its apoptosis-inducing relatives to moderate their action whilst Bax might 
interact with a number of survival proteins. It is interesting to note that increased colonic 
epithelial Bak expression results in apoptosis in these cells and decreased Bak expression 
has been observed in colon neoplasia (Moss et al., 1996). Also, increased Bak expression 
has been found during apoptosis of HT-29 cells, which have mutant p53, implying that the 
regulation of Bak in this cell line is p53-independent (Moss et al., 1996). Indeed, HT-29 
cells also express a constitutively phosphorylated form of Bcl-2, perhaps keeping Bak in an 
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Figure 1.15. Molecular and biochemical interactions that have been proposed to determine levels of apoptosis in the gastrointestinal tract. Lines indicate 
probable interactions that regulate events shown in shaded boxes. Links include physical association of proteins, as well as upregulation or downregulation of 
expression or activity. Most linkages are not intended to display a positive or negative interaction because of the tentative nature of current understanding of 
such events, with the exception of tha ability of nonsteroidal anti-inflammatory drugs (NSAIDS) to inhibit cyclooxygenase enzymes. Adapted from Potten, 
1997.
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(ii) Cell-cell interactions are also required to maintain epithelial survival. Most epithelia 
are cohesive tissues where the cells interact with each other as well as the basement 
membrane. It now appears that adhesion through cell-cell interactions contributes to the 
cohesive integrity of epithelia. A colon carcinoma cell line (LIM 1863), cultured as 
structural organoids containing polarised columnar and goblet cells, can be reversibly 
disaggregated in the absence of calcium. When cell-cell adhesion during the reaggregation 
process is prevented by a function-blocking anti-av integrin antibody, however, the 
intestinal cells enter an apoptosis programme termed anoikis (Bates et al., 1994 and Frisch 
and Francis, 1994). Cell-cell adhesion through the cadherin system has been implicated 
directly for epithelial cell survival in vivo (Metcalfe and Streuli, 1997). Cadherin-mediated 
adhesion provides a mechanistic basis for regulating epithelial integrity. Thus, survival 
signals from both cell-cell and cell-matrix adhesion molecules cooperate to ensure that cells 
with regional specialisation maintain their positional identity and do not migrate into 
innappropriate places.
When examined within the framework of the cell biology of the gastrointestinal tract and, 
taking into account the other genes known to be involved, genetic manipulations that result 
in gene deletions or overexpression offer the imminent prospect of a better understanding of 
how apoptosis is regulated and how apoptosis interacts with proliferation.
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1.7 AIMS
This study is based on the hypothesis that the intestinal epithelium constitutes an interface 
between the host and the environment and plays a crucial role as an outpost of the immune 
system located in the underlying gut mucosa. This is an exploration into their involvement in 
immune and inflammatory reactions under the control of immune and inflammatory 
mediators, such as cytokines and nitric oxide. The main objectives of the investigation were:
1. To investigate the intracellular signalling mechanisms involved in nitric oxide production 
and regulation in human colonic epithelial cells by pro- and anti-inflammatory cytokines.
2. To examine the role of the intracellular signalling enzyme, PI 3-kinase, on iNOS 
regulation, via IL-13.
3. To establish the profile of pro-inflammatory cytokines which induce apoptosis in human 
colonic epithelial cells and to characterise whether IL-13 and/or NO play any part in this 
process.
4. To examine the role of the PI 3-kinase pathway and some of its downstream targets on 
the apoptotic pathway induced in these cells.
The elucidation of the role of colonic epithelium in the inflammatory process and the 
mechanisms thereof could offer a novel approach in the development of new diagnostic 
tests and potential new therapeutic strategies for the effective treatment of intestinal 
inflammation.
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2. MATERIALS AND METHODS
2.1 MATERIALS
M aterial Source
(3-Glycerophosphate Sigma, Poole (UK)
a-Human Fas mAb (IgM CH-11 clone) Upstate Biotechnology (TCS Biologicals, 
Buckingham, UK).
[Y-32P]ATP (3000 Ci/mmol) DuPont NEN (Stevenage, UK)
[32P]-Orthophosphate (8500-9120 Ci/mmol) DuPont NEN (Stevenage, UK)
2,3-Diaminonaphthalene (DAN) Lancaster Synthesis Ltd.
2-Mercaptoethanol Sigma, Poole (UK)
3- [N-morpho lino]-propane-sulfonic acid 
(MOPS)
Sigma, Poole (UK)
4G10, monoclonal Ab Upstate Biotechnology, USA
5'Digoxygenin labelled iNOS probe R&D Systems (Abingdon,UK)
Absolute Ethanol Hayman Ltd., Witham, UK
Acrylamide/bis acrylamide Bio-Rad, UK
Adenosine triphosphate Sigma, Poole (UK)
Agarose Sigma, Poole (UK)
Ammonium persulphate BDH, Poole (UK)
Annexin-V-Fluo s Boehringer Mannheim (UK)
Apoptag Direct Oncor (Appligene, Durham, UK)
Apoptosis Detection Kit (R&D Systems, Abingdon, UK)
Bad, monoclonal Ab Transduction Laboratories, USA
Bad, polyclonal Ab Santa Cruz, USA
Bak polyclonal Ab Upstate Biotechnology, USA
Bcl-2, monoclonal Ab Upstate Biotechnology, USA
Bc1-Xl, polyclonal Ab Transduction Laboratories, USA
Blocking reagent (for Northern analysis) Boehringer Mannheim (UK)
Bovine serum albumin (BSA) Sigma, Poole (UK)
Bromophenol blue BDH, Poole (UK)
Cell culture plastics Nunc, UK
Chloroform Fisons, Loughborough (UK)
Coomassie blue Sigma, Poole (UK)
Cycloheximide Sigma, Poole (UK)
Diethyl pyrocarbonate (DEPC) Sigma, Poole (UK)
Digoxigenin chemiluminescent detection kit 
for Northern blotting
Boehringer Mannheim (UK)
Dimethyl sulphoxide (DMSO) Sigma, Poole (UK)
Dithiothretol (DTT) Sigma, Poole (UK)
DOTAP Boehringer Mannheim (UK)
ELISAplus Boehringer Mannheim (UK)
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Enhanced chemiluminescence detection kit 
for Western blotting (ECL)
Amersham International, UK
Ethidium bromide Sigma, Poole (UK)
Ethylenediaminetetraacetic acid (EDTA) Sigma, Poole (UK)
Flo-scint IV scintillation fluid Canberra Packard (UK)
Foetal bovine serum (FBS) Gibco BRL, Paisley, UK
Folch lipids Sigma, Poole (UK)
Formaldehyde BDH, Poole (UK)
Formamide BDH, Poole (UK)
Glacial acetic acid Fisons, Loughborough (UK)
Glycerol Sigma, Poole (UK)
Glycine Sigma, Poole (UK)
Goat anti-mouse peroxidase conjugate DAKO, Denmark
Goat anti-rabbit peroxidase conjugate DAKO, Denmark
Hank’s balanced salt solution Gibco BRL, Paisley, UK
Hepes (1M liquid) Gibco BRL, Paisley, UK
Histone H2B Boehringer Mannheim, UK. Stock stored at 
-20°C at 1 mg/ml in 20mM Tris pH 7.5
Hydrochloric acid BDH, Poole (UK)
IFN-y: human recombinant; specific activity 
> 2xl07 U/mg
Boehringer Mannheim, UK; stored in 
aliquots at -70°C
IL-la: human recombinant; specific activity 
5xl07 U/mg
Gift from Glaxo (Greenford, UK); diluted in 
sterile PBS + 0.25% (w/v) BSA and stored 
in aliquots at -70°C)
IL-13: purified from culture supernatants of 
stable transfected CHO cells (Minty et al., 
1993)
Gift from Dr. A. Minty (Sanofi Recherche, 
Labege, France); diluted in sterile PBS + 
0.25% (w/v) BSA and stored in aliquots at - 
70°C
IL-4: human recombinant; specific activity > 
lxlO7 U/mg
Genzyme
Insulin Donated by Dr. M. Welham
Iodine Sigma, Poole (UK)
IRS-1, polyclonal Ab Upstate Biotechnology, USA
IRS-2, polyclonal Ab Upstate Biotechnology, USA
Leupeptin Sigma, Poole (UK)




Maleic acid Sigma, Poole (UK)
McCoy’s 5A medium Gibco BRL, Paisley, UK
Methanol Fisons, Loughborough (UK)
Methylamine Fisons, Loughborough (UK)
Molecular weight markers Bio-Rad
Neutral buffered formalin Sigma, Poole (UK)
Nitrocellulose (Schleicher and Schuell)
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NP40 Sigma, Poole (UK)
Ovalbumin Donated by Dr. M. Welham
p70S6K, polyclonal Ab New England Biolabs, USA
p70S6K 41 *Ser, polyclonal Ab New England Biolabs, USA
p70S6K 42lThr/42'4Ser, polyclonal Ab New England Biolabs, USA
p85 (SH3/bcr), polyclonal Ab Dr. M. Welham, Bath, UK
p85a, monoclonal Ab Dr. D. Cantrell, I.C.R.F., UK
Phosphate buffered saline Gibco BRL, Paisley, UK
Phosphatidylinositol Sigma, Poole (UK)
Pho sphatidylserine Sigma, Poole (UK)
Phosphotyrosine antibody (4G10) Gift from Dr. M. Welham
PKB-a 473Ser, polyclonal Ab New England Biolabs, USA
PKBa polyclonal Ab Brian Hemmings (Friedrich Miescher- 
Institute, Switzerland)
PKB-a, polyclonal Ab Santa Cruz, USA
PKB-a, polyclonal Ab New England Biolabs, USA
PMSF Sigma, Poole (UK)
Polaroid film (type 55) Sigma, Poole (UK)
Ponceau S Sigma, Poole (UK)
Potassium oxalate Sigma, Poole (UK)
Propan-l-ol Fisons, Loughborough (UK)
Propan-2-ol Fisons, Loughborough (UK)
Propidium iodide Sigma, Poole (UK)
Protease Assay Kits Chemicon, USA
Protein A beads Pharmacia, UK
Protein G beads Sigma, Poole (UK)
Protein kinase inhibitor (PKI) Sigma, Poole (UK). Stored at -20°C as 
5|iM stock diluted in 0.05% BSA
RNase A Sigma, Poole (UK)
RNAzolB Tel Test, Texas, USA
Sarcosyl BDH, Poole (UK)
She, polyclonal Ab Upstate Biotechnology, USA
SHIP/SH2-GST fusion protein Mark Coggeshall, Ohio State University, 
USA
SHPTP2, polyclonal Ab Santa Cruz, USA
Sodium azide Sigma, Poole (UK)
Sodium chloride Sigma, Poole (UK)
Sodium dodecyl sulfate (SDS) Sigma, Poole (UK)
Sodium fluoride Sigma, Poole (UK)
Sodium hydroxide Sigma, Poole (UK)
Sodium molybdate Sigma, Poole (UK)
Sodium nitrite Sigma, Poole (UK)
Sodium ortho vanadate Sigma, Poole (UK)
TEMED Sigma, Poole (UK)
Materials and Methods 72
Tetrabutylammoniumhydrogen sulphate Fluka, Germany
Tissue culture reagents Gibco BRL, Paisley, UK
TNF-a: human recombinant; specific 
activity 6xl07 U/mg
Gift from Bayer (Slough, UK); diluted in 
sterile PBS + 0.1% (w/v) BSA and stored in 
aliquots at-70°C)
Trisodium citrate dihydrate Sigma, Poole (UK)
Triton X-100 Sigma, Poole (UK)
Trizma base Sigma, Poole (UK)
Tween-20 Sigma, Poole (UK)
Versene Gibco BRL, Paisley, UK
Wortmannin Sigma, Poole (UK)
X-OMAT film Amersham International, UK
Z-VAD-FMK Calbiochem (Nottingham, UK)
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2.2 METHODS
2.2.1 Cell Culture
The HT-29 colon adenocarcinoma cell line is a grade II human epithelial cell line that was 
isolated from a primary tumour in a 44 year old Caucasian female (ECACC). They are well 
characterised with features that match normal intestinal epithelium, such as epithelial 
polarity, presence of the actin-binding protein villin and the occurrence of an enterocytic 
differentiation (Chantret etal., 1988).
HT-29 cells were routinely cultured in 80cm2 tissue culture flasks in McCoy’s medium 
supplemented with penicillin (10 units/ml), streptomycin (10 pg/ml), fungizone (0.5pg/ml) 
and 10% (v/v) foetal bovine serum (FBS) (referred to as complete medium). Cultures were 
maintained at 37°C in an atmosphere of 5% C 02. The medium was changed every 3 days. 
To subculture confluent monolayers, the medium was removed and the cells were washed 
3x with PBS (w/o Ca2+ and Mg2+). Cells were then washed once with a 3ml Trypsin-EDTA 
mixture of 0.05% (w/v) Trypsin and 0.02% (w/v) EDTA. The excess solution was removed 
and the cells were incubated for approximately 5 min at 37°C until the cells had detached 
from the flask. Adding 10ml of complete medium inhibited the action of Trypsin-EDTA and 
the cell suspension was centrifuged at 200xg for 5 min. The cell pellet was resuspended in 
complete medium and cell counting and viability were checked in a Neubauer 
haemocytometer after mixing with Trypan Blue. Dead cells stained blue, due to the uptake 
of Trypan Blue. Cell viability was always greater than 95%. Cells were counted and then 
seeded at 2-3 x 104/ml of McCoy’s complete medium, into 80cm2 tissue culture flasks for 
further culture, or into 6-, 24- or 96- well plates or Petri dishes for experimental protocols.
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For storage, cells were resuspended at 4 x 106 cells/ml of freeze medium (Buffersand 
Solutions 2.3.1). The cell suspension was transferred to cryotubes at 1 ml/tube, gradually 
cooled in vapour phase of liquid nitrogen overnight and tubes were stored in liquid nitrogen 
tanks. For resuscitation of cells from liquid nitrogen, cells were rapidly defrosted at 37°C in 
a water bath, washed in McCoy’s medium, resuspended in complete medium and cells from 
one cryotube were seeded into 80cm2 tissue culture flasks in McCoy’s medium, continuing 
as above.
2.2.2 Experimental protocol
Unless otherwise stated, HT-29 cells were grown until confluent. Prior to experiments, 
monolayers were washed and cultured in McCoy’s without FBS for 24 hours. Growth- 
arrested cultures were treated with fresh FBS-free medium and stimulated with the 
appropriate doses of either drugs, cytokines or vehicle controls for the times described in 
the results section. Supernatants were collected, centrifuged to remove cellular debris and 
stored at -70°C until assayed for extracellular nitrite (see below). Total RNA and cellular 
proteins were extracted as described below.
2.2.3 Fluorometric nitrite assay
Nitric oxide (NO) production by HT-29 cells was determined by measuring the stable end- 
product nitrite in the cell culture supernatants by a fluorometric assay which is based upon 
the reaction of nitrite, under acidic conditions, with 2,3-diaminonaphthalene (DAN) to form 
the fluorescent product 1-(H)- naphthotriazole. The assay was modified for use on a Photon 
Technology International (PTI) spectrofluorimeter from the method previously described in 
(Misko et al., 1993). 200 (il of freshly prepared DAN (0.05 mg/ml in 0.62M HC1) was 
added to 2 ml of sample (culture supernatants) and vortexed immediately. After 10'
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incubation at room temperature in the dark, the reaction was terminated with 100 j l i I  of 
2.8N NaOH. The samples were measured using a PTI dual wavelength spectrofluorimeter 
(^ excitation365nm and ^emission405nm) and compared with known concentrations of sodium 
nitrite (10nM-2jiM sodium nitrite in FBS-ffee McCoy’s medium). Phenol red present in 
McCoy’s medium did not interfere with the assay. The sensitivity of the assay is 10 nM.
2.2.4 Northern analysis
Total cellular RNA was extracted from HT-29 cells using a commercial solution containing 
guanidinium thiocyanate (RNAzol B), a modification of the method described by 
{Chomczynski and Sacchi, 1987}. Buffers used for Northern analysis are detailed below 
and all solvents were "HPLC" grade.
2.2.4.1 RNA isolation
Monolayers were lysed directly in the culture dish by the addition of 1ml RNAzol B per well 
(3.5xl06 cells). The lysate was homogenised with a sterile cell scraper and transferred to 
sterile Eppendorf tubes by pipette. The addition of lOOjil chloroform to homogenates on ice 
for 5' was followed by centrifugation at 12 OOOxg (4°C) for 15'. The homogenate forms two 
phases and the upper colourless aqueous phase, containing the RNA, is transferred to a 
fresh sterile tube. An equal volume of isopropanol was added and kept on ice for 15 
minutes. After centrifugation at 12 OOOxg (4°C) for 15', the RNA precipitate forms a white 
pellet at the bottom of the tube.
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2.2A.2 Sample preparation
The RNA pellet was washed with 1ml of ice-cold 75% ethanol. The pellet was dried, 
resuspended in sterile RNase-ffee Milli-Q water and the concentration measured by 
absorbance of 2jll1 RNA in 1 ml 0.1 M NaOH at 260 nm. The amount of RNA (in p,g) 
present in each sample was calculated by:
A26o x dilution factor (500) x 40 x volume of remaining RNA solution in ml (0.048)
ODs were also read at 280 nm and 230 nm to assess the purity of RNA. A value of less than 
2 for the OD26o : OD28o ratio indicated protein contamination. A low OD26o : OD230 ratio 
indicated guanidine contamination. 30 |il of RNA sample buffer was added to 10|ig RNA 
and the samples were vortexed and heated for 15-30' at 80°C. The samples were cooled on 
ice and 2.5 |nl of bromophenol blue was added. Samples were mixed and pulse centrifuged 
prior to loading on agarose gels.
2.2.4.3 Gel preparation and transblotting
1 % agarose gel was prepared by dissolving 3 g agarose in 230 ml DEPC-treated water 
using a microwave oven. 15 ml 20X MOPS buffer and 54 ml formaldehyde were added and 
the gel solution allowed to cool to ~60°C before pouring. The gel was set with two 15-lane 
combs using tanks purchased from Hoefer Scientific Instruments (Newcastle, UK). After 
40', the gel was transferred to a submarine tank (Hoefer), which was surrounded with ice 
and covered with cold IX MOPS running buffer. 10 fig RNA per lane was loaded and the 
gel run at constant current of 100 mA, until the bromophenol blue band had migrated 1.3 
inches (~2 hours). The gel was placed under a UV light and the ethidium bromide stained 
18S and 28S ribosomal RNA bands observed to assess equal loading. The gel was 
photographed using a polaroid CU5 88-46 land camera (Genetic Research Instrumentation 
Ltd.) and type 55 polaroid film. The gel was agitated gently in DEPC-treated water for 30-
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60' to remove formaldehyde, prior to transblotting. The blotting tank consisted of a glass 
plate suspended in a sandwich box, which was half-filled with 20X SSC buffer. A wide strip 
of filter paper placed over the glass plate and reaching down into the buffer solution at each 
end acted as a wick. The gel was placed upside down on the filter paper and covered with a 
piece of positively charged nylon membrane with 3 pieces of similar size paper and a stack 
of paper towels. A 500 g weight was placed on top and left overnight to allow the RNA to 
transfer by capillary action. The RNA was fixed onto the nylon membrane by baking in a 
vacuum oven (Jouan) at 120°C for 20'. The membrane was sealed in a plastic bag and 
stored at room temperature prior to hybridisation.
2.2.4.4 Hybridisation with DIG-labelled oligonucleotides
Hybridisation of membranes and detection of bound probes was performed essentially as 
described in the Digoxigenin (DIG) chemiluminescent detection kit for Northern blotting 
from Boehringer Mannheim. The DIG detection system is based on the labelling of nucleic 
acid probes with a steroid hapten, digoxigenin. The DIG-labelled probes are hybridised to 
membrane-bound RNA. Specific hybridisation is immuno-detected with an alkaline 
phosphatase conjugated anti-digoxigenin antibody and visualised with the chemiluminescent 
substrate, CSPD, using X-ray film. Hybridisation temperature was optimised for the iNOS 
probe at 60°C, at a final concentration of 10 ng/ml. The volumes specified are for a 100 cm2 
membrane and prehybridisation, hybridisation and wash steps were all performed at 60°C. 
The membrane was prehybridised by incubating with 20 ml hybridisation solution for 1 hour 
in a sealed bag. The hybridisation solution was discarded and 2.5 ml of probe diluted to 10 
ng/ml in hybridisation solution was added. All air bubbles were removed and the bag 
resealed and incubated overnight. The membrane was transferred to a small sandwich box 
and washed twice for 5' each in 2X SSC, 0.1% SDS solution, followed by two washes of 5'
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each in 0.1 X SSC, 0.1% SDS solution at 60°C. The following steps were performed at 
room temperature on a shaking platform. Membranes were washed for 5' in wash buffer, 
prior to blocking for 30' in 100 ml buffer 2. Membranes were incubated for 30' with 20 ml 
alkaline phosphatase conjugated anti-DIG antibody diluted 1:10 000 in buffer 2. Membranes 
were then washed twice for 15' each in wash buffer and equilibrated for 2-5' in buffer 3. The 
membrane was drained and incubated for 5' between 2 plastic sheets with 1 ml of lumigen 
PPD substrate diluted 1:100 in buffer 3. The membrane was drained again, sealed in a 
plastic bag and incubated for 15' at 37°C in the dark, followed by exposure to Kodak X- 
OMAT X-ray film for 4-6 h at room temperature and the film developed using an RGII Fuji 
X-ray film developer.
2.2.5 Western blot analysis
2.2.5.1 Cell lvsis and sample preparation
Monolayers of HT-29 cells (107 cells/ Petri dish) were stimulated and incubated at 37°C in 
McCoy’s as described above. Stimulations were terminated at the appropriate times by 
aspiration of the supernatant and the addition of 1 ml ice-cold lysis buffer (Buffers and 
Solutions 2.3.4). Cells were solubilised using a cell scraper and the resulting lysates 
transferred to Eppendorf tubes which were incubated at 4°C for 15', followed by 
centrifugation at 12 OOOxg for 2' at 4°C. Supernatants were transferred to fresh Eppendorf 
tubes and kept on ice.
2.2.5.2 Protein assay
Total protein per lysate was estimated using the Bio-Rad DC Protein Assay. This assay is 
based on the Bradford dye-binding procedure (Bradford, 1976). Known concentrations of
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bovine serum albumin (BSA) diluted in lysis buffer were used as a standard curve. 5pl of 
sample or standard were placed in a 96-well plate with 25 pi of working reagent A' (20jnl 
reagent S into 1ml reagent A), plus 200pl of Bio-Rad reagent B, provided in the kit. After 
15', the plate was read at 595 nm on a Dynatech MR5000 platereader. The protein 
concentrations were calculated by linear regression from the standard curve and, if 
significantly variable, the lysate volumes were adjusted using lysis buffer, thus ensuring 
equal concentrations of protein in each sample.
2.2.5.3 Whole cell extracts
An aliquot, usually 20jll1, of lysate was removed, placed into a tube containing 5X SDS 
sample buffer, boiled for 2-5' and pulse spun before loading onto a gel.
2.2.5.4 Immunoprecipitation
The remaining lysate was precleared by adding 20pl of a 50% suspension (v/v) of either 
protein-A or protein-G sepharose beads (depending on the antibody to be used) and rotated 
for 15-30' at 4°C. The beads were spun down at 12000xg for 1' and the supernatant 
removed to a clean tube. The appropriate antibody was then added to the precleared 
extract, briefly vortexed and incubated on ice for 30' - 2h. After addition of a 50% (v/v) 
suspension of the appropriate protein sepharose beads, the samples were rotated for 30 - 60' 
at 4°C. The beads were captured by centrifugation at 12000xg for 1' at 4°C. When 
appropriate an aliquot (usually 20 pi) of each sample was removed to a tube containing 5X 
SDS sample buffer, boiled for 2-5' and pulse spun before loading the gel.
The remaining supernatant was aspirated and the pellet washed 3X in 1ml of lysis buffer, 
with the immunocomplexes spun down between washes. After the last wash, the
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supernatant was aspirated and any surplus supernatant was removed with a Hamilton 
syringe. The pellet was resuspended in 20 -  40 pi of IX SDS sample buffer, boiled for 2' 
and pulse spun before loading the gel.
2.2.5.5 Separation of cellular proteins bv electrophoresis
Proteins were analysed by one dimensional gel electrophoresis, which under reducing 
conditions separates proteins based on molecule size. Sodium Dodecyl Sulphate -  
Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out essentially as described 
by Laemmli (Laemmli, 1976). Proteins were separated by SDS-PAGE using the Bio-Rad 
Mini Protean II.
Minigels of the appropriate percentage were prepared as described in buffers and solutions. 
The resolving gel was poured into the gel equipment and overlaid with Milli-Q water. 
Polymerisation took 20 - 30', after which the water was aspirated off, the stacking gel was 
poured and a 10 or 15 lane comb inserted. Polymerisation took 20', the comb was removed 
and the wells washed thoroughly with Milli-Q water. The wells were then filled with IX 
SDS-PAGE running buffer.
20 fil of each sample was then loaded into the wells in parallel with molecular weight 
markers and the gels run at 80 V through the stacking gel, followed by 150 V through the 
resolving gel, until the bromophenol blue reached the bottom of the gel. Gels were then 
placed in transfer buffer.
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2.2.5.6 Semi-drv transfer of proteins to nitrocellulose
The graphite electrodes of the semi-dry transfer apparatus (Pharmacia-Biotech Multiphor 
II) were dampened with semi-dry transfer buffer, followed by placing a sandwich of 4 pieces 
of 3MM Whatmann paper (the same size as the gel), one piece of nitrocellulose membrane, 
the gel and another 4 pieces of 3MM paper, all soaked in transfer buffer. Each layer was 
rolled gently to expel air bubbles. The transfer was run for 60' at 0.8 mA/cm2 of membrane. 
The membrane was then stained with Ponceau S to check for transfer and even loading of 
the samples and to determine the location of the molecular weight markers. The stain was 
removed by washing the membrane in distilled water for 2', followed by a 10' wash in Tris 
buffered saline (TBS).
2.2.5.7 Blocking and Developing
The non-specific protein binding was blocked by overnight incubation of the membrane with 
the appropriate blocking buffer at room temperature on a rocking platform. After a 10' wash 
in TBS, the membrane was incubated with the primary antibody diluted in a 1:5 dilution of 
fresh blocking buffer for 2h -  overnight (usually 3h). Membranes were washed IX with 
TBS, 3X with TBSN, IX with TBS for -10' each wash. The membrane was incubated for 1 
-  2h with the appropriate secondary antibody diluted in TBSN (0.1 (ig/ml), followed by 
extensive washing as described above. An extra TBS wash for 10' was done before adding 
10 ml of Enhanced Chemiluminescent (ECL) reagent for 1'. The membrane was exposed to 
X-ray film for 30" - 30' and the film was developed using an RGII Fuji X-ray film developer.
2.2.5.8 Membrane stripping
Where appropriate, blots were stripped of bound protein and reprobed with a different 
primary antibody. After the ECL procedure described above, the membrane would be
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washed once in TBS for 10', placed in 50 ml of stripping buffer in a sealed sandwich box 
and incubated for 1 hour at 55°C. After extensive washing in at least three changes of 
TBSN and one wash in TBS, the membrane would be reblocked for 1 hour in blocking 
buffer. A different primary antibody could then be applied to the membrane for further 
protein detection.
2.2.6 Measurement of fCa2+li
The measurement of [Ca2+]i has been made possible by the development of a number of 
calcium sensitive dyes including fura-2 (review Walt et al., 1987). Fura-2 can be non- 
disruptively loaded into cells as the acetoxymethyl ester (AM), since the esterified fura-2 is 
uncharged and hydrophobic and can cross the plasma membrane. Once in the cells, 
endogenous esterases release the free fura-2, which cannot permeate out of the cell. The 
fluorescence excitation maximum of fura-2 shifts to a lower wavelength upon calcium 
binding, without any change in the emission maximum. Thus, fura-2 can be used as a dual 
excitation indicator. The excitation maxima for calcium-free and calcium-bound fura-2 are 
monitored at 380nm and 340nm respectively. The emission maximum is monitored at 
510nm.
2.2.6.1 Loading cells with fura-2/AM
HT-29 cells were grown on 22mm diameter glass cover slips. When subconfluent, the cells 
were washed twice in HBSS, and then loaded with 5jiM fura-2/AM at 37°C for 40' in 
complete HBSS. The adherent cells were then washed twice and placed in a 37°C chamber 
with HBSS.
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2.2.6.2 rCa2+li measurements
The chamber was positioned on a fluorescence microscope from Photon Technology 
International and a population of approximately 30 cells was selected by adjusting the field 
of view. Using a X40 oil immersion objective, the fluorescence changes were monitored 
over 40" for a basal intracellular calcium measurement. After addition of the agonist, the 
response was monitored for at least 1' and detected using dual excitation wavelengths of 
340nm and 380nm and a single emission of 510nm on a dual excitation/dual emission 
spectrofluorimeter from Photon Technology International. Due to the fact that when using 
this method, the fluorimeter can not be calibrated, the results were expressed as the 
fluorescence ratio at 340/380nm wavelengths.
2.2.7 PI 3-kinase activity
Two separate methods for measuring the agonist-induced activation of PI 3-kinase were 
employed in this study. The first method involves the measurement of the accumulation of 
D-3 phosphatidylinositol lipids in intact cells whereas the second method relies on the 
immunoprecipitation of the Class 1A PI 3-kinase enzyme using an antibody to the p85 
subunit, followed by an in vitro lipid kinase assay to analyse the immunoprecipitates. These 
two assays differ in the type of PI 3-kinase activity they measure. The former accounts for 
all PI 3-kinase activity that arises within the cells, whereas the latter only measures the 
activity of the PTK/SH2-coupled PI 3-kinase, which is immunoprecipitated by the p85 
antibody.
Materials and Methods 84
2.2.7.1 Accumulation of D-3 phosphatidylinositol lipids in intact cells
2.2.7.1.1 Sample preparation
HT-29 cells were dissociated from the flask using 3ml of Versene, washed three times in 
phosphate-free Dulbecco's Modified Eagles medium (DMEM) with 10-minute incubations 
at 37°C before each spin of 400xg for 5'. The cells were subsequently resuspended in 10ml 
phosphate-free DMEM containing 10% dialysed foetal bovine serum and 20mM HEPES at 
107 cells/ml and incubated at 37°C for 4 h with lmCi of [32P]-orthophosphoric acid 
(lOOpCi/ml, 185MBq).
After incubation, the cells were washed three times in phosphate-free DMEM and 
resuspended in McCoy’s (with 20mM HEPES, but without FBS). 107 [32P]-labelled cells 
were aliquoted in a volume of 120p,l into 1.5ml Eppendorf tubes and equilibrated at 37°C 
for 10'. Each point was stimulated with 12jll1 of agonist or vehicle for the appropriate times 
and the reaction quenched by the addition of 700|il of ice cold chloroform/methanol/water 
(32.6%/65.3%/2.1%) according to the method described by (Jackson et al., 1992). The 
samples were immediately placed on ice. 600pl of chloroform containing lOpg of Folch 
lipids as a carrier protein were then added along with lOOp.1 of 2.4M acid (HC1), 5mM 
tetrabutylammoniumhydrogen sulphate. The extraction mixtures were vortexed and 
centrifuged at 3000xg for 5'. The lower phase was removed and added to 400|il of 1M HC1, 
5mM EDTA. The mixtures were again vortexed and centrifuged at 3000xg for 5'. The 
lower phase was removed and dried in vacuo using a Savant SpeediVac. When dried down, 
lml of 25% (w/v) methylamine/methanol/N-butanol (4/4/1) was added to the residue and, 
after vortexing, the samples were incubated in a 53°C water bath for 40'. This deacylation 
procedure renders the glycerophosphorylinositol derivatives of PI (3) P (GroPI (3) P), PI
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(3,4) P2 (GroPI (3,4) P2) and PI (3,4,5) P3 (GroPI (3,4,5) P3) water soluble. The samples 
were then cooled for 1' on ice and dried in vacuo. Finally, 500jil of water and 600jll1 of N- 
butanol/40-60% petroleum ether/ethyl formate (20/4/1) were added. The samples were 
vortexed and centrifuged at 750xg for 30". The upper phase was removed and discarded 
and the lower phase was dried in vacuo. The samples were then stored at -20°C until 
analysis.
2.2.7.1.2 HPLC analysis of samples
Anion exchange high performance liquid chromatography (HPLC) was used to analyse the 
lipid content of the samples using a water and phosphate buffer gradient (Stephens et al., 
1989). The samples were resuspended in water and injected onto a Partisphere SAX 
column. The eluant was detected using a Canberra Packard A-500 Flo-One on-line beta 
radiodetector where it was mixed in a ratio of 1:3 with Flo-Scint IV scintillation cocktail, 
according to manufacturer’s specifications. The results were analysed on a FLO-one data 
program. The retention times were compared to standards of [H3]PI (4) P and [H3]PI (4,5) 
P2- The identity of the various peaks obtained using this separation technique has been 
defined previously (Stephens et al., 1991). The PI (3) P elution time was compared to that 
determined by Dr. Stephen Ward by immunoprecipitating PI 3-kinase using an anti-p85 
antibody and performing an in vitro lipid kinase assay. The PI (3) P was isolated by TLC 
and then extracted from the TLC plate and its elution time on the HPLC monitored 
(personal communication) (Ward et al., 1995). The elution times of the other 3- 
phosphorylated lipids were compared to those quoted in the literature (Stephens et al., 1991 
and Traynor-Kaplan et al., 1988). The levels of PI were used as an internal standard to 
confirm that each sample contained a similar amount of radioactivity as the PI pool should 
not vary upon agonist stimulation.
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2.2.7.2 Immunoprecipitation and in vitro lipid kinase assay
2.2.7.2.1 Coupling the antibody to protein G sepharose beads
The protein G sepharose beads from Sigma were provided in methanol and were therefore 
washed three times with 1 ml of PBS and then resuspended as a 50% suspension in PBS. 
500)11 aliquots were stored at 4°C until required. 50|il of anti-p85 antibody was added to 
500jll1 of 50% protein G bead suspension and the volume increased to 1ml with PBS. The 
suspension was rotated for 2 h at room temperature. Following rotation, the bead 
suspension was washed three times with 1ml of PBS and again resuspended as a 50% 
suspension by the addition of 250)il of PBS and stored at 4°C until required.
To confirm that the antibody had coupled to the beads, lOjil of the beads were denatured by 
heating to 90°C for 10' in reducing sample buffer. The samples were then separated by 10% 
SDS-PAGE, as described above. The gel was stained with Coomassie blue stain for 6 h and 
subsequently destained for 24 hours, in order to detect the heavy and light chains of the 
antibody.
2.2.6.2.2 Immunoprecipitation of the PI 3-kinase.
This was performed as described by (Ward et al., 1991). HT-29 cells were stimulated and 
lysed as described above. 20p,l of lysate was kept for a total kinase sample and the rest of 
the lysates were precleared with protein G sepharose beads.
The pre-cleared samples were centrifuged at 10 OOOxg for 5' and the supernatants removed 
and added to Eppendorf tubes containing 20|il of the antibody-coupled protein G beads. 
These suspensions were rotated for 2h at 4°C. Thereafter, the immunoprecipitates were
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washed 3 times with lysis buffer, once with PBS, twice with 500mM lithium chloride (LiCl) 
(pH 7.4), once with water and once with lipid kinase buffer, spinning at 10 OOOxg between 
each wash. After the final wash, surplus kinase buffer was removed using a Hamilton 
syringe.
2.2.6.2.3 In vitro lipid kinase assay.
Each of the samples, including the total lysate sample, was resuspended in 40|il of lipid 
kinase buffer. 50p.l of the lipid substrate mixture was added to the immunoprecipitates. The 
reaction was initiated by the addition of 5 jiCi of [y-32P]-ATP (S.A. 3000Ci/mmol, 
0.5mCi/ml, 18.5MBq) and 100|iM ATP. The samples were incubated in a 25°C water bath 
for 15' and the reaction quenched using lOOp.1 1M HC1 and 200pl 1:1 chloroform:methanol. 
The samples were spun for 30" at 10 OOOxg and then the lower chloroform layer removed 
and dried in vacuo.
The dried samples were resuspended in 50 j l l I  chloroform and applied to a 1% oxalate 
sprayed thin layer chromatography (TLC) plate. The plate was placed in a TLC tank that 
had been equilibrated for at least 6 h with propan-l-ol:2N glacial acetic acid (65:35 (v/v)) 
and lined with filter paper to ensure adequate vapour equilibration. The TLC plate was 
allowed to run for 15 hours.
Thereafter, the plate was air dried and exposed to iodine to detect the substrates, and finally 
exposed to a film for 1-12 hours at -70°C. The film was developed using an RGII Fuji X-ray 
film processor. The total lysate sample contained not only PI 3-kinase but also other kinases 
such as PI 4-kinase. This provided a positive control for the in vitro kinase assay to confirm 
that the assay was working.
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The Ptdlns (3) P product visualised by autoradiography was confirmed from previous 
experiments performed by Dr. Stephen Ward, in which the product was extracted from the 
TLC plate and analysed by HPLC (personal communication).
2.2.8 Detection of Apoptosis
In order to investigate whether HT-29 cells were undergoing programmed cell death and 
not necrosis, use was made of the relatively late apoptotic event of DNA fragmentation, 
whereby double stranded DNA is cleaved into mono- and oligonucleosomes which are 
histone-associated. Two of the methods described below utilise this event.
A relatively early apoptotic event is the extemalisation of phosphatidylserine (PS) residues 
from the inner part of the plasma membrane to the outer surface, in order to facilitate 
recognition and phagocytosis of the apoptotic cell by neighbouring cells or macrophages 
and prevent inflammation. Annexin V is a Ca2+-dependent phospholipid-binding protein with 
high affinity for PS and can be used as a probe for PS exposure and therefore to detect 
apoptotic cells.
Alternatively, due to the fact that cysteine proteases play an essential role in the onset of 
apoptotis, detection of protease activity in crude cell lysates from induced cells allows for 
another method of monitoring and confirming the apoptotic process in HT-29 cells.
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2.2.8.1 Apoptag Direct, In Situ Apoptosis Detection Kit, Fluorescein
Apoptosis was determined by direct fluorescence detection of end-labelled genomic DNA 
using the above kit. Residues of fluorescein-nucleotide are catalytically added to the DNA 
by terminal deoxynucleotidyl transferase (TdT), an enzyme which catalyses a template- 
independent addition of nucleotide triphosphate to the 3’-OH ends of double- or single­
stranded DNA. The incorporated nucleotides form a random heteropolymer, which, when 
excited by light of 494nm wavelength, the fluorescein generates an intense signal at 523nm. 
Treated and untreated cells were spun onto slides, fixed with 4% (v/v) neutral buffered 
formalin, equilibrated and stained with working strength TdT, according to the 
manufacturer’s instructions. As a negative control, some reactions were performed without 
the TdT enzyme. After washing in stop/wash buffer and PBS, slides were counterstained 
with propidium iodide staining solution and mounted with glass coverslips. The slides were 
observed under a fluorescence microscope. The results were scored by counting apoptotic 
cells (green) and viable cells (red) randomly in various fields. For each condition, 500 to 
1000 cells were counted.
2.2.8.2 Cell Death Detection ELISAplus
The detection of apoptosis was performed by determining the histone-associated DNA 
fragments (mono- and oligonucleosomes) generated by the apoptotic cells using the above 
kit. 104 cells/well were aliquoted into 96-well plates and allowed to adhere overnight. Cells 
were then treated, as indicated, pelleted and the supernatants were removed. Cell pellets 
were lysed (lysis buffer included in kit) and assayed according to the manufacturer’s 
instructions. Briefly, 20 |il of lysate was transferred into the strepdavidin-coated MTP along 
with a positive control (provided). 80 |il of the immunoreagent was added to each well, the 
plate was covered and incubated at room temperature for 2 hours. The plate was shaken
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periodically during incubation. The solution was then removed and the plate was washed 3X 
w i t h  incubation buffer. 100 jllI of substrate solution was added for 15' before photometric 
analysis was performed at 405 nm against the substrate solution as a blank (reference 
wavelength 490 nm), using a microtiter plate-reader (Dynatech MR5000). The specific 
enrichment of mono- and oligonucleosomes released into the cytoplasm was calculated 
using the following formula:
mU of the sample (dving/dead cells)________ = enrichment factor
mU of control sample (cells without treatment)
(mU = absorbance [10'3])
2.2.8.3 Annexin-V-Fluos
In some experiments, apoptosis was detected by measuring the externalisation of 
phosphatidyserine by FITC-labeled annexin-V binding using the Apoptosis Detection Kit. 
Cells were treated as indicated and stained according to the manufacturer’s instructions. 
Briefly, after stimulation cells were dissociated from the wells using Trypsin-EDTA, washed 
in PBS and centrifuged at 200xg for 5'. The cell pellet was resuspended in 100 (xl of 
labelling solution and incubated at room temperature for 10 - 15' in the dark. After the 
addition of 400 |xl incubation buffer, analysis by flow cytometry (Becton Dickinson FACS 
Vantage) was performed. Percentage increases in annexin-V- fluoroscein binding above 
controls were measured.
2.2.8.4 Detection of Caspase Activity
Activation of the caspase cascade is pivotal to the death execution phase of apoptosis and it 
appears that caspase-8 is the apical member of the apoptotic pathway with caspase-3 lying
Materials and Methods 91
downstream (G. M. Cohen, 1997). Colorimetric Protease Assay Kits for both caspase-8 and 
-3 (Chemicon, USA) allow for the detection of protease activity at two distinct points in the 
apoptotic cascade. The principle of the assay is based on spectrophotometric detection of 
the chromophore p-nitroanilide (p-NA) after cleavage from the labelled tetrapeptide 
substrate DEVD-pNA in the case of caspase-3 and IETD-pNA in the case of caspase-8. 104 
cells/well were aliquoted into 96 well plates and allowed to adhere overnight. Cells were 
then treated as indicated and pelleted after 24 hours to include any floating cells. The 
supernatants were removed and the cell pellets were lysed and assayed according to 
manufacturer’s instructions. Briefly, after centrifugation to remove cell debris, 50 jLil of cell 
lysate was transferred into a clean MTP and 50 jil of 2X reaction buffer (provided) 
containing 10 mM DTT was added. 5 pi of the 4 mM DEVD-pNA or IETD-pNA substrate 
(200 pM final concentration) was added and the plate incubated at 37°C for 2 hours. The 
pNA light emission was quantified using a microtiter plate reader at 405nm. Comparison of 
the absorbance of pNA  from the apoptotic sample with uninduced control determined the 
fold increase in caspase activity.
2.2.9 Protein Kinase B Assays
2.2.9.1 Western Analysis
Aliquots of cell lysate supernatant were boiled in 5X sample buffer and electrophoresed 
through 12.5% (v/v) acrylamide gels (with an acrylamide:bis-acrylamide ratio of 37.5:1) by 
SDS-PAGE and the proteins were transferred by electroblotting onto nitrocellulose as 
described above. The blots were probed with a phosphospecific PKB (0.5 pg/ml) which 
only has affinity for the active, 473Ser-phosphorylated forms of PKB antibody and proteins 
visualised by ECL with a goat anti-rabbit Ig (0.1 pg/ml) conjugated with horseradish
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peroxidase as a secondary antibody. Where appropriate, blots were completely stripped of 
antibodies by incubation at 55°C for 60 minutes with stripping solution. After extensive 
washing, blots were reblocked prior to reprobing with anti-PKB antibody (0.5 fig/ml).
2.2.9.2 In vitro kinase assays
Cells were stimulated as described above and PKB a  was immunoprecipitated from cell 
lysates with ljixg anti-PKBa (Santa Cruz) for 1 hour at 4°C. Immunocomplexes were 
captured with 30|iL of 50% suspension Protein G Sepharose at 4°C with rotation for 1 
hour. Beads were washed twice in lysis buffer, twice in LiCl wash buffer and once in kinase 
buffer. Kinase assays were performed by suspending beads in kinase buffer containing 2.5|ig 
histone H2B, 0.5p.M protein kinase inhibitor (PKI), 50jiM ATP, 3pCi ATP[y-32P] at room 
temperature for 30'. Reactions were stopped by the addition of 5x SDS PAGE sample 
buffer containing 2-mercaptoethanol followed by boiling for 5'. Samples were 
electrophoresed in 12.5% polyacrylamide gels as described above. The gel was cut in the 
middle so that the upper part contained the 60kDa PKBa protein and the lower part the 
phosphorylated 15 kDa histone H2B protein. The upper part was transferred as described 
above and immunoblotted for PKBa and the lower part was stained for 15' with Coomassie 
Blue to detect histone H2B and after destaining, the gel was dried and phosphorylated 
histone H2B detected by autoradiography at -70°C.
2.2.10 Detection of Bad phosphorylation
Bad was immunoprecipitated from cell lysates with 4 fig of anti-Bad mAb (Transduction 
Labs). After addition of 30 jllI protein G-Sepharose beads (50% suspension in PBS), 
immunoprecipitates were rotated for 1 h at 4°C and then washed three times in lysis buffer, 
resuspended in 5X sample buffer and boiled for 5' prior to electrophoresis through 12.5 %
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(v/v) acrylamide gels (with an acrylamide:bis-acrylamide ratio of 118:1). The proteins were 
transferred onto nitrocellulose and Bad was immunoblotted with 0.5 pg/ml anti-Bad 
polyclonal antibody (Santa Cruz) and proteins visualised by ECL with a goat anti-rabbit Ig 
(0.1 pg/ml) conjugated with horseradish peroxidase as a secondary antibody.
2.2.11 Statistical Analysis
Statistical significance was assessed by two-way analysis of variance followed by Dunnett’s 
test for multiple comparisons with control. Data are expressed as means ± SEM from three 
independent experiments, unless otherwise stated. p<0.05 was taken as the criterion for a 
significant difference. Throughout **denotes p<0.01 and * denotes p<0.05.
2.3 BUFFERS AND SOLUTIONS
2.3.1 Solutions and reagents for cell culture
Tissue culture reagents were used for cell cultures and all solutions were prepared using 
sterile MilliQ water.
Phosphate Buffered Saline, pH 7.4
140 mM NaCl 
2.7 mM KC1 
1.5 mM KH2HPO4 
8.1 mMNa2HP04
Hank’s Balanced Salts Solution (HBSS), 
pH 7.4
100 ml 1 OX Hank’s balanced salts 
ImM Ca2+/Mg2+
0.1% BS A
McCoy’s medium 5A 
Supplemented with penicillin (10 units/ml), 
streptomycin (10 pg/ml) and fungizone 
(0.5pg/ml) before use.
Foetal Bovine Serum
Stored at -20°C in 50 ml aliquots (heat- 
inactivated).
Freeze medium 
10% (v/v) DMSO 
40% (v/v) FBS 
50% (v/v) McCoy’s 5A
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2.3.2 Solutions and buffers for Nitrite assay
HC1 solution NaOH solution
0.62 M HC1 in Milli-Q water. 2.8 M NaOH in Milli-Q water.
2.3.2 Solutions and buffers for Northern Analysis
DEPC- treated water or buffer
Milli-Q water or buffer was treated with 1ml 
of diethyl pyrocarbonate per litre of water 
and incubated overnight at 37C. Autoclave 
(for 20 minutes at 121C).
20% (w/v) SDS solution
20g SDS diluted in 100ml sterile Milli-Q 
water
2M Tris-HCl stock solution, pH 8
2M Trizma base in Milli-Q water, adjust to 
pH 8 with HCL. Autoclave
0.5M EDTA stock solution, pH 8
0.5M EDTA in Milli-Q water, adjust pH. 
Autoclave
3M Sodium acetate, pH 5.2
3M sodium acetate dissolved in 250 ml 
Milli-Q water. Adjust pH with 3M glacial 
acetic acid. DEPC treat and autoclave.
75% (v/v) ethanol solution
75 ml absolute ethanol in 25 ml Milli-Q 
water.
20X MOPS running buffer
0.4M 3-[N-morpholino]-propane-sulfonic 
acid (MOPS)
0.02M EDTA (4 ml of 0.5M stock/100 ml) 
0.2M sodium acetate (6.64 ml of 3M 
stock/100ml)
Adjust volume to 100 ml with Milli-Q water 
and pH with solid NaOH. Filter sterilise
RNA sample buffer (per sample)
7 |xl 36% (w/v) formaldehyde
4 jllI 20X MOPS running buffer
2 pi 1 mg/ml ethidium bromide solution
20 pi formamide
Made up fresh before use.
IX MOPS running buffer
50 ml 20X MOPS in 950 ml DEPC-treated 
water.
lmg/ml Ethidium bromide solution
10 mg ethidium bromide in 10 ml DEPC- 
treated water.
Bromophenol solution
0.025g bromophenol blue 
3 ml glycerol
Adjust volume to 10 ml with DEPC-treated 
water
20X SSC, pH 7
3M NaCl
0.3M trisodium citrate dihydrate 
Milli-Q water, DEPC treat and autoclave
Buffer 1
0 .1M maleic acid 
0.15M NaCl
Adjust to pH 7.5 with solid NaOH, DEPC 
treat and autoclave.
Blocking stock solution
lOg blocking reagent in 100 ml buffer 1. 
Microwave to dissolve (do not boil). 
Autoclave.
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Hybridisation solution
5X SSC (25 ml of 20X stock/100 ml) 
0.1% sarcosyl (0.33 ml of 30% stock/100 
ml)
0.02% SDS (0.1 ml of 20% stock/100 ml) 
1 % blocking buffer (10 ml of 10% 
stock/100 ml) in DEPC-treated water.
2X SSC, 0.1% SDS solution
50 ml of 20X SSC
2.5 ml of 20% SDS stock
Adjust volume to 500 ml with DEPC-treated
water.
IX SSC, 0.1% SDS solution
2.5 ml of 20X SSC
2.5 ml of 20% SDS stock
Adjust volume to 500 ml with DEPC-treated 
water.
Buffer 3, pH 9.5
O.IMTris 
0.1M NaCl
in sterile Milli-Q water.
Washing buffer
0.3% (v/v) Tween-20 in buffer 1.
Buffer 2
10% (v/v) blocking stock solution in buffer 
1.
2.3.4 Solutions and buffers for SDS-PAGE and Western blotting
Lysis buffer
50 mM Tris pH 7.5 (stock 1M)
150 mM NaCl (stock 5M)
1% (v/v) Nonidet P40 (stock 10% (v/v)) 
10% glycerol
5 mM EDTA (stock 0.5M, pH 8.0)
1 mM sodium orthovanadate
1 mM sodium molybdate
10 mM sodium fluoride
40 |Lig/ml phenylmethylsulfonyl fluoride
(PMSF)
1 pg/ml pepstatin A (stock in methanol)
10 pg/ml aprotinin 
10 pg/ml leupeptin 
10 pg/ml soyabean trypsin inhibitor 
Milli-Q water
Stock solutions
1M Tris-HCl pH 8.8 (60.6 g trizma 
base/500 ml Milli-Q H20)
1M Tris-Hcl pH 6.8 (60.6 g trizma 
base/500 ml Milli-Q H20)
Acrylamide/bis acrylamide (30:0.8) (store 
at 4°C)
10% (w/v) SDS (100 ml, 10 g SDS + 
91 ml Milli-Q H20)
10% (w/v) ammonium persulphate (1 ml 
aliquots in Milli-Q H20 , store at 4°C) 
TEMED
SDS-PAGE running buffer
25 mM Trizma base 
192 mM glycine 
0.1% (w/v) SDS





200mM Tris-HCl pH 6.8 
Milli-Q water 
Bromophenol blue
5% 2-mercaptoethanol (50pl/ml) or 10% 
1M DTT (for reducing buffer)
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Semi-dry transfer buffer
39 mM glycine 
48 mM Trizma base 
0.0375% SDS 
20% (v/v) methanol
Tris-buffered saline (TBS) 
20 mM Tris-HCl pH 7.5 
150 mM NaCl 
Milli-Q water, pH 7.5
Tris-buffered saline (TBSN)
TBS + 0.05% (v/v) NP40
Ponceau S
0.1% (w/v) Ponceau S 
5% (v/v) acetic acid
Blocking buffer
(a) For most antibodies:
5% (w/v) non-fat powdered milk (Marvel) in 
TBS
0.05% azide





0.25% (w/v) Coomassie blue 
45.4% (v/v) methanol 
9.2% (v/v) glacial acetic acid 
Milli-Q water
Stripping buffer
62.5 mM Tris-HCl, pH 6.8 
2% (w/v) SDS 
100 mM 2-mercaptoethanol 
Milli-Q water
Destain solution
45.4% (v/v) methanol 
9.2% (v/v) glacial acetic acid 
Milli-Q water
Recipes for various percentage gels
Resolving gel -  5 ml is sufficient for 1 mini gel and 40 ml for 1 large gel 
Stacking gel* -  1.5 ml is sufficient for 1 mini gel and 8 ml for 1 large gel










Acrylamide 1.67 3.75 5 6 7.5
Milli-Q H20 6 5.6 4.35 3.35 1.85
lM Tris pH 8.8 5.6 5.6 5.6 5.6
lM Tris pH 6.8 1.25
10 % SDS 0.15 0.25 0.25 0.25 0.25
Total (mil 9.07 15.2 15.2 15.2 15.2
Plus 50jll1 10% APS 
Plus 20jil TEMED
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pH adjusted to 3.8 using orthophosphoric
acid
Lithium chloride
500 mM LiCl, pH 7.4
In vitro lipid kinase buffer
5 mM MgCl2 
0.25 mM EDTA 
20 mM Hepes 
pH adjusted to 7.4
Lipid substrate mixture
1 mg of phosphatidylinositol
1 mg of phosphatidylserine
Made up in 2ml of 25mM Hepes/ImM
EDTA
Dispersed by sonication 3X 15 second bursts 
on ice)
2.3.6 Solutions and buffers for anontosis assays
Phosphate buffered saline
50 mM sodium phosphate, pH 7.4 
200 mM NaCl
Stop/wash buffer
1 ml Stop/wash buffer, provided in kit
34 ml Milli-Ro water
35 ml Total 
Store at 4°C.
Working strength TdT
Amount for 5 cm2 (ie., per slide)
38 pi Reaction buffer, provided in kit 
16 |iil TdT enzvme 
54 pi Total 
Vortex and keep on ice.
Propidium Iodide staining solution
PI stock solution of 50 pg/ml.
For 10 mis: propidium iodide (50 pg) 
RNase A (50 U) (0.5 mg) 
PBS, pH7.4 (10 ml)
Make up fresh and keep on ice.
Immunoreagent
For 10 tests:
anti-histone-biotin mAb 40 pi 
anti-DNA-peroxidase mAb 40 pi 
incubation buffer, provided 720 pi 
Total 800 pi 
Vortex and use immediately.
Incubation buffer
10 mM Hepes/NaOH, pH 7.4 
140 mM NaCl 
5 mM CaCl2
Substrate solution
ABTS substrate tablet, (2,2’-azino-di-(3- 
ethylbenzathiazoline sulfonate)
15 ml sustrate buffer, provided in kit 
Protect from light.
Annexin-V-Fluos labelling solution
Annexin-V-Fluos labelling reagent 20 pi 
Incubation buffer 1 ml 
PI (from stock) 20 pi
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2.3.7 Solutions and buffers for PKB assays
LiCl wash buffer Kinase buffer
500mM LiCl 50 mM Tris-HCl pH 7.5
lOOmM Tris HC1 pH 7.5 10 mM MgCl2
ImMEDTA 1 mMDTT
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During the pathogenesis of IBD, human colonic epithelial cells express inflammatory 
mediators, such as chemokines and nitric oxide. Increased pro-inflammatory cytokines 
circulate in the underlying gut mucosa and exert their effects on many cell types, including 
epithelial cells. Using HT-29 cells as model colon epithelial cells, initial investigations 
sought to confirm the mechanisms involved in nitric oxide production and regulation by T 
cell-derived cytokines as proposed by Kolios et al, 1995.
Growth-arrested monolayers of HT-29 cells, when stimulated with vehicle produced a small 
constitutive amount of nitrite (Fig. 3.1 A). The pro-inflammatory cytokines IL -la  (10 
ng/ml), TNF-a (100 ng/ml) and IFN-y (300 U/ml) added alone to HT-29 cells did not 
induce a significant increase in nitrite generation after 24h as compared to the constitutive 
nitrite production in vehicle treated cells (Fig. 3.1 A). The combination IL-la/IFN-y was the 
minimal requirement for enhanced nitrite production, whilst other pairs of cytokines were 
ineffective. Stimulation with EL-la/IFN-y produced a significant (p < 0.01) increase in 
nitrite production of 175 ± 24 nM/106 cells (n=3) at 24 hours, compared to the basal 
production of 45 ± 8 nM/106 cells (n=3) (Fig. 3.1 A). The addition of TNF-a to the 
combination of IL-la/IFN-y produced approximately a 3 fold enhancement of IL-la/IFN- 
y induced nitrite generation, i.e., 384 ± 35 nM/106 cells (n=3) (Fig. 3.1 A).
Nvehicle
IL -la(10  ng/ml) 1
IFN-y (300 U/ml) 3
TNF-a (100 ng/ml) 3
IFN-y/ TNF-a
IL- l a  /TN F-a 1
IL-la/IFN -y H
IL-la/IFN-y/TNF-a J
■— I— :— I— :— I— :— I— :— I— :— I— :— T
0 50 100 150 200 250 300 350
nM nitrite/ 106cells
Figure 3.1 A. Growth-arrested HT-29 monolayers were stimulated with cytokines, as 
indicated. After 24 hours, nitrite in the supernatants was measured using the 
fluorometric nitrite assay, see section 2.1.1. Each point represents the mean ± SEM of at 
least three separate experiments.
oiNOS
28S --------- > (
18S -------- ►
Figure 3.1B. Growth-arrested HT-29 monolayers were stimulated with cytokines, as 
indicated. After 24 hours, cells were harvested for Northern analysis, as described in 
Section 2.3. The top panel shows the iNOS mRNA detected and the bottom panel 
indicates equal loading of total RNA. Data is representative of three experiments.
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To determine whether the inducible generation of nitric oxide by HT-29 cells was due to the 
induction of iNOS gene transcription, the iNOS mRNA was determined by Northern 
analysis after 24 hours stimulation. In cells stimulated with vehicle or individual pro- 
inflammatory cytokines, iNOS transcripts were not detected (Fig. 3.IB). Similar to the 
nitrite measurements, the combination IL-la/IFN-y was the minimal requirement for iNOS 
expression, whilst other pairs of cytokines were ineffective. However, the addition of TNF- 
a  to the combination of IL-la/IFN-y was without effect on the IL-la/IFN-y-induced iNOS 
mRNA expression in these cells (Fig. 3. IB), suggesting that the up-regulation by TNF-a on 
the IL-1 a/IFN-y-induced nitrite generation by HT-29 cells is at the post-transcriptional 
level.
Regulation o f iNOS activity by NOS inhibitors
The potential therapeutic role for iNOS inhibitors has led to their use in animal experimental 
models. Non-selective agents able to inhibit both ecNOS and iNOS seem to be effective in 
some experimental models (Hogaboam et al., 1995; Rachmilewitz et al., 1995 and Seago et 
al., 1995). However, suppression of ecNOS achieved by these agents can actually worsen 
intestinal injury (Pfeiffer and Qiu, 1995 and Dobosz et al., 1996) and prevent epithelial 
repair (Miller et al., 1993). However, selective inhibition of iNOS in a model of chronic 
colitis in monkeys did not reduce either histological inflammation or diarrhoea (Ribbons et 
al., 1997). It is possible that iNOS inhibitors are effective as protective agents only when 
administered at the time of induction of intestinal inflammation and do not exert substantial 
anti-inflammatory activities when administered after inflammation has already been 
established and iNOS expressed (Ribbons et al., 1997). Thus, the effect of various iNOS 
inhibitors on cytokine-induced iNOS activity was measured by treating HT-29 cells with
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iNOS-inducing combinations of pro-inflammatory cytokines concomitantly with available 
iNOS protein inhibitors. This different approach was thought could verify that the activity 
of iNOS was contributing to the nitrite being measured in the culture supernatant.
Co-stimulation of HT-29 cells with both pro-inflammatory cytokines and iNOS inhibitor 
resulted in a 75 ± 3 % (n=3) inhibition of nitrite accumulation by AG and a 91 ± 2 % (n=3) 
inhibition by NMMA (Table 3.1). The difference may be accounted for if one considers that 
NMMA may be concurrently inhibiting ecNOS. 1400W, at the higher concentration of 
lOOpM produced a 75 ± 4  % (n=3) inhibition of nitrite accumulation (Table 3.1), with the 
lower concentration of 10 pM only just producing a significant inhibition.
Induction of remission is the first line of defence in the management of IBD symptoms and 
the therapeutic use of anti-inflammatory agents is widespread (W. J. Sandbom, 1998 and 
D’Haens and Rutgeerts, 1998). To investigate whether these agents play a role in iNOS 
activity, two types of agent in common use were added to HT-29 cells 30 minutes prior to 
cytokine induction of iNOS.
Dexamethasone, a corticosteroid, is an anti-inflammatory drug that acts transcriptionally by 
binding to a cytosolic glucocorticoid receptor and then translocating to the nucleus and 
interacting directly in the promoter region of target genes. It is a known iNOS inhibitor in a 
wide variety of cell types and is thought to have both transcriptional and posttranscriptional 
effects (Radomski et al., 1990, Rachmilewitz et al., 1995 and Rees et al., 1995). However, 
in the HT-29 system, dexamethasone ( 1 - 1 0  pM) had no effect on nitrite accumulation 
over 24 hours post induction (Table 3.2).
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5-Aminosalicylate (5-ASA) is a nonsteroidal anti-inflammatory drug (NSAID) widely used 
for patients with active IBD. It has been shown to inhibit the activity of iNOS (J. F. 
Valentine, 1998 and Reynolds et al., 1995), although NO generation in cultured tissues 
from colitic patients was unaffected (Rachmilewitz et al., 1995). Interestingly, 250 pM of 5- 
ASA given prior to the addition of the iNOS-inducing cocktail of cytokines, gave no 
significant change in the nitrite accumulated over 24 hours (Table 3.2).
Sodium salicylate (4mM) is also an NSAID shown to inhibit transcription of iNOS and 
subsequent nitrite accumulation (Farivar et al., 1996). Interestingly, although a significant 
decrease in nitrite accumulation was seen (Table 3.2), more than 50 % of the HT-29 cells 
were found detached after 24 hours, perhaps suggesting that the concentration may be 
cytotoxic or this drug has an apoptotic mode of action. Also, it should be noted that the 
concentration may not reflect the physiologically relevant range. The concentration for 
sodium salicylate was taken from Farivar and Brecher, 1996.
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Table 3.1. Confluent HT-29 cells were starved of serum for 24 hours prior to treatment 
with IL-lot/IFN-y/TNF-a, with concurrent addition Of the iNOS inhibitor, as listed. 
Supernatants were collected after 24 hours and assayed for nitrite as described in Section 
2.2.3. * denotes pcO.OOl
NOS inhibitor % inhibition in nitrite
Aminoguanidine (AG) (500 pM) 75* ± 3 %
NMMA (500 pM) 91* ± 2 %
1400W (10 pM) 20 ± 5 %
1400W(100pM) 75* ± 4 %
Table 3.2. Confluent HT-29 cells were starved of serum for 24 hours prior to a 30 minute 
incubation with the therapeutic agent as listed, followed by stimulation with IL- loc/IFN- 
y/TNF-oc. Supernatants were collected after 24 hours and assayed for nitrite as described in 
Section 2.2.3. * denotes pcO.OOl
Therapeutic agent % inhibition in nitrite
Dexamethasone ( 1 - 1 0  pM) no significant change
5-ASA (250 pM) no significant change
Sodium salicylate (4mM) 88* ± 3 %
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The regulation of iNOS activity by other pharmacological agents
Existing data relating the role of iNOS to gut dysfunction have been obtained primarily in 
rodent models (Salzman, 1995) and may generalise imperfectly to the clinical setting 
because of differences in iNOS transcriptional regulation, cofactor requirements and 
susceptibility to pharmacological inhibitors. Given the importance of preserving gut barrier 
function in critical illness, agents that modulate the induction or activity of iNOS in the 
intestinal epithelium may have therapeutic potential.
Phorbol 12-myristate 13-acetate (PMA) mimics diacylglycerol (DAG) and is, thus, a direct 
activator of PKC, particularly the typical and novel isoforms. The role of kinases in the 
transcription of iNOS is not completely understood and this investigation sought to 
ascertain whether PKC activation could lead to changes in nitrite accumulation, which 
might indicate a change in iNOS expression. As shown in Table 3.3, both doses of 5 ng/ml 
and 50 ng/ml PMA caused a highly significant enhancement of nitrite present in the 
supernatants. Interestingly, the higher dose of 50 ng/ml resulted in an approximate 20 % 
reduced enhancement from that of the 5 ng/ml dose, perhaps suggesting that more chronic 
treatment by this phorbol ester might lead to the inhibition of certain PKC isoforms.
The MAPK pathways are involved in a number of cell signalling pathways. The availability 
of SB203580, a specific inhibitor of p38, has made it possible to identify effects mediated by 
or requiring active p38 protein kinase (Cuenda et al., 1995). Similarly, the availability of 
another inhibitor, PD098059, which inhibits MEK1 and MEK2 activation, has been used to 
study ERK-mediated responses (Dudley et al., 1995). Indeed, the use of these inhibitors 
was used in this study to investigate a role for these kinases in iNOS activity. SB203580 at
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30 pM completely abolished the cytokine-induced nitrite accumulation, whereas PD098059 
at 50 pM produced a significant but partial inhibition. These results strongly suggest a 
requirement for the stress-response pathway in either the expression of iNOS or its activity, 
although a role for the proliferation/differentiation pathway is also implicated.
Another important intracellular signalling pathway, already discussed in Section 1.5, is the 
PI 3-kinase pathway activated by growth and survival factors. At the time of this 
investigation there was no evidence to suggest that this family of lipid kinases had a role to 
play in NOS expression or activity. However, the Class Ia of PI 3-kinases also has protein 
serine kinase activity and the physiological role for this function has yet to be investigated. 
Hence, the fungal metabolite wortmannin, which irreversibly inhibits both the lipid and 
serine kinase activity of PI 3-kinase at 100 nM, and the structurally unrelated compound 
LY294002, which may be more specific, were used to investigate the role of PI 3-kinase on 
iNOS activity. Interestingly, neither inhibitor was able to upregulate iNOS on its own, but 
there was a differential effect when added with the pro-inflammatory cytokines (Table 3.3). 
Wortmannin at 100 nM made no significant difference to the cytokine-induced effect on 
nitrite accumulation, although the higher dose of 300 nM significantly enhanced this effect. 
Also, LY294002 made no significant difference to this measure of iNOS activity. These 
data are conflicting, but may indicate the participation of PI 3-kinase at some level of iNOS 
regulation.
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Table 3.3. Confluent HT-29 monolayers were starved for 24 hours, pre-treated with an 
agent, as listed, for the times indicated and followed by stimulation with the cocktail of 
cytokines IL-la/IFN-y/TNF-a. Supernatants were collected after 24 hours incubation and 
assayed for nitrite accumulation, as described in Section 2.2.3. * denotes p<0.01
Pharmacological agent Incubation 
time (mins)
% change in nitrite
Phorbol Myristate Acetate (PMA) (5 ng/ml) 30 63* ± 5 % enhanced
PMA (50 ng/ml) 30 43* ± 1 % enhanced
SB203580 (3 \iM) 60 59* ± 1 % inhibition
SB203580 (30 |xM) 60 99* ± 1 % inhibition
PD098059 (50 ^iM) 60 47* ± 3 % inhibition
Wortmannin (100 nM) 10 21 ± 2 % enhancedO
Wortmannin (300 nM) 10
J
2* ± 2 % enhanced
LY294002 (10 jiM) 15 No significant change
LY294002 (30 |iM) 15 No significant change
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Differential expression and activity o f iNOS in the presence o f cycloheximide
Cycloheximide is a translation inhibitor, which directly results in the interference of protein 
synthesis (Obrig et al., 1971). To determine whether de novo protein synthesis is a feature 
of iNOS expression and activity, experiments were performed whereby HT-29 cells were 
treated with a range of concentrations of cycloheximide one hour prior to the cytokine mix. 
Lower doses (0.25 - 1 |ig/ml) significantly enhanced both nitrite production (Fig. 3.2A) and 
iNOS mRNA transcripts (Fig. 3.2B). Higher doses (2.5 - 10 flg/ml) inhibited both nitrite 
production (Fig. 3.2A) and iNOS mRNA (Fig. 3.2B). This is an intriguing result, but it 
would appear that cycloheximide may have a broader range of targets than originally 
thought and that different doses may affect different sets of proteins.
Cytokine-induced inhibition o f iNOS activity
Pro-inflammatory cytokines are clearly involved in the up-regulation of iNOS and it would 
be reasonable to assume that anti-inflammatory cytokines may play a role in the down- 
regulation of either iNOS expression or activity or both. Preliminary data in our laboratory 
by Dr. George Kolios suggested that the anti-inflammatory cytokines IL-13 and IL-4 had 
largely inhibitory effects on IL-lcx/IFN-y/TNF-a-induced nitrite generation. In order to 
confirm this assertion, confluent monolayers of HT-29 cells were pre-treated for 1 hour 
with increasing doses of IL-13 (0.3 - 30 ng/ml), followed by the combination of cytokines 
IL-la/IFN-Y/TNF-a for 24 hours. IL-13 produced a partial, but significant suppression of 
nitrite accumulation (p<0.01- pcO.OOl), (Fig. 3.3), to the levels normally generated by the 
minimal combination of IL-la/IFN-Y. This possibly suggests that IL-13 down-regulates the 
post-transcriptional effect of TNF-a on the IL-la/IFN-Y-induced nitrite generation.
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Figure 3.2A. Growth-arrested HT-29 monolayers were stimulated with
cycloheximide (pg/ml) for 1 hour prior to the addition of cytokines, as indicated.
After 24h, nitrite in the supernatants was measured using the fluorometric nitrite
assay. Data is the mean ± SEM, n = 3.
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Figure 3.2B. Growth-arrested HT-29 monolayers were stimulated with cycloheximide 
(pg/ml) for 1 hour prior to the addition of cytokines, as indicated. After 24h, cell 
were harvested for Northern analysis. The top panel shows the iNOS mRNA detected 
and the bottom panel indicates equal loading. Data is representative of three 
experiments.
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Figure 3.3. Growth-arrested HT-29 cells were stimulated with increasing 
concentrations of IL-13 for 1 hour prior to the addition of cytokines, as indicated. After 
24 hours, nitrite production was measured in the supernatants using the fluorometric 
nitrite assay. Each point represents the mean ± SEM of three separate experiments
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However, it is interesting to note that only the higher concentrations of IL-13 (i.e., 1 0 -3 0  
ng/ml) are able to block iNOS mRNA induced by pro-inflammatory cytokines (Dr. George 
Kolios, personal communication), although the mechanism of this is unclear.
3.2 DISCUSSION
NO is produced at many sites of the gastrointestinal tract and it is considered as an 
important mediator in physiological and pathological events (M. Guslandi, 1994). At the 
beginning of this study, NO synthesis (Middleton et al., 1993) and NOS activity had been 
reported increased in the inflamed mucosa from patients with EBD compared to the 
uninflamed controls, (Rachmilewitz et al., 1995), but the type of cells responsible for this 
production was unknown. In our laboratories the source of NO generation had been 
examined in colonic mucosa using immunohistochemical analysis of human large bowel 
biopsies, cultures of the colonic adenocarcinoma cell line HT-29 and cultures of human 
colonic biopsies (Kolios et al., 1995). Immunohistochemical studies clearly showed that 
iNOS expression was localised to the surface epithelium and crypts and not detectable in the 
lamina propria or in the inflammatory leukocytes closely associated with the epithelial cells 
in the mucosa from patients with ulcerative colitis (Kolios et al., 1998). However, biopsies 
from newly diagnosed ulcerative colitis showed iNOS staining in the apical region of the 
superficial region of crypts in close association to areas of intense neutrophil infiltration of 
lamina propria and epithelium (Kolios et al., 1998). Thus, the epithelium appears to be the 
major source of NO in IBD, but iNOS expression by colonic epithelial cells is only present 
when there is an underlying inflammatory component within the colonic mucosa.
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In support of these findings, it was demonstrated that human HT-29 colonic epithelial cells, 
in response to specific combinations of cytokines, express iNOS mRNA and produce large 
quantities of nitrite (Kolios et al., 1995). The expression of iNOS activity in cells and 
tissues is controlled by a combination of pro-inflammatory cytokines and the profile of 
cytokine responsiveness varies with cell type. In this study, unstimulated HT-29 cells 
produced a small amount of nitrite, which may be due to ecNOS as no iNOS was present. 
None of the cytokines added alone increased the nitrite generation. The combination of IL- 
l a  and IFN-y was the minimal stimulation required for iNOS mRNA or significant increase 
of nitrite generation in HT-29 cells, whilst no other pair of cytokines was effective. The 
combination of IL-la/IFN-y/TNF-a was the most effective for increase in nitrite 
generation, with the effect of the TNF-a signal being at the post-transcriptional level.
It is most likely that the increased nitrite accumulation is due to iNOS enzyme activity 
because this activity was, 1) induced by a combination of pro-inflammatory cytokines that 
induce the expression of iNOS mRNA and, 2) blocked by pharmacological iNOS inhibitors, 
aminoguanidine and L-NMMA and, more specifically, by 1400W. These data suggest that 
human colonic cells can be considered as an important source of nitric oxide production.
As mentioned earlier, patients with active IBD have an increased secretion of pro- 
inflammatory cytokines in the mucosa, which may result in the greatly enhanced iNOS 
activity seen in these patients. The fact that anti-inflammatory drugs routinely used 
successfully on patients with active disease have variable effects on iNOS activity in HT-29 
cells reveals the complex aetiology of IBD. The steroid hormone dexamethasone had no 
effect on the nitrite produced by epithelial cells. This correlates with a study undertaken by 
Salzman et al, 1996, in which dexamethasone had no effect on cytokine-induced nitrite
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accumulation, but they did find a slight, but significant decrease in iNOS mRNA. It has been 
proposed that dexamethasone decreases transcriptional rate and increases degradation of 
iNOS mRNA (Kunz et al., 1996) or reduces translation and increases degradation of iNOS 
protein (Kunz et al., 1996). Transcription factor binding sites in the iNOS promoter region 
include NF-kB and the activation of this family of proteins is essential for cytokine-induced 
iNOS transcription (Xie et al., 1994). Glucocorticoids are thought to mediate their effects 
by inhibition of NF-kB activity, through the induction of IkB synthesis (Scheinman et al., 
1995 and Auphan et al, 1995). Alternatively, Salzman et al, 1996 found that dexamethasone 
caused a slight, but significant reduction in mitochondrial respiration, although the 
significance of this was not discussed. Other groups have failed to observe any difference in 
iNOS expression (Kimura et al., 1998 and Godkin et al., 1996), NO generation (Lundberg 
et al., 1994 and Boughton-Smith et al., 1993) and peroxynitrite formation (Kimura et al., 
1998) between steroid-treated and -untreated patients with UC. The therapeutic activity of 
dexamethasone might lie in its ability to inhibit iNOS expression and activity only if given at 
the very beginning of the inflammatory process, their effect being diminished once the 
inflammation is well under way (Godkin et al., 1996). Alternatively, dexamethasone might 
mediate its effects through its action on iNOS in leukocytes and not epithelial cells (J. 
Linehan, personal comm.).
Sodium salicylate has been shown to be a transcriptional inhibitor of iNOS in cultured 
cardiac fibroblasts (Farivar and Brecher, 1996), although the mechanism is not clearly 
understood. In HT-29 cells sodium salicylate was cytotoxic and this may account for the 
reduced levels of nitrite accumulated in the supernatants. Interestingly, sodium salicylate 
exacerbates IBD and it has been proposed that increased apoptosis is the cause (Elder et al., 
1997). Inhibition of the activity of cyclooxygenase, a key enzyme in biosynthesis of pro-
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inflammatory prostaglandins (J. R. Vane, 1971), through the inhibition of NF-kB and AP-1 
by salicylate (Xu et al., 1999 and Cronstein et al., 1999) could explain the anti­
inflammatory effects. How COX2 might play a role in apoptosis is unknown at present, but 
could explain the result seen in this study. 5-ASA, on the other hand, had no effect on nitrite 
measurements, although a recent finding suggests that it inhibits the impaired epithelial 
barrier function induced by IFN-y (Di Paolo et al., 1996). Additionally, it is thought that 5- 
ASA acts as a scavenger of reactive oxygen and nitrogen derived species (Miyachi et al., 
1987), but a recent study showed that 5-ASA was able to scavenge the potent neutrophil 
oxidant HOC1 and not H20 2 or NO (McKenzie et al., 1999). Thus, it would seem unlikely 
that modulation of colonic NO production is the major mechanism for explaining the 
therapeutic activity of the drugs currently used in treatment of IBDs.
Enhanced cytokine-induced nitrite generation by PMA suggests a dependency on the PKC 
pathway. However, there are 11 isoforms of PKC, some of which are sensitive to phorbol 
esters (namely, the classical and novel subfamilies). The identification of PMA-responsive, 
non-PKC proteins (e.g., protein kinase D and GTPase-activating proteins, GAPs) raises the 
need for caution in the interpretation of studies of PKC function that rely solely on the use 
of phorbol esters as an investigative tool (Mellor and Parker, 1998).
The classical MAP kinase cascade (i.e., Raf/MEK/ERK) can be triggered by phorbol esters 
and the evidence indicates the involvement of PKC being both necessary and sufficient 
(Alessandrini et al., 1992). This suggests that PKC activation in the HT-29 system might 
amplify the signal generated by both IL-1 and TNF-a through this kinase pathway. Both IL- 
1 and TNF-a activate of the JNK/SAPK and p38 stress response pathways (O’Neill and 
Greene, 1998 and Sluss et al., 1994), as well as the ERK pathway. This points to an
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important role for these pathways in the expression of iNOS. The inhibition of p38 by 
SB203580 resulted in the complete abrogation of iNOS activity, whilst the MEK inhibitor 
PD098059 produced only a partial effect. The p38 kinase and its upstream kinases are 
implicated in responses to cellular stress, inflammation and apoptosis, probably as a result of 
the activation of transcription factors, such as NF-kB (DaSilva et al., 1997 and Zhao and 
Lee, 1999). It is possible that the effects of protein kinases may be on the phosphorylation 
status of iNOS protein, an important feature of iNOS activity. However, Kleinert et al., 
1998 showed that only protein tyrosine kinases (in particular, JAK2) were important in the 
regulation of iNOS in human DLD-1 cells and not serine/threonine kinases.
The use of PI 3-kinase inhibitors (and, indeed, any pharmacological inhibitors or activators) 
has its limitations due to the broader range of targets that these compounds have. 
Wortmannin, for example, inhibits PI 3-kinases enzymic function at low nanomolar 
concentrations (e.g., <10 nM) (Arcaro and Wymann, 1993), but further targets have been 
identified. It can inhibit phospholipase A2 (with an IC50 of 2 nM) (Cross et al, 1995) and 
mammalian soluble PI 4-kinase (with an IC50 of 3-5 nM) (Nakanishi et al, 1995). At more 
elevated concentrations phospholipase D (Reinhold et al, 1990) and phospholipase C 
(Bonser et al, 1991) are inhibited. Additionally, wortmannin has been reported to inhibit the 
mammalian target of rapamycin (mTOR) which regulates p70S6 kinase, a potential PI 3- 
kinase target (see Section 1.6) (Brunn et al, 1996). Also, it is impossible to distinguish 
which class of PI 3-kinase is relevant because wortmannin inhibits different classes to 
different extents. Hence, the interpretation that there might be a role for PI 3-kinase in the 
slight enhancement of iNOS activity induced by the three cytokines has to be tempered with 
the knowledge that other signalling molecules could be involved, although it may indicate a 
level of regulation by this enzyme. The novel PI 3-kinase inhibitor, LY294002, appears not
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to have significant effects on the activity of other enzymes at 1.4|iM, including PI 4-kinase, 
src, MAP kinase, S6 kinase, DAG kinase, PKA and PKC (Vlahos et al, 1994). Taken 
together, this suggests that there might be a role for PI 3-kinase in the regulation of iNOS 
activity, although this is unlikely. Certainly, by itself it does not significantly affect the 
activity of iNOS, but there is a chance that PI 3-kinase inhibition with a simultaneous pro- 
inflammatory onslaught, may lead to changes in either iNOS activity or transcription. This 
hypothesis will be addressed in the next section.
By itself, the protein synthesis inhibitor, cycloheximide, did not affect iNOS production at 
10 jLLg/ml. It reduced the nitrite production to constitutive levels, regardless of maximal 
stimulation with IL-lcx/IFN-y/TNF-a, suggesting that the nitrite evoked by these cytokines 
is dependent on de novo protein synthesis, probably the iNOS enzyme and/or essential 
peptide cofactors. However, a differential dose response between low and high 
concentrations was seen in HT-29 cells.
Lower doses significantly enhanced both nitrite production and iNOS mRNA transcripts, 
perhaps by regulating the phosphorylation state of transcription factors or the activity of 
cNOS or eNOS. Higher doses inhibited both nitrite production and iNOS mRNA, again 
indicating the possibility that cycloheximide interferes with the phosphorylation status of 
proteins already synthesised in the cell. For example, interference with the function of 
RNAses would affect mRNA stability and/or accumulation. Indeed, it has been shown that a 
specific sequence in iNOS mRNA mediates its instability and the degradation is prevented 
by protein-synthesis inhibition (Evans et al., 1994). This would lead to an accumulation of 
translatable mRNA. Also, the negative feedback loop provided by the iNOS protein would 
not be present, leading to the accumulation of iNOS mRNA. Oguchi et al, 1994 suggest
Results and Discussion 115
that cycloheximide increases the synthesis of iNOS mRNA in macrophages by stimulating 
the transcription factors c-fos, c-jun and JE. Translation inhibitors such as cycloheximide 
also activate the p38 kinase of the MAP kinase pathway with resultant stimulatory effects 
on transcription factor activity. Cycloheximide leads to superinduction of immediate-early 
genes by the activation of intracellular signalling pathways involving both the MAPK and 
SAPK cascades. (Zinck et al., 1995). The likely involvement of NF-kB response elements 
on both basal and inducible transcription of the iNOS gene, would suggest that 
cycloheximide activation of these components leads to more efficient transcription of the 
iNOS gene. Casado et al., 1997 showed that cycloheximide potentiates NF-kB activity by 
increasing degradation of the IkB inhibitory subunit. Alternatively, incompletely blocked 
protein synthesis may allow translation of mRNAs encoding newly induced transcription 
factor(s), so that iNOS mRNA accumulation is a secondary, rather than a primary response 
to cycloheximide-regulated signals in the nucleus.
Since both T-cells and T-cell-derived cytokines, including IFN-y, IL-4/IL-13 and IL-10, 
have been detected in the mucosa of patients with EBD (R. B. Sartor, 1994), we have 
utilised human colonic epithelium (in the form of the HT-29 epithelial cell line) as a model 
to explore the regulation by IL-13 of epithelial iNOS activity. IL-13 produces a 
concentration related inhibition of nitrite accumulation induced by the optimal cytokine 
combination IL-la/IFN-y/TNF-a. This inhibition is significant at the high dose of IL-13 (30 
ng/ml) and, although only partial, it could be that the result reflects an inhibition of the post- 
transcriptional effect of TNF-a. It would be prudent to confirm that IL-13 can indeed 
inhibit iNOS transcription and to investigate the mechanisms of this function. These issues 
will be addressed in the next section.
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In summary, HT-29 cells can be induced by a combination of pro-inflammatory cytokines to 
express iNOS. Kinase activators and inhibitors, corticosteroids, non-steroidal anti­
inflammatory drugs and the anti-inflammatory cytokine, IL-13 can modulate the activity of 
iNOS. In conclusion, these data highlight the complexity of iNOS expression and activity 
(see Figure 3.4) and suggest a crucial role for pro-inflammatory and T-cell-derived 
cytokines in colonic mucosa during intestinal inflammation.
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Figure 3.4. A model system for nitric oxide production by colonic epithelial cells. 
1. Pro-inflammatory cytokines, IL -la  and IFN-y induce iNOS expression and 
activity. 2. Further stimulation with TNF-a has a largely post-transcriptional 
effect, increasing nitrite output. 3. An inhibitory effect on iNOS expression and 
activity is achieved by pre-treatment with the anti-inflammatory cytokine, IL-13. 
Pharmacological intervention is achievable at many points downstream of each 
cytokine’s receptor, see text.
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4. IL-13 SIGNAL TRANSDUCTION IN HT-29 CELLS
4.1 RESULTS
CALCIUM MOBILISATION
IL-13-induced inhibition of iNOS activity is not mediated by intracellular calcium 
mobilisation
Little is currently known about IL-13 signal transduction, so initial investigations were 
based on published data on EL-4 signalling and the little there was on IL-13 signalling. EL-4 
had been shown to trigger a unique second messenger pathway in human B cells. This is 
characterised by a rapid, transient production of inositol (l,4,5)-trisphosphate and 
mobilisation of Ca2+, followed after a brief lag period by an increase in intracellular cAMP 
(Finney et al., 1990). This pathway had also been shown to be activated by EL-13 in human 
monocytes and required for the IL-13-mediated inhibition of protein kinase C-triggered 
respiratory burst (Sozzani et al., 1995). However, IL-13 did not result in the mobilisation of 
Ca2+ ions in HT-29 cells (Fig. 4.1), as compared with bradykinin as a positive control. This 













Figure 4.1. Growth-arrested HT-29 cells were loaded with fura-2/AM on glass 
coverslips and stimulated with bradykinin, as a positive control, and IL-13 (30 ng/ml). 
The [Ca2+]i mobilisation was measured fluorometrically. The traces are representative 
of two separate experiments.
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ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE BY IL-13
IL-13 enhances the in vitro lipid kinase activity o f p85 immunoprecipitates
As IL-13 and IL-4 share many similarities with regard to function and signalling events (see 
section 1.4), it seemed likely that IL-13 might share the ability with IL-4 to activate PI 3- 
kinase (Gold et a l, 1994). In order to investigate this possibility, immunoprecipitates of the 
p85 regulatory subunit of PI 3-kinase were assayed for in vitro lipid kinase activity. 
Treatment of HT-29 cells with IL-13 (30 ng/nl) induced a transient increase in in vitro lipid 
kinase activity with maximum activity present in p85 immunoprecipitates derived from the 
30 second time point (Fig. 4.2A). The p85-associated lipid kinase activity declined back to 
basal levels after 10 minutes stimulation with IL-13. Also, treatment with IL-13 (0.3 - 30 
ng/ml) for 30 seconds resulted in a concentration-dependent increase in the in vitro lipid 
kinase activity present in p85 immunoprecipitates (Fig. 4.2B). The IL-13-induced increase 
in lipid kinase activity was also inhibited by 10 min pretreatment with wortmannin (10 - 300 
nM), (Fig. 4.3A) and 15 min pretreatment with LY294002 (1 - 30 ftM), (Fig. 4.3B). Taken 
together, these data have strongly identified PI 3-kinase as an important signalling enzyme 
activated by IL-13.
IL-13 induces the accumulation o f D-3 phosphatidylinositol lipids
PI 3-kinase activation was also determined by measuring the accumulation of D-3 
phosphatidylinositol lipids after stimulating 32P-labelled HT-29 cells with IL-13 (example 
traces from the HPLC shown in Fig. 4.4). Treatment with IL-13 (30 ng/ml) resulted in a 





Figure 4.2. HT-29 cells (3.5 x 106) were A, stimulated with 30 ng/ml IL- 
13 for the times indicated and B, stimulated with IL-13 at 37 °Catthe 
concentrations indicated for 30 seconds. Cells were lysed and subjected to 
immunoprecipitation with anti-p85 mAb and assayed for in vitro lipid 












Figure 4.3. HT-29 cells (3.5 x 106) were A, incubated for 10 minutes with 
wortmannin or B, for 15 minutes with LY294002 at the concentrations 
indicated , followed by treatment with IL-13 (30 ng/ml) for 30 seconds at 
37 °C. Cells were lysed and subjected to immunoprecipitation with anti- 
p85 mAb and assayed for in vitro lipid kinase activity, as described in 
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Figure 4.4. [32P]Orthophosphate-labelled HT-29 (2 x 107 cells/120 pi) were A, 
stimulated with vehicle or B, stimulated with IL-13 (30 ng/ml) for 1 minute. PI lipids 
were extracted and deacylated, followed by HPLC separation. Data is representative 
of original traces before analysis.
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Figure 4.5. [32P]Orthophosphate-labelled HT-29 (2 x 107 cells/120 pi) were 
stimulated with vehicle or IL-13 (30 ng/ml) for the times indicated. Phospholipids 
were extracted and deacylated, followed by HPLC separation and analysis as 
described in Section 2.2.7.1. A. PI (3,4,5) P3 and B. PI (3,4) P2 Data is the mean of 
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Figure 4.6. [32P]Orthophosphate-labelled HT-29 (2 x 107 cells/120 pi) were 
stimulated with vehicle or IL-13 at the concentrations indicated for A, 30 seconds or 
B, for 1 minute. A, PI (3,4,5) P3 and B, PI (3,4) P2 were extracted and deacylated, 
followed by HPLC separation and analysis as described in Section 2.2.7.1. Data is 
the mean of two separate experiments, and is representative of three separate 
experiments in total.
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accumulation occurring after 30 seconds (Fig. 4.5A). The levels of PI (3,4,5) P3 had 
declined back to basal levels within 10 minutes of IL-13 treatment. In addition, IL-13 also 
induced the accumulation of another D-3 phosphatidylinositol lipid, namely PI (3,4) P2 (Fig. 
4.5B). However, the accumulation of PI (3,4) P2 occurred with slower kinetics, such that 
maximum accumulation of PI (3,4) P2 occurred at 1 minute post-IL-13 treatment (Fig. 
4.5B), although the levels of PI (3,4) P2 also declined back to basal levels within 10 minutes 
of stimulation. The apparent lag time for the accumulation of PI (3,4) P2 compared with the 
accumulation of PI (3,4,5) P3 is consistent with the proposal that PI (3,4) P2 is the
metabolic breakdown product of PI (3,4,5) P3 (Stephens et al., 1993).
The effect of IL-13 on D-3 PI accumulation was concentration-dependent. Hence,
treatment of HT-29 cells with EL-13 (0.3 - 30 ng/ml) for 30 seconds resulted in the
concentration-dependent accumulation of PI (3,4,5) P3 (Fig. 4.6A). Equally, treatment with 
IL-13 (3 and 30 ng/ml) for 1 minute resulted in the concentration-dependent accumulation 
of PI (3,4) P2 (Fig. 4.6B). Moreover, the accumulation of PI (3,4,5) P3 (Fig. 4.7A and 
4.8A) and PI (3,4) P2 (Fig. 4.7B and 4.8B) after IL-13 treatment was inhibited by 
pretreatment with the PI 3-kinase inhibitors, wortmannin (0.5 nM - lpM) and LY294002 (1 
- 30 jiM) in a concentration-dependent manner.
IL-13 INDUCES PHOSPHORYLATION OF CELLULAR PROTEINS
IL-13 induces tyrosine phosphorylation o f IRS-1 and association with p85
To define more clearly the mechanism of interaction of the IL-13R with PI 3-kinase, 
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Figure 4.7. [32P]Orthophosphate-labelled HT-29 (2 x 107 cells/120 pi) were 
stimulated with vehicle or wortmannin at the concentrations indicated for 10 
minutes, followed by stimulation with either vehicle or IL-13 (30 ng/ml) for A, 30 
seconds or B, for 1 minute. A, PI (3,4,5) P3 and B, PI (3,4) P2 were extracted and 
deacylated, followed by HPLC separation and analysis as described in Section 












Figure 4.8. [32P]Orthophosphate-labelled HT-29 (2 x 107 cells/120 |xl) were 
stimulated with vehicle or LY294002 at the concentrations indicated for 15 minutes 
followed by stimulation with either vehicle or IL-13 (30 ng/ml) for A, 30 seconds or 
B, for 1 minute. A, PI (3,4,5) P 3 and B, PI (3,4) P2 were extracted and deacylated, 
followed by HPLC separation and analysis as described in Section 2.2.7.1. This is 
representative data.
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3-kinase involved the adapter molecules IRS-1 and/or IRS-2. Both IRS-1 and IRS-2 have 
previously been implicated in IL-4R- and IL-13R-mediated signal transduction events 
(Welham et al., 1995; Lefort et al., 1995; Keegan et al., 1994 and Schnyder et al., 1996). 
Both can associate with PI 3-kinase via specific phosphotyrosine-containing sequences that 
bind the p85 subunit (Sun et al., 1995 and Sun et al., 1991). Accordingly, 
immunoprecipitations were performed on cell lysates derived from IL-13-stimulated HT-29 
cells using antibodies directed against either the p85 subunit of PI 3-kinase, IRS-1 or IRS-2 
(Fig. 4.9). The resulting precipitates were immunoblotted with the 4G10 anti- 
phosphotyrosine mAb. Two tyrosine-phosphorylated proteins migrating at 165 and 170 
kDa, consistent with the molecular weights of IRS-1 and IRS2, respectively, were co- 
immunoprecipitated by the p85 mAb (Fig. 4.9A). Immunoblotting of the p85 
immunoprecipitates with the polyclonal anti-IRS-1 revealed a time-dependent increase in 
the association of IRS-1 with p85 that correlated with the kinetics of tyrosine 
phosphorylation of the proteins migrating at 165-170 kDa (Fig. 4.9A). Furthermore, 
immunoblotting of the IRS-1 immunoprecipitates from IL-13-stimulated HT-29 cells with 
the 4G10 anti-phosphotyrosine mAb confirmed that IL-13 stimulation induced the strong 
tyrosine phosphorylation of IRS-1 (Fig. 4.9B). However, similar experiments using IRS-2 
immunoprecipitates (Fig. 4.9C) revealed no detectable increase in IRS-2 tyrosine 
phosphorylation after IL-13 stimulation, although there was some basal phosphorylation of 
this protein. Each blot was stripped and reprobed with anti-p85 (Fig. 4.9A), anti-IRS-1 
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Figure 4.9. HT-29 cells (3.5 x 106) were stimulated with IL-13 (30 ng/ml) at 37 °C for 
the times indicated. Cells were lysed, subjected to immunoprecipitation with A, a-p85 
mAb, B, a-IRS-1 and C, a-IRS-2 and subjected to Western analysis Nitrocellulose 
membranes were immunoblotted with the antiphosphotyrosine antibody, 4G10, after 
which they were stripped and reprobed with the antibodies indicated. Each blot is 
representative of at least three separate experiments.
Results and Discussion 121
PI 3-kinase inhibitors prevent IL-13 suppression o f pro-inflammatory cytokine-induced 
iNOS expression and nitrite production
As shown previously (Kolios et al., 1995) and results from the previous section, growth- 
arrested HT-29 monolayers stimulated with the IL-la/IFN-y/TNF-a combination of pro- 
inflammatory cytokines result in the optimal generation of nitrite (Fig. 4.10A) and 
expression of iNOS mRNA (Fig. 4.10B). Both functional events can be inhibited by 
pretreatment with IL-13 (30 ng/ml) for 1 hour before the addition of the cytokine mixture. 
However, the addition of wortmannin (10 - 300 nM) to HT-29 cells 10 minutes before EL- 
13 treatment prevents the inhibitory effects of IL-13 on iNOS mRNA expression (Fig. 
4.10B) and nitrite production (Fig. 4.10A). Similarly, the addition of the structurally 
unrelated LY294002 (1 -  30 |iM) for 15 minutes before IL-13, resulted in a dose- 
dependent reversal of the IL-13 inhibition of iNOS transcripts (Fig. 4.1 IB) and nitrite 
production (Fig. 4.11 A). Taken together, these results strongly suggest a role for the 
signalling enzyme, PI 3-kinase, in the transduction of the IL-13-induced signal, which 
down-regulates the iNOS gene.
4.2 DISCUSSION
It has been shown that IL-13 activates PI 3-kinase in a human colonic epithelial cell line as 
determined by the accumulation of D-3 PI lipids from intact cells and increased lipid kinase 
activity present in immunoprecipitates of the p85 regulatory subunit of PI 3-kinase. In 
addition, IL-13 stimulates the tyrosine phosphorylation of the adapter molecule IRS-1, 
which has previously been reported to facilitate receptor coupling to PI 3-kinase (Sun et al., 
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Figure 4.10A. Growth-arrested HT-29 monolayers were treated with vehicle or 
wortmannin (nM) for 10 minutes prior to the addition of IL-13 for 1 hour, followed by 
the cytokines, as indicated. After 24 hours, nitrite in the supernatants was measured 
using the fluorometric nitrite assay. Data is the mean ± SEM, n = 3.
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Figure 4.10B. Growth-arrested HT-29 monolayers were treated with wortmannin 
(nM) for 10 minutes prior to the addition of either vehicle or IL-13 for 1 hour, 
followed by cytokines, as indicated. After 24 hours, cells were harvested for Northern 
analysis. The top panel shows the iNO mRNA detected and the bottom panel verifies 
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Figure 4.11 A. Growth-arrested HT-29 monolayers were treated with LY294002 (pM) 
for 15 minutes prior to the addition of IL-13 for 1 hour, followed by the cytokines, as 
indicated. After 24 hours, nitrite in the supernatants was measured using the 
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Figure 4.1 IB. Growth-arrested HT-29 monolayers were treated with LY294002 (pM) 
for 15 minutes prior to the addition of either vehicle or IL-13 for 1 hour, followed by 
cytokines, as indicated. After 24 hours, cells were harvested for Northern analysis. The 
top panel shows the iNOS mRNA detected and the bottom panel verifies equal 
loading. Data is representative of two experiments
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of PI 3-kinase and is an important observation given that D-3 PI lipids are increasingly 
thought to act as important regulatory molecules utilised by a plethora of receptors involved 
in diverse outcomes (see section 1.4).
Accordingly, the two structurally unrelated PI3-K inhibitors, wortmannin and LY294002, 
have been used to demonstrate the IL-13-mediated activation of PI 3-kinase. The resulting 
accumulation of D-3 PI lipids has also been shown necessary for the IL-13-induced 
suppression of iNOS mRNA expression and nitrite production induced by the mixture of 
pro-inflammatory cytokines EL-la, EFN-y and TNF-a. The ability of IL-13 to inhibit nitric 
oxide production and iNOS activity in macrophages (Doyle et al., 1994 and Doherty et al.,
1994), mesangial cells (Saura et al., 1996) and now HT-29 carcinoma cells (this work) 
induced by pro-inflammatory cytokines seems to be an important function of IL-13. Until 
now, however, the signalling cascades that mediate the effects of IL-13 on iNOS have not 
previously been characterised. This demonstration that PI 3-kinase inhibitors prevent the 
effects of IL-13 on iNOS is similar to a previous report that demonstrated that insulin- 
induced inhibition of phosphoenolpyruvate carboxykinase is dependent on PI 3-kinase 
activation (Gabbay et al., 1996). This further demonstrates an important role for PI 3-kinase 
in the negative regulation of the induction of specific mRNA (Reif et al., 1997).
To date, several forms of mammalian PI 3-kinase have been identified, and these include 
various isoforms of the p85/pl 10 heterodimer (Otsu et al., 1991), The G protein-coupled PI 
3-kinase y (Stoyanov et al., 1995 and the Ptdlns-specific 3-kinase (Volinia et al., 1995). 
The p85/pll0 heterodimer is the best studied of these lipid kinases, and reagents to either 
p85 or p i 10 are readily available and reliable. In contrast, studies relating to PI 3-kinase y 
and Ptdlns 3-kinase are hampered by a lack of reliable and commercially available
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antibodies. In vitro assays for associated lipid kinase activity revealed that IL-13 treatment 
increased the amount of lipid kinase activity present in p85a immunoprecipitates. These 
data strongly indicate that the p85/pl 10 heterodimeric PI 3-kinase is coupled to and 
activated by the IL-13R. However, coupling of the IL-13R to other PI 3-kinase family 
members cannot be entirely discounted, and these lipid kinases may potentially contribute to 
the production of total PI (3,4,5) P3 extracted from IL-13-stimulated 32P-labelled HT-29 
cells. Although the precise nature of the IL-13R is unclear, the known p85 binding motifs 
have not so far been identified in the intracellular domain of the related IL-4R. Nevertheless, 
the IL-4R has been demonstrated to associate with and/or activate PI 3-kinase (Izuhara et 
al., 1993; Gold et al., 1994 and Wang et al., 1992). This coupling is thought to occur via an 
intermediate adapter such as IRS-2, which does contain several YXXM motifs (Sun et al.,
1995). IRS-2 is tyrosine phosphorylated after IL-4 treatment, and this phosphorylation may 
be required for association of IRS-2 with PI 3-kinase (Sun et al., 1995). IRS-2 has also 
been demonstrated to be tyrosine phosphorylated and to associate with PI 3-kinase after IL- 
13 treatment (Welham et al., 1995 and Lefort et al., 1995), suggesting that IRS-2 may also 
facilitate the coupling of the IL-13R to the putative signalling cascades regulated by PI 3- 
kinase. Interestingly, this study revealed that IL-13 was not able to induce detectable 
tyrosine phosphorylation of IRS-2 in HT-29 cells, although it did stimulate a rapid and 
strong tyrosine phosphorylation of IRS-1 within 1 minute post-stimulation. Generally, the 
kinetics of IL-13-stimulated IRS-1 tyrosine phosphorylation correlated with the kinetics of 
IL-13-stimulated PI 3-kinase activation. Data indicate that IRS-1 may potentially have an 
important role in coupling the IL-13R to PI 3-kinase in HT-29 cells. However, a role for 
IRS-2 in the coupling of IL-13R to PI 3-kinase in HT-29 cells cannot be entirely ruled out 
because low stoichiometric tyrosine phosphorylation of IRS-2 after IL-13 stimulation may 
be sufficient to allow IRS-2 to recruit PI 3-kinase to the IL-13R.
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This demonstration that IL-13 differentially stimulates the tyrosine phosphorylation of IRS- 
1, but not IRS-2, correlates with previous observations that IRS-1 is a major 
phosphoprotein of non-haematopoietic cells. IRS-2 phosphorylation is induced principally in 
murine haematopoietic cell types by various growth factors and cytokines (Keegan et al., 
1994a; Sun et al., 1992; Keegan et al., 1994b; Morla et al., 1988; Wang et al., 1993 and 
Welham et al., 1997). Other evidence exists to indicate considerable heterogeneity in both 
receptor structure and signal transduction in different cell types for both IL-4 and IL-13. 
For instance, in immune cells IL-4 is a growth and differentiation factor, and the common y 
chain is associated with the IL-4R (Callard et al., 1996). However, the common y chain is 
not expressed in colon carcinoma cells in which IL-4 mediates a growth inhibitory effect 
(Murata et al., 1996a). Moreover, both IL-4 and IL-13 induce the tyrosine phosphorylation 
of JAK2 in colon carcinoma cells (Murata et al., 1996a and Murata et al., 1996b). Neither 
are able to tyrosine phosphorylate JAK2 in immune cells (Welham et al., 1995; Murata et 
al., 1996a; Yin et al., 1994; Witthuhn et al., 1994 and Malabarba et al., 1995). Similarly, 
IL-4 is unable to phosphorylate JAK3 in colon carcinoma cells (Murata et al., 1996a), but is 
able to phosphorylate JAK3 in immune cells (Welham et al., 1995; Yin et al., 1994 and 
Malabarba et al., 1995). In addition to phosphorylation of cellular proteins, IL-4 has been 
shown to trigger a unique second messenger pathway in human, but not mouse, B cells. 
This is characterised by a rapid, transient production of inositol (l,4,5)-trisphosphate and 
mobilisation of Ca2+, followed after a brief lag period by an increase in intracellular cAMP 
(Finney et al., 1990). This pathway is also activated by IL-13 in human monocytes and is 
required for the IL-13-mediated inhibition of protein kinase C-triggered respiratory burst 
(Sozzani et al., 1995). It is interesting to note, however, that no detectable changes in 
intracellular Ca2+ concentration occurred in HT-29 cells after IL-13 stimulation. The
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diversity and heterogeneity of both receptors and signalling pathways activated by IL-4 and 
IL-13 may therefore facilitate the differential functional effects of these related cytokines. 
Given the possible heterogeneity of signal transduction pathways coupled to the IL-13R, it 
will be necessary to determine whether IL-13 is able to activate PI 3-kinase in other cell 
types such as immune cells and to investigate the relevance of PI 3-kinase to other IL-13 
functional events. This will undoubtedly help in evaluating the potential of the PI 3-kinase 
pathway as new and specific therapeutic target for intestinal inflammation.
In summary, IL-13 activates PI 3-kinase via the recruitment of IRS-1. In conclusion, this 
study provides the first evidence that PI 3-kinase activation is an important signal in 
determining the IL-13R-mediated inhibition of iNOS mRNA expression in response to 
inflammatory cytokines in the epithelial cell line HT-29 (Figure 4.12). Additional work is 
necessary to determine the precise downstream events that occur after PI 3-kinase 




*> /4 * gene promoter
---------------------------------► NF-kB -------- ^
Figure 4.12. IL-13 mediated signalling events in HT-29 cells. IL-13 recruits IRS-1 (1) and activates PI 3-kinase (2), which leads to the formation of the 
signalling products, PI (3,4) P2 and PI (3,4,5) P3. Potential downstream targets include protein kinases B and C, as well as p70 S6-kinase (3). PI (3,4,5) 
P3. Could have a direct effect on transcription factors, such as STAT6 and NF-kB (4) or an indirect effect mediated by activated downstream targets (5).
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5. INDUCTION AND MODULATION OF APOPTOSIS IN HT-29 CELLS
As previously shown in section 3, a combination of pro-inflammatory cytokines (IL- 
1 a/IFN-y/TNF-a) up-regulates iNOS expression and generates NO in a human colonic 
epithelial cell line HT-29 (Kolios et al., 1995). Also, it has recently been shown that IFN-y, 
in combination with TNF-a or anti-CD95, induces apoptosis in HT-29 cells (Abreu-Martin 
et al, 1998) and an increased frequency of epithelial apoptosis mediated by the CD95- 
CD95L system is seen in ulcerative colitis (UC) (Strater et al., 1997 and Iwamoto et al.,
1996). However, colonic epithelial cell injury, resulting in impaired barrier function, could 
contribute to the pathogenesis of EBD (Gardiner et al., 1998).
It has been postulated that overproduction of nitric oxide (NO) by inflamed mucosa may 
play a role in the pathophysiology of EBD due to the increased expression of the inducible 
form of nitric oxide synthase (iNOS) found in biopsies taken from patients with active UC 
as compared with normal colon (Kolios et al., 1998). The production of NO might play a 
critical role in the resolution of inflammation (McCafferty et al., 1997), possibly by inducing 
apoptosis in the leukocytic population recruited to the area (eg., neutrophils) (McCafferty et 
al., 1997). Whilst NO has also been reported to inhibit apoptosis in several settings 
(Dimmeler et al., 1997; Genaro et al., 1995; Mannick et al., 1997 and Kim et al., 1997), it 
has also been reported to mediate cell death through mechanisms consistent with apoptosis 
in various cells including peritoneal macrophages (Messmer et al., 1996; Albina et al., 1993 
and Sarih et al., 1993), (3-cells (Kaneto et al., 1995 and Ankarcrona et al., 1994) and 
thymocytes (Fehsel et al., 1995).
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Overproduction of NO may lead to oxidant-induced injury of the colon epithelial crypt 
(McKenzie et al., 1996), possibly by the reaction with superoxide to form peroxynitrite 
which in turn results in the nitration of proteins on tyrosine residues (Singer et al., 1996).
In this study, we sought to ascertain whether there is a relationship between NO production 
and apoptosis of HT-29 epithelial cells observed in response to a combination of cytokines 
and/or CD95 ligation. In addition, given that the ability of IL-13 to inhibit iNOS expression 
and NO generation in this system is driven by PI 3-kinase-dependent pathway, we 
investigated whether IL-13 could provide a cell survival signal through PI 3-kinase to 
protect against cytokine-driven apoptotic signals.
5.1 RESULTS
Apoptosis o f colon epithelial cells induced by pro-inflammatory cytokines is inhibited by 
IL-13
Initial investigations took the form of determining the cytokine requirements for the 
induction of cell death. Growth arrested HT-29 monolayers stimulated with a combination 
of the pro-inflammatory cytokines IL -la  (10 ng/ml), IFN-y (300 U/ml)) and TNF-a (100 
ng/ml), resulted in a 25-80% increase in the expression of apoptotic markers over a time 
course of 4-24 hours (Table 5.1 and Fig. 5.1). This was assessed by a number of assays 
which measure early and late stage markers of apoptotic events, namely DNA fragmentation 
(Fig. 5.1 A), externalisation of phosphatidylserine (Fig. 5.IB) and DNA-histone-association 
(Fig. 5.1C). In contrast, treatment with individual cytokines was insufficient to increase cell 
death above basal levels (Table 5.1).
Figure 5.1A. Photographs of HT-29 cells treated as indicated for 24 hours and 
stained to assess DNA fragmentation (Apoptag, see section 2.2.8.1) in A. 
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Figure 5.1B. FACS analysis of HT-29 cells stimulated as indicated for 8 hours and 
stained with Annexin V (LR quadrant) to assess phosphatidylserine translocation 
(apoptotic cells). LL indicates the % of live cells, whereas UR indicates both apoptotic 
and necrotic cells. A. Vehicle stimulated cells. B. IL-loc/IFN-y/TNF-a. C. IL-la/IFN- 
y/TNF-a pretreated with IL-13 for 1 hour.
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Having established a profile of cytokines that induce dell death in HT-29 cells, it was sought 
to establish whether the anti-inflammatory cytokine IL-13 played a role in the inhibition of 
cell death. Pre-treatment of the HT-29 cells with IL-13 (30 ng/ml) markedly inhibited 
apoptotic events stimulated by the pro-inflammatory cytokines (Table 5.1 and Fig. 5.1). 
These experiments indicate that IL-13 consistently inhibited the induction of apoptotic 
markers in cells treated with the combined stimuli of IL-la/IFN-y/TNF-ot by 50-65%.
Treatment of HT-29 cells for 24 hours with IL-13 had no effect on the level of expression 
of TNFR1 (Fig. 5.2A) as assessed by flow cytometry using a receptor-specific antibody, 
thus confirming previous observations ((Manna and Aggarwal, 1998). Similarly, flow 
cytometry using appropriate receptor antibodies also revealed that IL-13 had no effect on 
the levels of expression of IL-1RI (Fig. 5.2B) or IFN-y receptor (Fig. 5.2B), indicating that 
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Figure 5.1C. IL-loc/IFN-y/TNF-a-induced apoptosis in HT-29 cells is inhibited by IL- 
13. HT-29 cells (104 cells/well) were aliquoted into 96-well plates and allowed to 
adhere overnight. Cells were then either left untreated or treated with 30 ng/ml IL-13 
for 1 hour. Where indicated, the cells were then further treated with IL-la/IFN-y/TNF- 
a  or left untreated. At the times indicated, the supernatants were removed and the cell 
pellets were lysed and apoptosis determined by the detection of the histone-associated 
DNA fragments (mono- and oligonucleosomes) using the photometric cell death 
detection ELISAPLUS assay. The data is the mean ± SEM of three separate experiments.
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Table 5.1. IL-13 protects against IL-la/IFN-y/TNF-a-induced apoptosis of HT-29 
cells. Growth arrested monolayers of HT-29 cells were either left untreated or treated with 
30 ng/ml IL-13 for 1 hour. Where indicated, the cells were then treated with IL -la  (10 
ng/ml), IFNy (300 U/ml) and TNFa (100 ng/ml) or left untreated. After the times indicated, 
the expression of apoptotic markers by HT-29 cells was determined using either the 
commercial FITC-labeled annexin V binding kit or the Apoptag apoptosis detection kits as 
described in Experimental Procedures. The data is the mean ± sem of five separate 
experiments. **p<0.01; *p<0.05
Percentage cells presenting apoptotic markers (%) 
Annexin V Apoptag
Treatment (hours) 8 12 24 48
Control 3.1 ±0.9 5.2 ±0.9 7.1 ±0.7 13.4 ±1.1
IL -la 2.8 ±0.3 4.8 ± 0.7 7.8 ± 1.6 14.2 ±0.8
IFN-y 3.3 ±0.9 5.6 ± 1.4 9.2 ±0.8 14.7 ± 1.7
TNF-a 4.1 ±0.8 7.8 ±0.3 10.1 ±1.6 16.1 ±2.3
IL1 a/IFNy/TNFa 24.3** ±1.2 32.3** ±0.2 61.3** ± 1.4 81.2** ± 1.1
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5.2. IL-13 effects on cytokine receptor expression. Confluent HT-29 cells 
were either stimulated with vehicle or IL-13 (30 ng/ml) for 24 hours. 1 x 105 
cells were incubated with FITC-conjugated antibodies to surface receptors. 
A. TNF-R1 and B. IL -la  R and IFN-y R. Data is representative of two 
separate experiments.
Results and Discussion 130
IFN-y is required in combination with the death-inducing factor TNF-ot or CD95 ligation 
to induce apoptosis
Ligation of CD95 (Fas/APO-1), which is a member of the TNF receptor superfamily, is 
associated with the induction of apoptosis in several cell types (S. Nagata, 1997). Flow 
cytometry has revealed the presence of CD95 on HT-29 cells used in this study (Fig. 5.3A). 
We therefore performed experiments to investigate whether or not CD95 ligation stimulates 
apoptosis of HT-29 cells. In this respect, ligation of CD95 with the antibody CHI 1 did not 
induce apoptosis above control basal levels (Fig. 5.3B). However, treatment of HT-29 cells 
with IFN-y in combination with the anti-CD95 mAb CH11, induced an approximate 9-fold 
increase in DNA fragmentation over 24 hours, which was comparable to the apoptosis 
induced by IFN-y and TNF-a (Fig. 5.3B). By contrast, the minimum cytokine combination 
for the induction of iNOS and NO generation, namely IL-lcx/IFN-y, induced only a 5-fold 
increase in DNA fragmentation above basal levels. Preincubation with IL-13 again reduced 
the prevalence of apoptotic markers induced by IFNy/CHll and IFN-y/TNF-a by 
approximately 50%, but did not inhibit apoptosis driven by IL-lcx/IFN-y (Fig. 5.3B).
Cytokine-driven iNOS activation and apoptosis are independent functional events
Several studies have demonstrated that nitric oxide regulates apoptosis in a number of 
settings (reviewed by Briine et al., 1998). Given that concentrations of IL-la/IFN-y/TNF-a 
that are known to induce iNOS expression and that NO production can also stimulate 
apoptosis, the possibility that this apoptotic response may be NO-dependent was 
considered. To investigate this possibility, HT-29 cells were pretreated with the iNOS
JJ
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Figure 5.3A. CD95 (Fas) receptor expression in unstimulated HT-29 
cells. Confluent HT-29 cells were left untreated for 24 hours. 1 x 10 5 cells 
were incubated with FITC-conjugated anti-CD95 as described in section 
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Figure 5.3B. IFN-y is required in combination with the death-inducing factors 
TNF-a or CD95 ligation to induce apoptosis. HT-29 cells were either left untreated 
or treated with 30 ng/ml IL-13 for 1 hour. Where indicated, the cells were then further 
treated with combinations of IL -la (10 ng/ml), TNF-a (100 ng/ml), IFN-y (300 U/ml) 
or CHI 1 (100 ng/ml) or left untreated. After 24 hours, the supernatants were removed 
and the cell pellets were lysed. Apoptosis was determined using the photometric cell 
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Figure 5.4A. Effect of iNOS inhibitor on cytokine-induced nitrite production. HT-
29 cells (3.5 x 106 cells/well) were treated for 10 minutes with vehicle or with 500 pM 
aminoguanadine (AG) as indicated at 37°C. The cells were then further treated with 
combinations of IL -la  (10 ng/ml), TNF-a (100 ng/ml) or IFN-y (300 U/ml) as 
indicated or left untreated. Nitrite production in the supernatants was measured after 24 
hours. The data is the mean ± SEM of three separate experiments.
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Figure 5.4B. Effect of iNOS inhibitor on cytokine-induced apoptosis. HT-29 
cells were treated for 10 minutes with vehicle or with 500 pM aminoguanadine 
(AG) as indicated and then treated with combinations of IL -la  (10 ng/ml) TNF-a 
(100 ng/ml) and IFN-y (300 U/ml) as indicated or left untreated for 24 hours. 
Supernatants were removed and the cell pellets were lysed. Apoptosis was 
determined by using the photometric cell death detection ELISAPLUS assay. The data 
is the mean ± SEM of three separate experiments.
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inhibitor 500pM aminoguanidine, which markedly inhibited the concentration of nitrite 
generated by IL-la/IFN-y/TNF-a over 24 hours (Fig. 5.4A). Less inhibition was observed 
with the minimum combination of IL-la/IFN-y. Aminoguanidine had no effect on the 
apoptotic signals provided by combinations of either IL-la/IFN-y/TNF-a or IL-lcx/IFN-y 
(Fig. 5.4B).
Initial apoptotic events are known to result in the activation of the proteolytic enzyme 
cascades involving caspases, which cleave specific proteins and irreversibly commit the cell 
to apoptotic death (Salvesen and Dixit, 1997). Inhibition of this proteolytic cascade can be 
achieved using a broadly selective caspase inhibitor Z-VAD-FMK (Villa et al., 1997). To 
assess whether cytokine-driven iNOS production was dependent upon activation of 
caspases, cells were pre-treated with 50 |i,M Z-VAD-FMK, which completely abrogated the 
apoptosis of HT-29 cells stimulated by IL-la/IFN-y/TNF-a, IL-la/IFN-y, IFN-y/TNF-a 
and IFN-y/CHll (Fig. 5.5A). However, the caspase inhibitor did not interfere with the 
observed ability of HT-29 cells to generate nitrite in response to IL-la/IFN-y/TNF-a or IL- 
la/IFN-y (Fig. 5.5B), as does pretreatment with IL-13. Furthermore, IFN-y/TNF-a and 
IFN-y/CHl 1 are not able to induce iNOS or stimulate the generation of nitrite, but are able 
to stimulate apoptosis (Fig. 5.5A). Together, these data indicate that cytokine driven iNOS 
activation and apoptosis are separable, independent events.
Reversal o f IL-13-induced inhibition o f apoptosis by wortmannin and LY 294002
As previously shown, IL-13 strongly activates the lipid kinase PI 3-kinase (Wright et al.,
1997). Activation of this pathway is believed to be a pivotal upstream component of a 
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Figure 5.5A. Effect of the caspase inhibitor Z-VAD-FMK on cytokine-induced 
apoptosis. HT-29 cells were either left untreated or treated with 50 JJ.M Z-VAD- 
FMK or 5 pg/ml insulin for 1 hour . Where indicated, the cells were then further 
treated with combinations of IL -la  (10 ng/ml), TNF-a (100 ng/ml), IFN-y (300 
U/ml) or CH11 (100 ng/ml) or left untreated. After 24 hours, the supernatants were 
removed and the cell pellets were lysed. Apoptosis was determined by using the 
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Figure 5.5B. Effect of the caspase inhibitor Z-VAD-FMK on cytokine-induced 
nitrite production. HT-29 cells (3.5 x 106 cells/well) were treated for 1 hour with 
vehicle or with 50 pM Z-VAD-FMK as indicated. The cells were then further treated 
with combinations of IL -la  (10 ng/ml), TNF-a (100 ng/ml) or IFN-y (300 U/ml) as 
indicated or left untreated. Nitrite production in the supernatants after 24 hours was 
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Figure 5.6A. PI 3-kinase inhibitors prevent IL-13 suppression of cytokine-induced 
apoptosis of HT-29 cells. HT-29 cells were treated for 10 minutes with vehicle, 
wortmannin or LY294002 as indicated. Cells were then either left untreated or treated 
with 30 ng/ml IL-13 for 1 hour. Where indicated, cells were then further treated with 
IL-la/IFN-y/TNF-a or left untreated. After 24 hours, the supernatants were removed 
and the cell pellets were lysed. Apoptosis was determined by the ELISAPLUS assay. The 
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Figure 5.6. PI 3-kinase inhibitors prevent IL-13 suppression of cytokine-induced 
apoptosis of HT-29 cells. HT-29 cells were treated for A. 10 minutes with vehicle or 
wortmannin (nM) or B. LY294002 ( pM) for 15 minutes, as indicated. Cells were then 
either left untreated or treated with 30 ng/ml IL-13 for 1 hour. Where indicated, the 
cells were then further treated with IFN-y/TNF-a or IFN-y/CH-11 or left untreated. 
After 24 hours, apoptosis was determined by the ELISAPLUS assay. The data is the mean 
± SEM of three separate experiments.
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Zeh et al., 1997; Dudek et al., 1997; Kulik et al., 1997 and Yao and Cooper, 1995). Hence, 
to investigate the role of PI 3-kinase in mediating the anti-apoptotic effects of IL-13 on IL- 
la/IFN-y/TNF-a-stimulated apoptosis of HT-29 cells, the PI 3-kinase inhibitors 
wortmannin and LY294002 were used. Pre-incubations of wortmannin (10-300 nM) for 10 
minutes before cytokine treatments were able to dose dependently reverse the ability of IL- 
13 to protect HT-29 cells from cytokine-induced apoptosis (Fig. 5.6A). Equally, the 
structurally unrelated PI 3-kinase inhibitor, LY294002 (1-30 pM), was also able to reverse 
the IL-13 effect (Fig. 5.6A). Similarly, treatment of HT-29 cells with either wortmannin 
(Fig. 5.6B) or LY294002 (Fig. 5.6C), also prevented the IL-13-mediated inhibition of 
apoptosis induced by either IFN-y/TNF-a or IFN-y/CH-11.
IL-13 activates the PI 3-kinase effector protein kinase B
PKB is a major downstream effector of the PI 3-kinase-dependent signalling cascade and 
has been shown to be a key mediator required for growth factor-induced cell survival and 
protection against c-Myc-induced cell death in fibroblasts (Kauffman-Zeh et al., 1997; 
Dudek et al., 1997 and Kulik et al., 1997). We therefore investigated whether the 
protective affects of IL-13 on IL-la/IFN-y /TNF-a-stimulated apoptosis in HT-29 cells, 
correlated with IL-13 activation of PKB. Hence, cell lysates derived from resting and IL-13 
stimulated cells were immunoblotted using a phosphospecific antibody to the 
phosphorylated active form of PKB. IL-13 can be shown to activate PKB within 5 minutes 
stimulation, up to a maximum at 10 minutes, and is comparable in magnitude with PKB 
activation observed in response to insulin (5pg/ml) treatment as a positive control (Fig. 
5.7A). Insulin however, provided only a 10-15% protection against cytokine-induced 
apoptosis (Fig. 5.5A). The IL-13-stimulated activation of PKB appears to be sustained for
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Figure 5.7A. HT-29 cells (107) were treated for 10 minutes with vehicle (left panel), 
30-300 nM wortmannin (right panel) or 1-30 pM LY294002 (right panel) as indicated 
at 37°C. Cells were then left unstimulated or further treated with 30 ng/ml IL-13 or 5 
pg/ml insulin (as a positive control) at 37°C for the times indicated. The HT-29 cells 
were lysed and the lysates were immunoblotted with a phosphospecific PKB antibody 
with affinity for the 473Ser-phosphorylated, active form of PKB. Data is from a single 
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Figure 5.7B. 107 HT-29 cells were stimulated with 30 ng/ml IL-13 for the times 
indicated with or without a 10 minute pre-incubation of 100 nM wortmannin. After cell 
lysis and immunoprecipitation with a-PKB, immunocomplexe were subjected to an in 
vitro kinase assay as described in section 2.2.9.2. Data is from a single experiment 
representative of at least three others.
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Figure 5.8. Effect of IL-13 on Bad hyperphosphorylation in HT-29 cells. 107
HT-29 cells were either left untreated or treated with 30 ng/ml IL-13 for the 
times indicated. Cells were lysed and the lysates were subjected to 
immunoprecipitation with an anti-Bad mAb. The immunoprecipitates were 
washed and proteins separated by SDS-PAGE using a low-bis gel, transferred to 
nitrocellulose and immunoblotted for Bad expression. FD6  cells stimulated with 
insulin were used as a positive control for Bad expression. Representative data 
of at least three experiments.
Results and Discussion 133
up to 20 minutes, but has returned to control levels after 1 hour. Both wortmannin and 
LY294002 were able to inhibit this signal, adding further evidence that the activation of PI
3-kinase by IL-13 leads to the activation of PKB and that this pathway is anti-apoptotic in 
this system. Blots were stripped and reprobed with an anti-PKB antibody provided in the kit 
to verify equal loading and efficacy of protein transfer (Fig. 5.7A). In addition, endogenous 
PKB was immunoprecipitated from IL-13-stimulated cells in the presence and absence of 
the PI 3-kinase inhibitor, wortmannin, and the immunoprecipitates were assayed for in vitro 
PKB activity. This approach confirmed that PKBa was activated by IL-13 in a PI 3-kinase- 
dependent manner (Fig. 5.7B).
The mechanism by which PKB is believed to promote cell survival involves the serine 
phosphorylation of the death promoting Bcl-2 family member, Bad. This results in the 
dissociation of Bad from B c 1 - x l ,  thus allowing Bcl-xL to act as a survival factor (Datta et 
a l, 1997; del Peso et al., 1997 and J. Downward, 1999). Immunoblotting of HT-29 whole 
cell extracts revealed no detectable amounts of Bad. However, immunoprecipitation and 
immunoblotting of Bad, after electrophoresis through a low-bis, 12.5% acrylamide gel, 
revealed a barely detectable hyperphosphorylated form of Bad as characterized by its shift in 
gel mobility (Fig. 5.8).
SH2-containing inositol 5-phosphatase induced to bind to an unknown protein by IL-13
SHIP hydrolyses the signalling molecule, PI (3,4,5) P3 and has a negative function by 
terminating signals (Majerus et al., 1999). There was the possibility that activation of SHIP 
in HT-29 cells may serve as a negative regulator of IL-13-induced PI 3-kinase activation. 
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Figure 5.9. HT-29 cells (107 ) were stimulated with vehicle or wortmannin (lOOnM) for 
10 minutes prior to either vehicle or IL-13 (30 ng/ml) for the times shown. Lysates 
were subjected to immunoprecipitation with an antibody raised against the SH2 domain 
of SHIP and Western analysis. This is an anti-phosphosphotyrosine blot showing the 
tyrosine phosphorylation of a broad band between 65-70 kDa. Data is representative of 
two separate experiments. Membranes generated from both experiments were stripped 
and reprobed for She and SHPTP2 with negative results.
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Figure 5.10 HT-29 cells (107) were treated with vehicle or wortmannin (lOOnM) for 10 
minutes prior to the addition of vehicle or IL-13 (30 ng/ml) for the times indicated. 
Whole cell extracts were subjected to SDS-PAGE and Western analysis. Two 
phosphorylated forms of p70 S6 kinase, as indicated, were used to probe for activity of 
this kinase post-IL-13 stimulation. In addition, membranes were stripped and reprobed 
with pan-p70 S6 kinase (bottom panel) to verify equal loading. n=2.
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of SHIP, conjugated to the GST fusion protein (a kind donation by Heather Bone), was 
performed and subjected to Western analysis with the anti-phosphotyrosine antobody, 4G10 
(Figure 5.9). An unknown protein, of approximately 65 -  70 kDa, was basally tyrosine 
phosphorylated and this activity increased over 10 minutes. Wortmannin was able to inhibit 
this activity in a concentration-dependent manner. This would suggest a direct interaction 
between this protein and the SH2 domain of SHIP, an interaction that might be PI 3-kinase- 
dependent. In an attempt to identify the unknown protein, blots were stripped and reprobed 
for the adapter protein She and the phosphotyrosine phosphatases SHP1 and SHP2 (all of 
which fall within the kDa range of the unknown protein) with negative results.
IL-13 induces the phosphorylation o f p70 S6-kinase
The translational control of mRNA transcripts containing 5’ polypyrimidine tracts involves 
p70 S6-kinase and the complex regulation of this enzyme involves phosphorylation at many 
sites (C. G. Proud, 1996). As p70 S6-kinase is a downstream effector of PI 3-kinase (Weng 
et aL, 1995 and Chung et al., 1994), resting and stimulated HT-29 whole cell extracts were 
immunoblotted using phosphospecific antibodies to two phosphorylated forms of p70 86- 
kinase (Fig. 5.10). IL-13 induced an increase in phosphorylation at the ^ T h r /^ S e r  sites 
over 10 minutes, but not at the 41 ^ e r  site. Wortmannin was able to inhibit the IL-13- 
induced phosphorylation, although not to basal levels. Blots were also stripped and 
reprobed with an anti-p70 S6-kinase antibody to verify equal loading and efficient transfer.
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IL-13 delays cytokine-induced activation o f the caspase cascade
Activation of the caspase cascade is pivotal to the death execution phase of apoptosis and it 
appears that caspase-8 is the apical member of the pathway induced by CD95 and TNFR-1 
with caspase-3 lying downstream (Boldin et al., 1996; Muzio et al., 1996 and Enari et al.,
1996). Hence, we investigated whether the induction of apoptotic markers induced by 
various cytokine combinations also correlated with activation of caspase-8 and -3. Indeed, 
treatment of cells with IFN-y/TNFa and IL-la/IFN-y/TNF-a, but not IL-la/IFN-y, 
stimulated both caspase-8 and caspase-3 activity (Fig. 5.11 A). In comparison, while 
treatment with IL -la  did not stimulate caspase activity, both TNF-a and IFN-y elicited 
modest activation of these caspases (Fig. 5.11 A). Interestingly, pre-treatment of HT-29 
cells with IL-13 consistently induced a partial inhibition of IL-lot/IFN-y/TNF-a-stimulated 
caspase-8 and caspase-3 activity at early time points (e.g., 12 hours) which may constitute a 
delay in caspase activation by IL-13 (Figs. 5.1 IB and C).
5.2 DISCUSSION
In this report it has been demonstrated that a combination of pro-inflammatory cytokines, 
namely IL-la/IFN-y/TNF-a, stimulates the expression of apoptotic markers in 
approximately 25 - 80% of cytokine-treated HT-29 cells (depending on time of analysis) as 
evidenced by assays that detect DNA fragmentation and extemalisation of 
phosphatidylserine. Apoptosis can also be stimulated to varying extents by the combination 
of IL-la/IFN-y or IFN-y /TNF-a. Moreover, we present evidence that the induction of 
these apoptotic markers is not dependent on the expression of iNOS and NO production.
caspase-8 caspase-3
4
Figure 5.11A. Effect of IL-13 on cytokine-induced activation of caspase-8 and caspase-3 in HT-29 cells. HT-29 cells were either left 
untreated or treated with 30 ng/ml IL-13 for 1 hour. Where indicated, the cells were then further treated with combinations of cytokines as 
indicated or left untreated. After 24 hours, cells were pelleted to include any floating cells, the supernatants were removed and the cell 
pellets were lysed and assayed for caspase-8 and caspase-3 activity. Data is the mean of triplicates from one experiment ± SEM, 
representative of two independent experiments.
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Figure 5.11. HT-29 cells (3.5 x 106) were either left untreated or treated with IL-13 
(30 ng/ml) for 1 hour. After 24 hours, cells were pelleted to include any floating cells, 
the supernatants removed and the cell lysed and assayed for B. caspase-8 and C. 
caspase-3 activity, as described in section 2.2.8.4. Data are the mean of triplicate 
from one experiment ± SEM, representative of three independent experiments.
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Furthermore, pre-treatment with the anti-inflammatory cytokine IL-13 protects against IL- 
la/IFN-y/TNF-a-, IFN-y/TNF-a- and IFN-y/CH 11-induced (but not IL-la/IFN-y-induced) 
cell death in this system via a PI 3-kinase-dependent mechanism. IL-13 is also known to 
prevent induction of NO production by HT-29 cells in response to IL-lcx/IFN-y/TNF-a 
(Kolios et al., 1995 and Wright et al., 1997). This correlates with the first demonstration 
that IL-13 stimulates activation of the major downstream PI 3-kinase effector PKB, a 
signalling pathway thought to mediate the promotion of cell survival in a number of cell 
systems (Kauffman-Zeh et al., 1997; Dudek et al., 1997 and Kulik et al., 1997). However, 
IL-13-induced phosphorylation of the downstream target of PKB, Bad, was barely 
detectable, suggesting that this is an unlikely target for PKB activity in this system. In 
addition, IL-13 pre-treatment partially delayed, but did not did not prevent cytokine- 
stimulated activation of either caspase-8 or caspase-3.
Individually, IL -la, IFN-y and TNF-a do not induce apoptosis of HT-29 cells. However, 
our observation that combinations of IL-la, IFN-y and TNF-a induce apoptosis of HT-29 
cells, correlates well with recent reports that IFN-y increases the sensitivity of HT-29 cells 
to pro-apoptotic agents such as TNF-a by directly and indirectly inducing select apoptosis- 
related genes (Ossina et al., 1997). In addition, it has been shown previously that this 
combination of cytokines stimulates NO production from HT-29 cells and there is 
considerable evidence that NO can promote apoptosis in other systems (Briine et al., 1998). 
Indeed, iNOS transcripts can be detected 6 hours after cytokine treatment (Kolios et al.,
1995) and this appears to precede cell death, which is detectable at 8 hours post-cytokine 
stimulation. However, there are several lines of evidence to indicate that cytokine-driven 
iNOS and apoptosis are independent functional events. First, the iNOS inhibitor 
aminoguanadine prevented IL-la/IFN-y /TNF-a and IL-la/IFN-y -induced NO production,
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but had no effect on the apoptosis stimulated by these combinations of cytokines. Second, 
apoptosis can also be stimulated by IFN-y/TNF-a and IFN-y/CH 11 which are unable to 
stimulate NO production. Third, inhibition of IL-la/IFN-y/TNF-a-induced apoptosis by Z- 
VAD-FMK had no effect on NO production induced by these cytokines. Although markers 
of cytokine-stimulated apoptosis, such as DNA fragmentation and phosphatidylserine 
externalisation, are detectable from 8-24 hours, time course experiments have revealed that 
other functional responses continue unabated. For instance, identical cytokine treatment can 
also stimulate up-regulation of iNOS and chemokine mRNA up to 24 hours post­
stimulation (Kolios et al., 1995 and 1996) and these responses can be down-regulated by 
pre-treatment with IL-13 (Kolios et al., 1996 and 1999 and Wright et al., 1997). So, 
cytokine-induced expression of apoptotic markers and events does not necessarily correlate 
with abrogated cell function, at least in the time frame studied here.
Activation of the proteolytic cascade by caspases appears to be essential to cytokine- 
induced apoptosis of HT-29 cells, given our observation that pre-treatment with the caspase 
inhibitor Z-VAD-FMK completely prevents apoptosis induced by IL-1 a/IFN-y/TNF-a, IL- 
la/IFN-y, IFN-y/TNF-a and IFN-y/CHll. This is particularly interesting given that both 
IL -la  and TNF-a (Schutze et al., 1994) and CD95 (Cifone et al., 1994) ligation have been 
reported to activate the ceramide pathway, which has also been implicated as a signalling 
pathway involved in apoptosis (Obeid et al., 1993 and Pushkareva et al., 1995). However, 
since the apoptosis of HT-29 cells stimulated by these cytokine combinations is completely 
inhibited by the caspase inhibitor Z-VAD-FMK, this may indicate that ceramide production 
is not sufficient for cell death in this system. Indeed, it has recently been shown that IFN-y 
was unable to induce changes in sphingolipid levels in HT-29 cells (Veldman et al., 1998), 
suggesting that ceramide-mediated signalling pathways may be cell-type specific. It is also
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interesting to note that while treatment of HT-29 cells with TNF-a or IFN-y resulted in 
modest stimulation of caspases -8  and -3, this is insufficient to drive cell death, since 
neither TNF-a nor IFN-y alone stimulated apoptosis in this system. This is in marked 
contrast to the TNF-a-induced apoptosis observed in neutrophils and T lymphocytes which 
correlates well with caspase activation (Aggarwal et al., 1999 and Yamashita et al., 1999).
Even though IL-13 exerts a protective effect against cell death induced by IL-la/IFN- 
y/TNF-a, IFN-y/TNF-a and IFN-y/CHll, IL-13 pre-treatment was unable to completely 
inhibit cytokine-activated caspase-8 and caspase-3. Rather, it appears that IL-13 delays 
activation of these caspases by IL-la/IFN-y/TNF-a and in this respect it is interesting to 
note that IL-13 provides only a partial protection against cell death induced by IL-la/IFN- 
y/TNF-a, IFN-y/TNF-a and IFN-y/CHll. Caspase activation is required for the execution 
of cell death in an apoptotic manner, reviewed in (Salvesen and Dixit, 1997), but the order 
of caspase activation cascades is not absolute and the commitment to live or die may 
originate from the mitochondria, reviewed in (Green and Kroemer, 1998). Hence, while IL- 
13 partially inhibits and possibly delays activation of caspases -8  and -3, there may well be 
additional targets of IL-13-activated biochemical signals that mediate cell survival at some 
point distal to the apical caspase-8 and the downstream caspase-3, possibly involving 
mitochondrial activity. It is certainly possible that the cytokine combinations used in this 
study activate other upstream and downstream caspases. Indeed, it has recently been shown 
that the kinase Akt can phosphorylate caspase-9 and inhibit its protease activity (Cardone et 
al., 1998). This would fit nicely with these observations, in that IL-13 can provide only 
partial protection against cell death induced by IL-la/IFN-y/TNF-a, IFN-y/TNF-a, 
whereas apoptosis stimulated by IL-la/IFN-y was unaffected by IL-13. Hence, it appears
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that multiple death promoting pathways with different sensitivity to IL-13-activated cell 
survival mechanisms, are activated by the cytokine combinations used in this study.
The protective effects of IL-13 against IL-loc/IFN-y/TNF-a-, IFN-y/TNF-a- and IFN- 
y/CH 1 1-induced apoptosis are dependent on the PI 3-kinase dependent signalling pathway, 
since the PI 3-kinase inhibitors wortmannin and LY29002 abrogated the protective effects 
of IL-13. These observations are consistent with demonstrations that the PI 3-kinase 
dependent signalling pathway and, in particular, its downstream effector PKB are involved 
in growth factor-dependent cell survival (Kauffman-Zeh et al., 1997; Dudek et al., 1997; 
Kulik et al., 1997 and Yao and Cooper, 1995). Indeed, it was shown previously that IL-13 
strongly activates PI 3-kinase as evidenced by PI (3,4,5) P3 accumulation (Wright et al.,
1997). Moreover, data in this study demonstrates that IL-13 also activates PKB and this 
activation is abrogated by pre-treatment with PI 3-kinase inhibitors. PKB is now known to 
promote cell survival by phosphorylating a critical serine residue (136Ser) on the death 
promoting protein Bad, causing it to dissociate from and thus allow activation of the cell 
survival factor, Bc1-xl (reveiwed by J. Downward, 1999). However, consistent with 
observations from other groups (Ossina et al., 1997), Bad is expressed at very low levels in 
HT-29 cells, such that the band shift of Bad to the serine phosphorylated form was barely 
detectable. It would seem unlikely, therefore, that the cell survival effects of IL-13 are 
solely mediated by PKB phosphorylation of Bad in the system described here. However, 
there are three alternative explanations to account for IL-13-stimulated PI 3-kinase/PKB 
dependent cell survival mechanisms. First, other death promoting Bcl-2 family proteins may 
be regulated by PKB-dependent phosphorylation in a manner similar to that described for 
the regulation of Bad. Indeed, expression of the pro-apoptotic protein Bak, a related Bcl-2 
family member, can be directly induced by .IFN-y (Ossina et al., 1997). It would be
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interesting to investigate further whether IL-13 can induce hyperphosphorylation of Bak. It 
remains possible that other Bcl-2 family proteins may act as targets for IL-13-activated 
PKB. Second, an alternative target for the PI 3-kinase-dependent cell survival signals 
provided by IL-13 may be the transcription factors of the NF-kB family which have been 
reported to be important in cell survival by regulating unidentified, anti-apoptotic genes 
(Wu et al., 1998). Recent evidence has identified the inhibitor of-apoptosis (IAP) proteins, 
c-IAPl and C-IAP2, as gene targets of NF-kB transcriptional activity (Wang et al., 1998). 
The c-IAPl and C-IAP2 proteins specifically inhibit the active forms of caspase-3 and 
caspase-7 (Wu et al., 1998). In other systems, such as T lymphocytes, activation of NF-kB 
has been reported to be dependent on p70 S6-kinase (Lai and Tan, 1994). This in turn has 
been reported to be a target for phosphorylation by either PKB (Burgering and Coffer,
1995) and/or its upstream kinase(s) PDK-1 and the putative PDK-2 (Alessi et al., 1997 and 
J. Downward, 1998). Hence, one possibility is that the observed cell survival effects of IL- 
13 involves PI 3-kinase dependent activation of NF-kB transcriptional activity, although this 
hypothesis does not fit easily with the recent report demonstrating that IL-13 downregulates 
TNF-a-mediated activation of NF-kB (Manna and Aggarwal, 1998). Third, PKB has been 
shown to phosphorylate and consequently deactivate the Forkhead transcription factor 
FKHRL1 (Brunet et al., 1999). In so doing PKB mediates the downregulation of pro- 
apoptotic gene transcription and this may well occur in this system through IL-13-induced 
PKB activation.
This study has some preliminary data on the potential activation of p70 S6-kinase. It would 
appear that IL-13 is able to induce phosphorylation of certain sites in the auto-inhibitory 
region. This is thought to relieve a conformation inhibition, which allows for the 
phosphorylation of 389Thr and subsequent phosphorylation of 229Thr (J. Downward, 1998).
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Wortmannin abrogated the IL-13-induced phosphorylation sites in the auto-inhibitory 
domain, suggesting a role for PI 3-kinase in this activity. However, whether this would 
constitute an active p70 S6-kinase is unknown. It is tempting to imply a role for IL-13 in 
cell growth and proliferation, but this is, as yet, unproven. However, this result could 
implicate a self-regulatory event for the IL-13-induced NF-kB inhibition, in that IL-13 
mediates both the inhibition and reactivation of NF-kB, which may account for the partial 
effect on iNOS, chemokines and survival. Alternatively, IL-13-induced p70 S6-kinase 
phosphorylation might imply the requirement for protein translation in the mediation of IL- 
13 effects.
It would be tempting to speculate that the unknown protein pulled down with the SHIP- 
SH2 domain is the IL-13Ral chain, which is the same weight (65-70 kDa). This would 
again imply that IL-13 could both activate PI 3-kinase and mediate its breakdown. 
However, there are no commercially available antibodies to test this hypothesis, but could 
constitute further investigations in the future.
In summary, apoptosis of HT-29 epithelial cells observed in response to a combination of 
cytokines and/or CD95 ligation is not dependent on NO production. In addition, IL-13 can 
provide a PI 3-kinase-dependent cell survival signal to HT-29 cells which protects against 
cytokine-driven apoptotic signals (see Fig. 5.12). The mechanism underlying this cell 
survival effect of EL-13 is unclear and apparently distinct from the known cell survival 
signals provided by PKB-dependent phosphorylation of Bad. Nevertheless, our observations 
indicate a potential role for IL-13 in regulating the controlled program of cell death and 
survival, a process which plays an important role during several stages of normal colonic 
epithelial cell development and maturation. Hence, dysregulation of cell survival and death
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Figure 5.12. Cytokine-induced apoptosis in HT-29 colon epithelial cells. 1. IFN-y is required in combination with either TNF-a or CD95 
ligand in order to induce apoptotic markers, such as caspase activation. 2. IL-13 promotes survival through the activation of PI 3-kinase and 
its downstream target PKB, 3. The ability of IL-13 to mediate these effects is either direct, 4, through the phosphorylation of proteins which 
participate in apoptosis, such as the caspases or the Bel family, or 5, indirect through downregulation of target genes at the transcriptional 
level. See text for further details.
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Understanding how cells integrate signals from a variety of chemically diverse 
information-containing molecules into complex orchestrated responses such as cell 
proliferation, differentiation and apoptosis is an extensive goal of cell biology. The ligand 
molecules that act on the cell surface receptors, including those that mediate proximal 
aspects of signal transduction, utilise tyrosine phosphorylation events to recruit 
downstream signalling elements and initiate intracellular signalling pathways. In this study, 
four different cytokines, namely IL-la, IFN-y, TNF-a and IL-13 utilise at least four 
different pathways to propagate their signals. These include the PI 3-kinase, MAP kinase, 
JAK-STAT, ceramide and JNK/SAPK pathways. There are some common elements within 
these pathways. It is possible that a consolidation of signals occurs at various control 
points such as the adapter molecule, IRS-1 and/or the transcription factor complex, 
IkB/NF-kB, at which there is modulation of interfering signals and feedback mechanisms. 
Some of these aspects will be considered in the next section. The phosphorylation status of 
multifunctional enzymes is likely to affect their activity and for the purposes of this study, 
the activity of iNOS will be discussed. Interaction between gene products, or cross-talk, 
may serve as a means to monitor the cell’s ongoing response to the many stimuli. An 
example relevant to this study will also be commented on. Overall, this is an attempt to 
bring together some of the published work that impinges on the cell model established in 
this project.
How else could IL-13 regulate apoptosis?
IL-13 may mediate its effects via the IL-4Ra chain. Evidence for this comes from 
Zamorano et al, 1998. They analysed the role that tyrosine-containing domains within the 
cytoplasmic tail of IL-4Ra play in IL-4-mediated protection from apoptosis. Since the IL- 
13R in HT-29 cells is comprised of IL-13Ral and IL-4Ra chains, some of their findings
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may well explain the effects mediated by IL-13 in these cells. IL-4 has been found to 
regulate apoptosis in a variety of systems (W. E. Paul, 1991; Illera et al, 1993; Parry et al, 
1994; Foote et al, 1996; and Dancescu et al, 1992). The IL-4Ra cytoplasmic domain 
contains five tyrosine residues. Y497 is surrounded by a sequence motif (I4R) that is 
homologous to sequences found in the insulin and insulin-like growth factor (IGF)-l 
receptors and is regarded as the growth-promoting domain (see figure 6.1). It appears to be 
important for IL-4-induced IRS and She phosphorylation (Ohara et al, 1987 and Wolf et al,
1995), cell proliferation and protection from apoptosis (Keegan et al, 1994 and Zamorano 
et al, 1996). Y575, Y603 and Y631 comprise the STAT6 docking site, which is regarded 
as the gene-induction domain (Keegan et al, 1994; Wang et al, 1996; Pemis et al, 1995 and 
Ryan et al, 1996). In addition, the most carboxyl-terminal domain of the huIL-4Ra 
contains the conserved Y713 surrounded by a pro line-rich sequence. Zamorano et al, 1998 
suggest that the carboxyl-terminal domain can positively regulate IL-4-induced protection 
from apoptosis and that the STAT6 domain diminished the protection from apoptosis 
mediated by the I4R domain, in the absence of the carboxyl-terminal domain. Also, their 
results suggest that IRS-1 is not essential for the carboxyl-terminal-mediated protection 
from apoptosis, but that Y713 is involved. IL-4Ra was able to phosphorylate SHIP, an 
ITIM docking site being found on the carboxy-terminal of the IL-4Ra chain (Damen et al,
1996), although, Y713 was not essential for this recruitment. They concluded that both She 
and SHIP activation does not correlate with the carboxy-terminal domain’s ability to signal 
protection from apoptosis. Interestingly, they found by site-directed mutagenesis that Y497 
and Y713 were able only partially to protect cells from apoptosis, but cooperate to give 
maximal protection. This finding might bear some relevance to the IL-13-induced 
inhibition of apoptosis seen in HT-29 cells, where the protection is only partial. 
Importantly, the ability of the I4R domain to protect from apoptosis seems linked to its
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Figure 6.1. Hypothetical model of signalling through the IL-4Ra chain.
The cytoplasmic tail of the IL-4Ra chain has five tyrosine residues. These 
residues are involved in the recruitment of intracellular adapter proteins and 
the activation of the transcription factors, such as STAT6. These signals have 




ability to activate IRS-1, whereas the protection mediated by the carboxyl-terminal domain 
is not related to the induction of IRS-1 phosphorylation. Alternatively, it might be that the 
STAT6 domain is activating a pathway that negatively regulates protection from apoptosis 
and the balance of signals promoted by each domain determines the outcome. Put another 
way, STAT6 could negatively modulate the protective signal mediated by the other 
domains or block the protective effect when one of the positive signals is off. However, it 
might be possible that a novel protein involved in anti-apoptotic signals could require both 
the I4R and the carboxyl-terminal domains to dock to the receptor and perhaps bridge 
Y497 and Y713 via a dual docking site (Zamorano et al, 1998).
Serine/threonine phosphorylation of IRS-1 has been implicated as a negative regulator of 
insulin signalling (Tanti et al, 1994) and TNF-a increases serine phosphorylation through 
the inhibition of serine phosphatases or activation of serine kinases (Kanety et al, 1995). 
This increased serine phosphorylation interferes with the tyrosine phosphorylation of IRS- 
1 and also its association with PI 3-kinase (Ricort et al, 1997 and Staubs et al, 1998). 
Interestingly, Li et al, 1999 found that this serine phosphorylation was mediated by PKB 
(as a result of PI 3-kinase activity) through, possibly, mTOR or FRAP (R. T. Abraham, 
1998; Scott et al, 1998 and Burnett et al, 1998), suggesting a feedback inhibition. These 
findings lend support to the idea that there exist complex interactions between signalling 
pathways and that multisite phosphorylation of IRS-1 allows for the integration of signals.
Beyond the cytokine receptors, there may be compound modulation of the activities of 
downstream signalling proteins (that is, cross-talk between signalling cascades), which 
may be important in determining the final outcome of multiple cytokine stimulation. 
Considerable attention has recently been focused on the role played by different kinase 
cascades in the control of apoptosis (Xia et al., 1995). Berra et al, 1998 suggest that the
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inhibition of ERK, by the inactivation of the atypical PKCs, triggers the caspase system 
which, in turn, stimulates p38. Atypical PKCs are activated by PI 3-kinase products 
(Akimoto et al, 1996; Herrera-Velit et al, 1997; Mendez et al, 1997 and Sontag et al,
1997), which would favour survival through the ERK pathway. Active PKB can directly 
affect the caspase cascade by deactivating caspase-9 (Cardone et al, 1998), whereas, 
Widmann et al, 1998 suggest that caspases cleave signalling molecules such as PKB and 
MEKKl, thus rendering them inactive. Thus, a critical balance between the ERK, 
JNK/SAPK, p38 and PI 3-kinase/PKB pathways determines the death or survival of a cell.
Why isn’t NO involved in cell death?
HT-29 cells have mutant p53 and are resistant to apoptosis when challenged with a variety 
of toxic stimuli (Canman et al., 1992) This may be at least partially due to the cells’ 
inability to up-regulate wild-type p53 and the absence of the resulting consequences 
(induction of Gi arrest or apoptosis). Ho et al., 1996 found that NO induced nuclear 
accumulation of p53 protein in a dose- and time-dependent manner, this process mainly 
being regulated by post-translational modification. Apoptosis was easily induced by NO in 
COLO205 cells, which contain a wild-type p53, whereas HT-29 cells were resistant to NO- 
mediated cell death. This is an interesting point because recent work by Ambs et a l, 1999 
shows that colon tumours from patients exhibit high NOS2 staining in the tumour- 
infiltrating mononuclear cells. This data correlated with an increase in the number of p53 
mutations as the tumours progressed. Tumour-associated NO production may modify DNA 
directly (Wink et a l, 1996) or it may inhibit repair mechanisms (Graziewicz et a l, 1996) 
and, because NO production also induces accumulation of wild-type p53 (Messmer and 
Brune, 1996 and Forrester et a l, 1996), the resulting growth inhibition can provide an 
additional strong selection pressure for nonfunctional, mutant p53 (Ambs et a l, 1997).
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In addition to the effects of NO on the control of the expression of p53 (Agarwal et al.,
1998) and proteins of the Bcl-2 family (Messmer et al., 1996; Xie et al., 1991; Melkova et 
al., 1997 and G. Kroemer, 1997), this molecule regulates cell viability through the release 
of mitochondrial pro-apoptotic mediators that trigger DNA degradation (Kroemer et al., 
1997; C. Richter, 1997 and Hortelano et al., 1997). Regarding this apoptotic mechanism, 
NO induces a large mitochondrial permeability transition, the release of cytochrome c and 
the activation of the caspase cascade (Bosca and Hortelano, 1999). Bcl-2 and Bcl-xL can 
prevent the release of cytochrome c to the cytosol (Vander Heiden et al., 1997).
Expression of wild-type p53 in HT-29 cells interestingly stimulated an increase in both 
Bax and Bcl-xL protein expression (Merchant et al., 1996) and, although cell cycle 
progression was halted, there was no loss in the cell population. Presumably, apoptosis 
depends on other variables, although, there could be two additional reasons why NO- 
mediated apoptosis in the HT-29 cells is dysfunctional and could explain some of the 
results in this study:
(i) Without the normal NO-induced wild-type p53 rise, Bax levels would not increase. 
This pathway would normally favour apoptosis, but may not do so in HT-29 cells. It is also 
thought that p53 regulates accumulation of Bak (Jones et al., 1998), although it can be 
upregulated by IFN-y in HT-29 cells (Ossinna et a l , 1997), independently, therefore, of 
p53. It may be that the survival effect of IL-13 may lie in an ability to inhibit IFN-y- 
induced Bak expression.
(ii) If Bcl-xL levels were to increase as a result of NO-mediated increases of p53, an 
anti-apoptotic signal would arise, so one could argue that NO should be pro-apoptotic in 
p53-defective HT-29 cells. However, since this does not appear to happen, there may be
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some other factor involved. Interestingly, Bcl-xL is subject to caspase cleavage, which 
releases the pro-apoptotic C-terminal fragment Bcl-xs, thereby converting it from a 
protective protein to a lethal one (Clem et al., 1998), so perhaps p53-mediated increases in 
Bcl-xL could still favour apoptosis in the ‘normal’ setting and does not in HT-29 cells. 
L0mo et al., 1997 found that IL-13, in combination with CD40L, augmented the 
expression of Bcl-xL and Mcl-1, suggesting this as a possible intracellular mechanism of 
induced survival in B cells.
(iii) There are p53-independent signalling pathways in which NO mediates apoptosis 
(Messmer and Brune, 1996) and it is, therefore, theoretically possible that these pathways 
are dysfunctional in HT-29 cells (see Fig. 6.2).
It is conceivably possible that NO still contributes to cell death in colon epithelial cells. An 
intriguing side issue is the current view that NO can be generated by NOS-independent 
pathways, such as human xanthine oxidase (Zhang et al., 1998), bacterial nitrate/nitrite 
reductases (Roediger et al., 1986) and the reaction between hydrogen peroxide and D- or L- 
arginine (Nagase et al., 1997). These sources of NO are valid alternatives to iNOS in UC 
(Zhang et al., 1999). Thus, NO may still mediate cell death in HT-29 cells via functional 
p53-independent pathways and may, indeed, contribute to some extent to the apoptosis 
seen in this system, an event that would be undetectable with the use of the NOS inhibitor, 
aminoguanidine. The use of NO donors might help to clarify this question.
Nitric oxide donors are thought to induce stress signalling via ceramide formation (Huwiler 
et al., 1999). They propose that chronic up-regulation of ceramide levels is achieved by the 
NO-mediated activation of shingomyelinases and a concomitant inhibition of ceramidases. 
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Figure 6.2. Nitric Oxide: A tumour Promoyer or a Tumoricidal Agent? The
NO formed by the action of iNOS reacts with oxygen radical and forms highly 
reactive nitrogen intermediates that serve as endogenous antimicrobial agents. 
However, excessive production of NO via iNOS, in conjunction with TNF, is also 
largely involved in IBD. Increased iNOS expression in human cancers indicates 
that NO has a pathophysiological role in carcinogenesis. The induction of iNOS 
has also been implicated in increased blood flow and angiogenesis contributing to 
tumour growth and metastasis. NO is cytotoxic, partly due to its effects on 
mitochondria. High concentrations of NO can mediate tumoricidal activity, 
whereas lower concentrations promote tumour growth. On the other hand, 
generation of high levels of endogenous reactive nitrogen intermediates contribute 
to induction of apoptosis and inhibition of tumour growth.
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of ceramide levels that correlated with apoptosis, unlike TNF-a, which activates both the 
sphingomyelinases and ceramidases with only transient changes and no net change in 
chronic ceramide levels. Perhaps this explains why endogenous cytokine-induced NO does 
not lead to apoptosis, in that there is an internal counterbalance not present with 
exogenously produced NO (Miihl et al., 1996 and Nitsch et a l, 1997).
Phosphorylation of the NOS isoforms is of particular interest, as it would permit cross talk 
between NO and other signalling pathways and may also serve as a modulator of other 
post-translational modifications of the NOSs (Michel and Feron, 1997). A new 
development may have some relevance with regard to the phosphorylation status of iNOS. 
Activated PKB has now been shown to phosphorylate eNOS and result in NO production 
(Fulton et al., 1999 and Dimmeler et a l, 1999), as well as the demonstration that AMP- 
activated kinase can phosphorylate human eNOS (Chen et al., 1999). The phosphorylation 
status of iNOS is largely unknown, although tyrosine phosphorylation has been shown to 
be important in increasing enzyme activity (Pan et a l, 1996). It may well prove to be the 
case that multisite phosphorylation allows for the integration of signals at iNOS.
Is it all down to NF-kB?
Most of the molecules involved in immune and inflammatory responses are controlled at 
the transcriptional level by a co-ordinated group of transcription factors. It has been shown 
that the IkB/NF-kB system is critical in mediating, amongst other things, cytokine-induced 
iNOS and COX-2 gene expression in intestinal epithelial cells (Jobin et al., 1998).
Jobin et al., 1997 show that HT-29 cells have an altered IkB degradation and incomplete 
NF-kB nuclear translocation, but that nevertheless, suggest that not only does TRAF-2
Summary Discussion 149
play a key role in TNF-a signalling, but that IL-1 also signals through this adapter protein 
in HT-29 cells (Jobin et al., 1999). Overexpression of IKK in HT-29 cells leads to 
complete IkB degradation following cytokine stimulation (Didonato et al., 1997) and 
unpublished work by Jobin et al suggests that both IKK activity and IicBa serine 32 
phosphorylation are strongly reduced in HT-29 cells. Thus, HT-29 cells have an aberrant 
cytokine signalling cascade in respect to their IkB/N F-kB axis and this should be taken 
into account when trying to interpret the outcome of multiple cytokine stimulations.
IL-13 has been shown to inhibit TNF-a-induced NF-kB activation both in vivo and in vitro , 
(Lentsch et al., 1997 and Manna and Aggarwal, 1998). The mechanism for this is quite 
complex. IL-13 has no effect on either of the TNF receptors, but rather, mediates its effects 
by inhibiting IkB degradation (that is, it preserves the protein) and, thus, blocks NF-kB 
translocation to the nucleus. In addition, IL-13 can block TNF-a-induced MEK kinase 
(Manna and Aggarwal, 1998), which is a component of the JNK pathway and required for 
NF-kB activation (Lee et al., 1997). IL-13 was also able to inhibit the activation of NF-kB 
by a wide variety of agents, including PM A and ceramide (Manna and Aggarwal, 1998). 
Interestingly, the ability of IL-13 to inhibit NF-kB activation was PKC-, PLC- and PI 3- 
kinase-dependent. By inhibiting NF-kB activation, IL-13 inhibits NF-KB-dependent gene 
expression, an important event in both iNOS and COX-2 gene transcription (Jobin et al.,
1998).
Besides NF-kB, TNF-a is a potent activator of another transcription factor, AP-1 (Brenner 
et al., 1989) regulated by the TNF-a-induced activation of JNK (Minden et al., 1994). 
Manna and Aggarwal, 1998 showed that IL-13 was able to inhibit AP-1 activation by 
inhibiting JNK activation. In addition, IL-13 was able to inhibit the cytotoxic effects of
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TNF-a by the inhibition of caspase-3 in U937 cells. Taken together, it would appear that 
IL-13 is able to suppress all the effects of TNF-a (Manna and Aggarwal, 1998).
Another intriguing mechanism for IL-13-induced inhibition of NF-kB activation might be 
the antagonistic role of STAT6. Bennett et al., 1997 found that STAT6 activation by IL-4 
blocked TNF-a-induced NF-kB DNA binding in the nucleus, due to overlapping binding 
sites. They postulate that STAT6 acts as a transcriptional repressor and hypothesise that 
STAT6 might compete for the IFN-y-activated transcription factor (GAF) binding sites 
where there is an overlap. Whether this is a significant mechanism for regulation of all IL-
4- and IL-13-responsive genes is unknown at present. Thus, a common theme might be that 
multisite phosphorylation of the IkB/NF-kB complex allows for an integration of signals.
What has COX-2 got to do with it?
Two cyclooxygenase (COX) isoforms, COX-1 and COX-2, catalyse the synthesis of 
prostaglandins (O’Neill and Ford-Hutchinson, 1993). COX-1 is expressed constitutively 
and the prostaglandins produced by COX-1 are thought to play a major role in the 
maintenance of gastrointestinal homeostasis (T.A. Miller, 1983). COX-2 is induced by pro- 
inflammatory cytokines IL-1 and TNF-a (Eckman et al., 1997) and the prostaglandins 
synthesised through COX-2 mediate the inflammatory response (Maier et al., 1990 and 
Lee et al., 1992). In the normal colonic epithelium there is no significant COX-2 
expression, but in ulcerative colitis and Crohn’s colitis COX-2 is expressed in epithelial 
cells in the upper crypts and on the surface but not in the lower crypts (Singer et al., 1998). 
COX-2 expression may be the result of exposure of cells to pro-inflammatory cytokines 
(Jung et al., 1995). COX-2 is also expressed in colon cancer and adenomas (Dubois et al.,
1996). The mechanism of COX-2 induction in colon cancer is not known, but once
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expressed it continues to be expressed and plays a role in carcinogenesis (Oshima et al.,
1996). A role for COX-2-derived prostaglandins in colorectal carcinogenesis has been 
demonstrated using a selective COX-2 inhibitor (Kawamori et al., 1998). These studies on 
prostaglandins suggest that they play a broad role in regulating epithelial cell proliferation 
and apoptosis in response to injury and may account for both gastrointestinal tract toxicity 
of nonsteroidal anti-inflammatory drugs and the role of prostaglandin synthesis in 
colorectal carcinogenesis (Houchen and Stenson, 1999).
IL-13 down-regulates both iNOS and COX-2 transcription by down-regulation of NF-kB 
activity (Jobin et al., 1998 and Dfaz-Cazorla et al., 1999). This is a potentially confusing 
picture, in that if COX-2 inhibition results in the abolition of its anti-apoptotic activity (Ho 
et al., 1998), one could hypothesise that IL-13-induced inhibition would be pro-apoptotic. 
Due to the multiple anti-inflammatory actions of IL-13, it would not be difficult to 
presume that multiple controls exist, whereby the many and various ways in which 
signalling pathways can interact need to be consolidated by the cell before the final 
outcome can be interpreted. This assertion may account for the partial inhibitory effects of 
IL-13 on apoptosis because it may be that its anti-inflammatory actions are mediated by the 




In this research project, it has been shown for the first time that the cytokine IL-13 
activates the signalling enzyme PI 3-kinase, mediated by the adapter protein IRS-1. In 
addition, the activation of this enzyme leads to the down-regulation of cytokine-induced 
iNOS expression and activity. This data was published in 1997 (Wright et al., 1997) and 
since then there have been a number of publications confirming the role of PI 3-kinase in 
the regulation of iNOS (Kleinert et al., 1998; Chen et al., 1998; Salh et al., 1998; Pahan et 
al., 1999; Diaz-Guerra et al., 1999 and Kaliman et al., 1999). Concomitant with this is the 
ability of IL-13 to delay the onset of cytokine-induced apoptosis, again mediated by the 
activation of PI 3-kinase and possibly by the activation of its downstream effector, PKB. 
IL-13 inhibits two crucial effectors of apoptosis, namely caspase-8 and caspase-3, which 
may constitute the delay seen in cytokine-induced apoptosis. This work has also been 
published (Wright et al., 1999).
An important clinical arena for the ability of IL-13 to mediate these effects is that of the 
inflammatory bowel diseases, in that endogenous IL-13 may help to ameliorate some of the 
symptoms of these diseases. By inhibiting iNOS, the deleterious effects of NO might be 
ablated and by inhibiting apoptosis, wound healing and the abolition of barrier dysfunction 
may occur. Interestingly, therapeutic effects have been found for IL-4 gene transfer in 
experimental inflammatory bowel disease in rats (Hogaboam et al., 1997). However, given 
the diminished responsiveness of certain elements of the immune system to IL-4 in human 
IBD patients (Schreiber et al., 1995), it is conceivable that IL-13 gene transfer may 
circumvent this problem and provide therapeutic potential (Kucharzik et al., 1996). This 
lends support to the notion that there is therapeutic potential in restoring the balance of 
cytokines in inflammatory diseases.
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Future Directions
Future directions for this work could take many directions:
(i) First, the ability of IL-13 to modulate the activity of NF-kB and activate STAT6 
needs to be addressed in the intestinal setting. Establishing whether the PI 3-kinase/PKB 
pathway modulates these factors, as well as others, such as FKHR, might shed some light 
on the role of these enzymes in regulating gene transcription. Mimicking these modulatory 
effects with the use of active mutants of PI 3-kinase and active mutants of PKB, 
independently of IL-13, with functional readouts including iNOS/chemokine expression 
and activity, could further clarify the role of this pathway.
(ii) Different IL-13 receptors may have different signalling capacities and this may 
affect the outcome. Additional work could be carried out in the primary system where the 
existence of these different receptor complexes is unknown. Culture of primary colonic 
epithelial cells, although notoriously difficult to do, with further evaluation of the model 
presented in this project could provide data that would be clinically more relevant.
(iii)It could be clinically beneficial to understand which kinases (for example, PKB) and 
phosphatases are involved in the post-translational modification of iNOS and whether 
differential phosphorylation status could modulate the activity of iNOS in different 
inflammatory settings.
(iv) Using regulated expression of dominant negative versions of class Ia PI 3-kinases 
would clarify whether the primary role for this class of kinase was proliferation or cell 
survival. It might also establish a link between PI 3-kinase and caspases in the intestinal
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setting. Overall, an investigation into the molecular signalling events which IL-13 uses to 
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